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ABSTRACT
Human genetic factors confer protection or susceptibility to malaria. Classical 
examples include sickle cell trait, which confers up to 90% protection from severe 
Plasmodium falciparum malaria and Duffy antigen negativity, which offers almost 
complete resistance to Plasmodium vivax infection. Unfortunately, such genetic 
factors are insufficiently understood to design interventions. I conducted the current 
study in Asembo, western Kenya by recruiting a paediatric cohort, characterizing 
malaria epidemiology, genotyping for single nucleotide polymorphisms (SNPs) to 
identify genetic factors affecting malaria incidence and investigating their possible 
relationships with naturally acquired immunity. In addition, I investigated the effect 
of co-inheritance o f genetic factors on malaria incidence. Children under 12 years were 
followed up over a 6 year period (2008-2013) to calculate malaria incidence. Odds 
ratios for malaria were also calculated for categorical risk factors identified during a 
nested cross sectional survey. The parasite density threshold associated with a malaria 
fever was investigated through a logistic regression approach. Interactions between the 
gene variants, and between the gene variants and age were investigated using the 
likelihood ratio test (LRT). Evidence for differences in age-specific rates o f malaria 
was also investigated by LRT. Through these studies, risk factors o f malaria were 
identified. I established differences in age and genotype specific incidence, suggesting 
that malaria candidate genes affect naturally acquired immunity to malaria. In addition, 
this study identified pairs o f genes that may interact to affect malaria incidence. Gene 
frequencies of various malaria candidate genes as typed in this study may be an 
important consideration in interpreting results o f intervention trials in this population.
The high frequency o f the G6PD deficiency genotypes determined in this study is 
clinically relevant as it determines the use of primaquine, a key drug which causes 
haemolysis in deficient individuals, but which is useful in malaria elimination due to 
its gametocytocidal activity.
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CHAPTER 1: Background and literature review
1.1 The global malaria problem
Malaria is estimated to have caused 207 million cases globally in 2012, resulting in 
approximately 600,000 deaths (WHO, 2013). Although higher estimates o f mortality 
exist depending on the measurement method (Murray et al., 2012), taken together 
these estimates show that malaria mortality remains unacceptably high. The current 
high mortality estimates persist despite a 42% decrease in reported mortality between 
2002 and 2012, underlining the magnitude o f the global malaria problem, such that in 
2012, 104 countries were still considered malaria-endemic (WHO, 2013). While sub- 
Saharan Africa accounts for about 80% of malaria cases, other major malaria endemic 
countries include parts o f South America, South- and South-East Asia and the Pacific 
(Gething et al., 2010; WHO, 2013). This burden of malaria is not uniform across age 
groups, with children under 5 years accounting for about 80% o f malaria cases 
worldwide, and up to 90% of malaria mortality occurring in sub-Saharan Africa 
(WHO, 2013). Currently approximately 48% of the global population live in areas at 
risk of malaria (Hay et a l, 2004). Challenges still remain in malaria control, gaps in 
financing malaria control (WHO, 2013) and the threat o f insecticide and drug 
resistance (Feachem et al., 2010; McCann et al., 2014) being among the most serious.
1.2 Malaria Biology
Five Plasmodium species have been shown to cause malaria in humans, P. falciparum, 
P. vivax, P. ovale, P. malariae and, most recently, P. knowlesi (Singh et al., 2004).
Although these species differ in morphology and clinical presentation, in large part 
they share a common life cycle as described below.
1.2.1 The Parasite
1.2.1.1 Life cycle
Modem malaria study is anchored on the work of Laveran, Manson, Ross, and Grassi, 
which established the life cycle o f malaria parasites in the late 19th century (Grassi, 
1900; Grassi et a l, 1899; Laveran, 1881, 1884; Manson, 1879; R. Ross, 1897). 
Laveran exclusively observed protozoa in blood from individuals who presented with 
malarial fevers (Laveran, 1881, 1884) (reviewed by Bruce-Chwatt (Bruce-Chwatt, 
1981)). Following from clues offered by evidence implicating mosquitoes in 
transmission of the filarial worm Wuchereria bancrofti by Manson (Manson, 1879), 
Ross showed that malaria parasites could infect particular species o f mosquitoes (R. 
Ross, 1897), thus implicating mosquitoes as the vectors of malaria. Grassi and 
colleagues later showed mosquito transmission of human malaria, and noted that only 
female anopheles mosquitoes transmit malaria (Grassi, 1900; Grassi et a l, 1899).
The current understanding o f the life cycle o f malaria parasites in man is summarized 
in Figure 1.1. The life cycle can broadly be classified into asexual stages in the human 
host (exo-erythrocytic stage, erythrocytic stage), gametocytogenesis and sexual stages 
in the mosquito.
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1.2.1.1.1 Asexual stage
1.2.1.1.1.1 Exo-erythrocytic stage (hepatic schizogony)
When infected mosquitoes take a human blood meal, they inject their saliva into 
subcutaneous tissues prompting a vasodilatory response and facilitating feeding. 
Sporozoites in the mosquitoes’ saliva are incidentally injected into the host, migrate 
into the bloodstream and infect the human host. Sporozoites travel in the blood stream 
to the liver. The process o f liver infection has been observed by fluorescent 
microscopy in a mouse model (Frevert et al., 2005), where P. berghei binds to the 
sinusoidal cell layer, crosses the Kuppfer cells and finally binds to the hepatocyte. Cell 
passage through Kuppfer cells is crucial to hepatocyte invasion (Ishino et al., 2004). 
In the liver, each sporozoite infects the liver cells (hepatocytes), asexually reproduces 
and develops into merozoites. Merozoites eventually rupture from the liver cells and 
enter into the blood stream.
1.2.1.1.1.2 Erythrocytic stage
Merozoites released from the liver rapidly invade erythrocytes, a process that has been 
studied by video and electron microscopy (Aikawa et al., 1981; Dvorak et a l, 1975). 
Merozoites invade the erythrocytes in a series o f four steps. First, contact with the red 
blood cell occurs at any point of the ovoid shaped merozoite. The merozoite then 
reorients itself so that its apical membrane is in direct contact with the erythrocyte. 
Secretory organelles on the apical end mediate the formation o f an invaginated 
moving-junction with the erythrocyte membrane. The merozoite then enters the red 
blood cell, in the process forming a parasitophorous vacuole that surrounds the 
merozoite inside the erythrocyte. This complex process takes less than 2 minutes 
(Gilson & Crabb, 2009). Various parasite proteins mediate this process. Merozoite
Surface Proteins mediate initial contact with the erythrocyte. The P. falciparum 
erythrocyte binding like (EBL) antigen family, related to the P. vivax Duffy binding 
protein (PvDBP) is thought to play a key but redundant role in invasion. However, in 
P. vivax the role of the PvDBP is more crucial, leading to the almost complete 
refraction o f the erythrocyte to invasion in the absence o f its erythrocyte receptor, the 
Duffy antigen (Miller et al., 1976). The P. falciparum reticulocyte-binding-like 
protein homologue (PfRH) family also mediate binding to reticulocytes and play an 
important role in host cell recognition and invasion. Recent interest in this family has 
been centred on PfRH5, which binds to basigin in the host (Baum et al., 2009). 
Polymorphisms in this ligand have been shown to confer virulence to previously non- 
virulent strains o f P. falciparum , allowing them to infect Aotus monkeys (Hayton et 
al., 2008). A further important parasite protein identified to play a role in invasion is 
Apical Membrane Antigen-1 (AMA-1), which atypically binds to a parasite protein 
the Rhoptry Neck Protein-2 (RON-2) which is in turn bound to the red blood cell.
After invasion, the parasites grow inside the erythrocyte. This necessitates uptake o f
nutrients from the extracellular environment, which is thought to take place either
through increased permeability o f the erythrocyte membrane or through formation of
channels to the extracellular environment. Kirk and colleagues (Kirk, 2001) have
reviewed the evidence for increased permeability o f the erythrocyte membrane
following infection by merozoites and have posited that new permeation pathways of
the infected erythrocyte allow uptake o f nutrients and solutes. The parasites are also
believed to form tubular vesicular membranes (TVM) which are channels linking them
to the extracellular environment for uptake o f nutrients (Lauer et al., 1997). Nutrient
uptake allows growth and further asexual reproduction within the red blood cell. The
growth stages include ring stages and eventually schizont stages within the
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erythrocyte. Within 48 hours o f invasion, the erythrocyte ruptures, releasing more 
merozoites that in turn invade more red blood cells. The rupture o f the red blood cells 
correlates with the symptoms o f malaria experienced by the host including fever, 
nausea and vomiting.
1.2.1.1.1.3 Gametocytogenesis
A subset o f parasites undergo differentiation to form gametocytes, named micro­
gametes (male) and macro-gametes (female). The mechanism involved is not fully 
understood. Recently, the parasite protein P. falciparum Histone Deacetylase-2 has 
been shown to regulate gametocyte conversion (Coleman et al., 2014). Only mature 
gametocytes are seen in the host peripheral circulation leading to the hypothesis that 
immature stages sequester in deep vascular tissues. Human autopsy studies show 
disproportionately higher burdens of gametocytes in the tissues, especially the bone 
marrow (Joice et al., 2014). This may happen for at least two reasons, either tissue 
specificity is required for gametocyte formation, or particular conditions that are found 
in the tissues favour the development o f gametocytes. Evidence for both exists; for the 
latter, Kaushal and colleagues (Kaushal et al., 1980) used in-vitro culture techniques 
to show that static cultures with high parasite densities favour gametocytaemia 
whereas gametocytes form at lower rates in conditions favouring rapid proliferation. 
Extracellular cyclic AMP has also been shown to induce gametocyte formation. 
Regarding tissue specificity, Joice and colleagues (Joice et al., 2014) have shown that 
immature stages of gametocytes accumulate in the erythroid precursor cells, 
implicating these cells as specific sites for gametocytaemia (Joice et al., 2014).
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1.2.1.1.2 Sexual cycle (sporogony)
During a blood meal, female anopheles mosquitoes ingest gametocytes from an 
infected host. Macrogametes and microgametes fuse to form zygotes that mature to 
form motile ookinetes, which attach to the mosquito’s midgut. Eventually, ookinetes 
pass through the midgut and attach to the other side of the midgut surface where they 
undergo meiosis (Sinden & Hartley, 1985). Mitotic division results in formation of 
mature oocysts, which contain haploid sporozoites. Oocysts then rupture, allowing the 
sporozoites to access the coelomic cavity and migrate to the salivary glands. When the 
mosquito feeds on human hosts, the parasites in the saliva are injected into the human 
host, thus completing the cycle o f infection.
6
Figure 1. 1 Life cycle o f  malaria parasites
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1.2.2 Vector
Mosquitoes of the Anopheles genus are responsible for malaria transmission. The 
genus consists of a total of 468 formally recognised species and more than 50 unnamed 
members of species complexes. Members of the genus differ in their geographical 
distribution and competence of transmission, with more dominant members being 
described as dominant vector species (DVS). Recently, information on their global 
distribution has been collated by the Malaria Atlas Project (Hay et al., 2010; Sinka et 
al., 2012), as shown in Figure 1.2. Although malaria has been eliminated from Europe 
and much of the Americas, dominant vector species still exist in these countries (Sinka
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et a l, 2012), therefore potential for transmission exists beyond malaria endemic 
countries.
Only female anopheles mosquitoes transmit malaria. This is because such mosquitoes 
fulfil two basic criteria for malaria transmission: firstly, they require a blood meal as 
a protein source for development of their eggs, and therefore feed on humans/animals 
and secondly; the parasite is able to infect them in the process of taking a blood meal 
and subsequently develop in the mosquitoes gut, allowing the parasite’s transmission 
the next time the mosquito takes a blood meal. It is possible to quantify the vector’s 
infectious rate using measures o f entomological inoculation rate (EIR).
Figure 1. 2 Global distribution of dominant vector species of malaria. Adapted from 
(Sinka et al., 2012)
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1.2.3 H u m a n  host
Various factors influence malaria in the human host, including intensity of 
transmission, clinical presentation, malaria immunity, host genetics and their 
interactions and the age of the host population. These are considered briefly in the 
following sub-sections.
1.2.3.1 Intensity of m alaria transm ission
Common measures of malaria transmission intensity include:
(i) Spleen Rate
(ii) Parasite Rate (PR)
(iii) Entomological Inoculation Rate (EIR)
i) Spleen rate
Initial transmission metrics were based on spleen rates, which was essentially a 
measure of the prevalence of palpable spleens. Such endemic malaria classifications 
were first formalized by a World Health Organization (WHO) conference in 1950 
(WHO, 1951) as follows:
Hypoendemic malaria: Spleen rate in children 2-10 years of age, 0-10%.
Mesoendemic malaria: Spleen rate in children 2-10 years, 11-50%.
Hyperendem ic malaria: Speen rate in children 2-10 years, constantly over 50%, 
spleen rates in adults high.
Holoendemic malaria: Spleen rate in children 2-10 years, constantly over 75%, spleen 
rate in adults, low; it is in this type of endemicity that the strongest adult tolerance is 
found.
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ii) Parasite rates
A more recent classification o f malaria endemicity quantifies malaria risk based on the 
parasite rate (PR), which has been defined as the proportion o f individuals infected 
during a survey.
The parasite rate has been used to define malaria risk classes (Hay et a l, 2008) as 
follows:
No risk areas: Parasite rate 0
Unstable risk P. falciparum annual parasite index (PfAPI) <0.1 per 1,000 per annum; 
Low risk P. falciparum Parasite Rate in children 2-10 years old (PfPR2-io<5%); 
Intermediate risk (PfPR2-io 5-40%);
High risk (PfPR2-io >40%).
The 2-10 year category denotes children who bear the brunt o f malaria infection.
iii) Entomological inoculation rate (EIR)
This is the most rigorous measure o f transmission, and aims to estimate the average 
number of infectious bites received per person per year. EIR is calculated as a product 
of the vector biting rate and sporozoite rate (SR), which is the proportion o f mosquitoes 
with sporozoites in their salivary glands (Sylla et al., 2000). Due to the rigour involved, 
data on EIR are fewer, but remain the most accurate measure of transmission (Burkot 
& Graves, 1995). Despite their accuracy, EIR data points are sparse and therefore the 
generalizability o f the measure faces challenges. As such, modelling approaches 
represent one way to increase the generalizability o f EIR over geographical locations 
that have not been sampled (Amek et a l,  2012).
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1.2.3.2 Clinical presentation of m alaria in the host
Infection with malaria results in highly heterogeneous outcomes in the host, ranging 
from asymptomatic carriage o f the parasite, mild disease or even life threatening or 
fatal disease. Factors affecting this progression include the intensity o f transmission 
and host immune factors. In individuals with clinical symptoms, presentation can be 
broadly classified into two forms; uncomplicated malaria and severe malaria.
1.2.3.2.1 Uncomplicated m alaria
Most episodes o f malaria in endemic areas are not complicated by life-threatening 
features. Uncomplicated malaria episodes are commonly characterised by symptoms 
such as malaise, dizziness, fatigue, headaches, muscular and joint pains, diarrhoea and 
vomiting. Within 2-3 days the infected individual presents with characteristic 
paroxysms o f fever that are the hallmark o f malaria infection. Nevertheless, the 
clinical picture o f malaria is difficult to distinguish from other childhood illnesses, and 
therefore a slide positive for malaria is usually required to confirm malaria in 
individuals presenting with such symptoms. However, many individuals in malaria 
endemic areas may have malaria parasites in their blood but remain asymptomatic, 
complicating the diagnosis o f malaria even further. A threshold o f parasites specific to 
a particular endemic population is often used to determine which individuals 
presenting with suspected malaria fevers are actually suffering from malaria (Smith et 
al., 1994).
1.2.3.2.2 Severe m alaria
A small subset of individuals develop life threatening complications during clinical 
episodes of malarial infection (Greenwood et al., 1991). These are most common
during infections caused by P. falciparum (Organization, 2014; WHO, 2000), although 
there is growing evidence that life threatening malaria can also, on occasion result 
from infections with P. vivax (Baird, 2009). Such presentations of malaria are 
generally termed severe malaria, and include syndromes that include impaired 
consciousness, respiratory distress due to acidosis, severe anaemia, renal failure, 
hypoglycaemia and jaundice (Organization, 2014; WHO, 2000). The classical 
symptoms o f severe malaria are not the same in all patients, as presentation varies with 
transmission settings, underlying conditions, and background immunity o f the host 
(WHO, 2000). For example, in hyper-endemic areas, severe malarial anaemia is the 
most common complication of severe malaria encountered, whereas in areas o f low 
endemicity, cerebral malaria is a more common presentation. It is worth noting that 
overlaps exist between the various conditions termed severe malaria (Marsh et a l, 
1996), but these complications are conceptually understood as distinct syndromes such 
as impaired consciousness, respiratory distress, severe anaemia, hypoglycaemia and 
jaundice.
1.2.4 Host genetics and malaria
In many malaria holoendemic areas, young children experience several clinical attacks 
of malaria each year but only a small proportion o f these attacks lead to life threatening 
illness (Greenwood et al., 1991). As described above, malaria associated mortality is 
mostly due to severe malaria syndromes such as severe malarial anaemia, metabolic 
acidosis, seizures, prostration and coma. Human host genes have been shown to be 
important determinants of the progression from mild clinical attacks to severe and life 
threatening malaria (Greenwood et a l, 1991; Mackinnon et a l,  2005).
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The most commonly distributed genotypes that appear to offer host protection from 
malaria are the ABO blood groups (Rowe et a l, 2009) and the haemoglobinopathies, 
such as haemoglobin S (HbS), haemoglobin C (HbC) and a+thalassaemia. Although 
human populations vary widely in their genetic structure (Tishkoff et al., 2009), 
malaria endemicity presents a common selection pressure in selection for particular 
protective variants o f genes, and can predict the gene frequencies in populations as 
shown by global evidence based maps o f HbC (Piel et a l, 2013), HbS (Piel et a l, 
2010), glucose-6-phosphate dehydrogenase (G6PD), deficiency (Howes et a l, 2012) 
and Duffy antigen negativity (Howes et a l, 2011).
A contemporary meta-analysis o f the effects of haemoglobinopathies such as HbS, a +- 
thalassaemia and HbC on malaria has recently been conducted by Taylor and 
colleagues (Taylor et a l, 2012). Common genes conferring malaria resistance are 
considered below.
1.2.4.1 Classical malaria protective genes
1.2.4.1.1 Sickle cell trait
The malaria protective effect o f sickle cell trait (HbAS) was first suspected over 60 
years ago (Allison, 1954; Beet, 1946). It is now clear that HbAS confers protection 
against all forms o f clinical malaria including severe malarial anaemia (SMA), 
cerebral malaria (CM) and malaria related convulsions (May et a l, 2007; Williams, 
Mwangi, Wambua, Alexander, et a l, 2005). Furthermore, the fewer cases o f malaria 
in HbAS individuals are associated with lower parasite densities than in normal 
(HbAA) individuals (Williams, Mwangi, Wambua, Alexander, et a l, 2005). The 
mechanism of protection afforded by HbAS has been o f interest and while some
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reports attribute it to innate mechanisms (Friedman, 1978; Friedman et al., 1979; 
Pasvol et a l, 1978; Roth et al., 1978), the adaptive immune mechanism has been 
implicated in some in vitro studies which show higher lympho-proliferative responses 
to P. falciparum soluble antigens in children with HbAS compared with children of 
normal genotype, HbAA (Abu-Zeid et a l, 1992; Bayoumi, 1987). Regarding 
antibody-mediated protection, studies demonstrated higher titres of antibodies in 
HbAS compared with normal individuals (Marsh et a l, 1989). Another observational 
study found evidence of a possible interaction between trans-placentally acquired 
antibodies and HbAS in the delay o f onset of clinical malaria in new-borns. This 
protection was only present when HbAS and the antibodies were present together, and 
was abolished when they were present separately, indicating an interactive effect o f 
HbAS in antibody-mediated immune protection (Achidi et a l, 1996). There is a 
scarcity of population genetic epidemiology studies to assess differences in immune 
protection between normal and HbAS individuals. One such study found differences 
in lymphocyte proliferative responses to P. falciparum antigens between normal and 
HbAS children, which varied with age (Le Hesran et a l, 1999). Similarly, 
observational age-stratified longitudinal cohort studies conducted in Kilifi, Kenya 
have shown that the protection afforded by HbAS against malaria is not the same in 
different age categories. Incidence rate ratios o f HbAS compared to HbAA show 
protection from malaria increasing from only 20% in children <2 years to a peak of 
56% at 8-10 years of age, strongly arguing for an immune component in HbAS 
mediated protection (Williams, Mwangi, Roberts, et a l, 2005). As such, the current 
study aimed to document the age-specific susceptibility to malaria in HbAS children 
to investigate further the evidence o f adaptive immunity in malaria protection 
conferred by HbAS.
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1.2.4.1.2 a-thalassaemia
a-thalassaemia results in a deficiency in the a-chains o f the haemoglobin molecule due 
to deletions or mutations in one or more genes encoding these chains. Previous studies 
have shown that a-thalassaemia, results in as much as 40% protection from severe 
malaria anaemia (Wambua et al., 2006). As in the case with HbAS, in vitro studies 
suggest possible mechanisms of a-thalassaemia protection. Yuthavong (Yuthavong et 
al., 1988) demonstrated increased susceptibility o f infected a-thalassaemic red blood 
cells (RBCs) to phagocytosis while others have shown altered surface antigen 
expression (Luzzi et a l, 1991; Udomsangpetch et a l, 1993), a phenomenon that may 
be relevant to immunogenicity and pathogenicity. Other reports showed a common 
mechanism o f enhanced phagocytosis in ring-parasitized mutant RBCs with HbAS, 
G6PD deficiency and p-thalassaemia, however, this was not the case in a-thalassaemic 
RBCs suggesting a different mechanism o f protection from malaria (Ayi et a l, 2004; 
Cappadoro et a l, 1998).
A genetic epidemiology study in the Pacific found higher susceptibility to mild malaria 
in children with a-thalassaemia relative to normal children, suggesting that protection 
conferred against severe malaria by a-thalassaemia might be due to priming o f the 
immune system by the mild malarial infections (Williams et a l, 1996). In contrast, 
another study on the Kenyan coast did not find evidence o f increased risk o f mild 
malaria in a-thalassaemic children but instead demonstrated a trend towards a reduced 
incidence o f uncomplicated malaria (Wambua et a l, 2006). In this study, a- 
thalassaemia protection against severe malaria was specific to SMA. A similar 
observation was made in a study conducted in Ghanaian children (May et a l,  2007). 
Finally, in another population-based study, humoral responses in children with a-
thalassaemia were no different from those in normal individuals (Allen et al., 1993). 
As such, there is a need for further population-based genetic studies to delineate the 
precise association between a-thalassaemia and susceptibility to severe malaria.
1.2.4.1.3 Complement receptor 1 (CR1) polymorphisms
The Swain Langley (SI) and McCoy (McC) genotypes of red cell complement receptor 
1 (CR1) have been associated with protection from CM (Thathy et al., 2005). In 
addition, one hypothesis implicated in the protection of a-thalassaemia against severe 
malaria has been demonstrated to be through reduced expression of the CR1 in a- 
thalassaemic RBCs. This may partly be due to the in vitro rosetting property o f the 
CR1 protein (Rowe et al., 1997). Rosetting has been associated with severe malaria in 
a number o f studies in Africa (Stoute, 2005) and therefore population genetic studies 
of polymorphisms in the CR1 gene may provide an opportunity for exploring the role 
of CR1 in the pathophysiology o f severe malaria.
1.2.41.4 G6PD deficiency
G6PD is a key enzyme in the pentose phosphate pathway that protects RBCs from 
oxidant damage. G6PD deficiency is an enzymopathy that has been known to protect 
against malaria for about 50 years (Allison & Clyde, 1961). It is an X chromosome- 
linked condition, meaning males, with only one X chromosome, are hemizygous 
whereas females, who have two X chromosomes, can either be homozygous or 
heterozygous for the deficiency. The non-deficient genotype is referred to as G6PD B. 
Different allelic variants may cause deficiency, but in Kenya, the mutant responsible 
for deficiency is the 202 C>T mutation, referred to as G6PD A- (Carter et a l,  2011; 
Shah et al., 2014). This A- mutation (202C>T) is associated with approximately 40%
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of the normal G6PD B enzyme activity, and only occurs in the background of the 376 
(T>C) mutation. Individuals with only the 376 T>C mutation have G6PD A, which is 
associated with 85% enzyme activity of G6PD B. The role of G6PD deficiency in 
protection from malaria remains controversial since many reports attribute different 
levels of protection (Allison & Clyde, 1961; Bienzle et al., 1972; T. Butler, 1973; 
Gilles et al., 1967; Guindo et al., 2007; Ruwende et al., 1995). However, since these 
studies were heterogeneous, they are difficult to compare especially in the light o f the 
different diagnostic methods used and the different outcomes assessed for protection. 
Recently, the debate on mechanisms o f protection has been informed by two 
contrasting studies suggesting different mechanisms. In one study, both hemizygotes 
and heterozygotes were protected from severe malaria (Ruwende et al., 1995) whereas 
in another investigation, only the hemizygous males were protected but not 
heterozygous females (Guindo et al., 2007). It is evident that more population-based 
epidemiological studies are required to inform the debate on mechanisms o f G6PD 
deficiency protection.
1.2.4.2 Recently identified malaria-protective polymorphisms
Classical malaria resistance genes like HbAS have been shown to account for only a
small fraction o f genetic resistance to severe malaria, suggesting that many other genes
act out to protect individuals from malaria (Mackinnon et al., 2005). These have been
the subject o f association studies to identify novel genes and confirm replication of
protection across populations (MALGEN, 2008). Recently, genome wide association
studies have succeeded in identifying 2 new SNPs with reproducible protection across
populations, the rs4951074 at chromosome lq32.1, ATP2B4 locus and the rs2334880
at chromosome 16q22.2 linked to the MARVELD3 locus (Timmann et al., 2012). The
statistical association between these genes and differential malaria outcomes is
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augmented by the functional role of these loci. ATP2B4 locus encodes the major 
calcium pump in erythrocytes, which are the main pathogenic host cells, whereas 
MARVELD3 is a protein expressed on endothelial cells and as such sequestration of 
parasitized erythrocytes may be aided by variants of MARVELD3. Many o f the 
genetic associations have recently been confirmed in large multicentre studies 
(MALGEN, 2014).
1.2.4.3 Human genetic studies may lead to malaria interventions
Based on an understanding o f the malaria lifecycle (see Figure 1.2), interventions 
against malaria commonly target the parasite, vector or the human host risk factors. 
Parasite and vector targeting is quite recent, meaning that human host genetic factors 
have been the ‘natural interventions’ or determinants o f malaria outcomes for 
millennia. For example, the use of quinine, which kills the parasite in the blood stages, 
has been documented in the last 400 years (circa 1600) in the Andes ranges by Jesuit 
missionaries (A. R. Butler et al., 2010), though ancient populations probably used it 
for millennia (Waterfall CM, 2001). Vector based interventions that are aggressive and 
o f a large scale have targeted the mosquito since the discovery o f mosquitoes as the 
vectors for malaria transmission by Ronald Ross in 1898 (R. Ross, 1897). Human 
genetic factors protecting from malaria are likely to have played a vital role in 
distinguishing between survival and death from malaria in the millennia before the 
introduction o f chemotherapy and vector control.
Studies o f human genetic polymorphisms represent a natural experiment o f which 
genetic make-ups are better suited to survive the malaria challenge. Such studies can 
result in interventions. For example the discovery that Duffy antigen negativity makes
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red blood cells refractive to P. vivax malaria (Miller et a l, 1976) infection has led to 
the identification o f a parasite protein, the P. vivax Duffy binding protein (PvDBP) as 
a major target for vaccine development (Chitnis & Sharma, 2008). This discovery has 
also led to better descriptions o f populations at risk o f infection, for example P. vivax 
is delimited from most o f Africa because the majority o f the African population is 
Duffy antigen negative (Guerra et a l, 2010). Recent evidence suggests that P. vivax 
originated in Africa (Liu et a l, 2014) and led to the selection o f the Duffy negative 
allele to fixation (Hamblin et a l, 2002). Similarly, the discovery o f the association 
between Human Leukocyte Antigen (HLA) type and the risk o f severe P. falciparum 
malaria (Hill et a l, 1991) has provided a rationale for the development o f vaccines 
that target the pre-erythrocytic stages of parasite development by inducing T-cell 
responses.
Another example o f how genetic polymorphisms interact with interventions is offered 
by G6PD deficiency; individuals harbouring deficiency associated mutations 
experience haemolysis when treated using primaquine (Howes et a l, 2012). The 
numbers o f individuals carrying such mutations are an important measure when 
considering this treatment option, especially in the current age o f malaria elimination 
since it is the only available drug in the pharmacopeia that can both prevent 
transmission by attacking gametocytes and preclude relapse by killing hypnozoites 
that may otherwise relapse (Eziefula et a l, 2012). Careful characterization o f G6PD 
deficient populations in such campaigns may lead to better deployment and delineation 
o f where such campaigns are likely to be most effective.
The classical human host genes associated with malaria resistance affect the RBC
where the malaria parasite mainly resides in its life cycle in the human host (Williams,
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2006). So far, mechanistic studies have shown that some o f these conditions are 
associated with enhanced production of antibodies directed towards the infected red 
cell surface that enhance their destruction through phagocytosis. This raises the 
possibility o f using agents that mimic the antigenic presentation caused by these 
conditions as new therapeutic agents (Kennedy, 2001).
1.2.4.4 Age- and genotype-specific m alaria incidence
1.2.4.4.1 Relationship between genetic variants and age patterns of disease
Severe malarial disease and mortality predominate among the youngest children 
(WHO, 2013) and tapers off sharply in the older individuals in endemic populations. 
In order for genetic variants that confer protection to achieve high population 
frequencies, they would need to protect from death at the youngest ages that bear the 
highest mortality burden and be fit enough for passage to future generations. The 
classical gene associated with malaria protection, HbAS, meets these criteria, as 
epidemiological evidence shows it protects from the most severe malaria symptom 
among those under 5 years old (Williams, Mwangi, Wambua, Alexander, et al., 2005) 
and allows survival from life threatening malaria. Survivors with the carrier status are 
able to pass it on to their offspring, with the continual malaria selective pressure in 
succeeding generations leading to more carriers o f the gene surviving to propagate the 
gene. Thus, the gene achieves high population frequencies as a result o f the protective 
effect that it confers against malaria (Piel et al., 2010).
However, Mackinnon and colleagues (Mackinnon et a l, 2005) found that the HbAS 
could only account for 2% of the heritability o f protection from malaria, out o f a total 
genetic heritability of approximately 25%. Given that other canonical examples of
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malaria protective genes may not account for more than 2% of genetic heritability, one 
would expect that approximately 90% of genetic heritability o f malaria protection 
remains to be explored. Mackinnon and colleagues concluded that most likely, many 
monogenic causes each contribute a small fraction to overall susceptibility. More 
recently, Alcais and colleagues (Alcais et al., 2010) have proposed that single gene 
variations underlie the severity of paediatric infectious diseases and that this effect is 
reflected in the age specific incidence patterns o f various variants o f protective genes.
According to Alcais and colleagues (Alcais et a l, 2010), infectious diseases show 
characteristic age profiles o f morbidity and mortality, with each pathogen showing a 
characteristic age pattern o f morbidity/mortality. Examples include the U shaped 
pattern o f higher disease in the youngest and oldest individuals with an intervening dip 
in adolescents and the middle aged as seen in invasive pneumococcal disease and 
herpes simplex encephalitis; and the L shaped pattern o f higher disease in only the 
youngest children, as seen in diseases such as malaria, measles, tetanus and in 
diphtheria and poliomyelitis before the widespread use o f vaccination. These patterns 
are sensitive to changes in the pathogen or the host. For the pathogen, peak shifts in 
the burden of disease may represents a change in the pathogen to more virulence or 
higher transmission, examples being pandemic influenza and Ebola (Alcais et a l, 
2010).
Alternatively, a shift in the age burden could reflect immunological changes in the 
host. In the case o f malarial disease, the characteristic L shape o f the age specific 
incidence curve occurs because the youngest children bear the highest burden o f 
clinical malaria as they lack adaptive immunity. As they age and acquire immunity,
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clinical disease sharply tapers off to a more uniform risk after puberty (Baird, 1995). 
This age incidence curve is characteristic o f endemic populations. However, in non­
endemic populations, the majority o f the population is immunologically naive to the 
pathogen and the incidence pattern may be more similar across the population.
In P. falciparum, changes in transmission intensity shift the peak prevalence o f 
infection to younger age groups as transmission intensity increases (Molineaux L, 
1980). Acquisition o f immunity in the host is associated with the peak shift 
phenomenon (Woolhouse, 1998). Conversely, the age incidence curves normally shift 
to older age groups in response to interventions, because the interventions reduce 
exposure, thereby delaying the development o f acquired immunity. It has been 
observed that declines in malaria transmission result in shift of malaria morbidity to 
older children, especially in the current push towards malaria elimination (Ceesay et 
a l , 2008; O'Meara et a l, 2008; Schellenberg et a l, 2004). Importantly, the peak shift 
phenomenon is not limited to malaria, but is also seen in other infections where 
immunity is acquired (Woolhouse, 1998).
Knowledge of the patterns of age-malaria incidence has been used to target 
interventions to the worst affected, children less than 5 years in the case o f malaria 
(WHO, 2013). The age-specific incidence o f malaria is therefore an important tool in 
monitoring the shifting burden o f malaria as transmission intensity declines, and 
allows an appropriate response to clear reservoirs o f malaria as transmission declines 
(WHO, 2013).
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I.2 .4 .4 . 2 A ge-specific incidence o f  m alaria by genotype
From the foregoing, it is clear that the age-incidence curve is a proxy for the rate o f 
acquisition o f naturally acquired immunity. It is conceivable that genetic factors 
protecting from malaria can have the same effect as the protective interventions and 
may shift the age curves to older age groups. This has previously been investigated in 
an age cohort by studying the effect of protection afforded by the sickle cell trait across 
a variety o f various ages (Williams, Mwangi, Roberts, et a l , 2005). Williams and 
colleagues argued that if  immune mechanisms are involved in the protection afforded 
by the sickle cell trait, the degree o f protection should increase up to the age when 
children would normally become functionally immune to malaria, and that any 
immunological advantage beyond this time would not result in any increased level o f 
protection. It was shown that the level o f protection increased approximately 
threefold, from only 20% in the first 2 years o f life to about 56% in those who were 
10 years o f age and thereafter a reduction to 30% in those older than 10 years. This 
was therefore consistent with an immune basis o f protection.
In another study, Gong and colleagues (Gong et al., 2012) followed a cohort o f 
children 1-10 years o f age and compared their establishment o f parasitaemia, 
symptomatic malaria and parasite density. Sickle trait carriers were protected against 
the establishment o f parasitaemia and development o f symptomatic malaria at older 
ages but not at younger ages. However, the younger children were protected against 
high parasite density compared with the older children in the cohort. Effects only seen 
at older ages suggest acquired mechanisms o f protection, compared to effects that are 
seen at younger ages, which suggest innate mechanisms o f protection. Thus, it appears 
that the protection afforded by sickle cell trait has both innate and acquired 
components.
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Age incidence patterns can also give insights into possible mechanisms o f protection 
associated with immunity. For example, in a study of age specific incidence of malaria 
in the pacific (Williams et al., 1996), young a-thalassaemia homozygous (-a/-a) 
children (< 4 years old) had more clinical malaria than their normal (aa/aa) 
counterparts. The effect was not seen in those who were 5-9 years. This was 
paradoxical, as a+thalassaemia is known to protect against malaria. The authors 
concluded that a+thalassaemia may beneficially predispose to malaria in early life to 
avoid later severe disease, what they termed a ‘natural’ vaccine i.e. a genetic condition 
that predisposes to disease in early life in order to avoid the severe symptoms o f the 
disease in later life. The authors argue that since diseases such as rubella and 
poliomyelitis cause least morbidity when contracted early in childhood, this is 
evidence o f priming the immune system through exposure to less severe episodes to 
avoid the life threatening illnesses in later life. Interestingly, when I considered the 
poliomyelitis age incidence curve reported by Alcais (Alcais et a l, 2010), I observed 
that it is L shaped, similar to that for malaria. This led me to hypothesize that ‘natural 
vaccination’ may be conferred by different genes and may be replicated in different 
populations or transmission settings. This study investigates this by observing age- 
and genotype-specific malaria incidence in Lwak, Asembo area o f Western Kenya. A 
characteristic age incidence pattern o f malarial diseases is illustrated in Figure 1.3 
below:
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Figure 1. 3 Characteristic age incidence patterns of severe, mild and asymptomatic 
malaria.
Adapted from (Langhorne et al., 2008).
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The figure shows how indices o f  malaria change over time in an endemic area. Green represents severe malaria, 
most prevalent in the children the least exposed members (under 5 years) whereas purple shows the proportion o f  
mild malaria in older children, adolescents and young adults, and while orange shows asymptomatic infection most 
prevalent in the most exposed members o f  the population, the oldest.
Through this study, I will seek evidence for age and genotype-specific changes in 
peaks of infection, consistent with different rates of acquired immunity in different 
ages and genotypes respectively. If stratification by the protective variants o f the genes 
shows a difference in peak shift towards older children, this provides evidence o f the 
role of immunity in protection, whereas if stratification by the protective genes does 
not show a peak shift, immunity may play no role in the protection afforded by these 
genes.
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1.2.4.5 R ole o f  ep istasis in m alaria incidence studies
Epistasis is simply interaction between loci that predicts the phenotype. Carlborg and 
colleagues (Carlborg & Haley, 2004) have reported that it is more common than 
previously thought, and should be considered in genetic studies. For example, it has 
recently been observed that the separate malaria-protective effects of HbAS and a- 
thalassaemia are each abrogated when these conditions are inherited together 
(Williams, Mwangi, Wambua, Peto, et al., 2005). Together with the previous 
observations regarding HbAS and a-thalassaemia above, this finding suggests 
contrasting mechanisms of malaria protection for HbAS and a-thalassaemia. In co­
inheritance between HbAS and a-thalassaemia, there is reduced synthesis of HbS due 
to a lower availability o f a  chains to combine with ps chains (Mouele et al., 2000). 
Since the HbS component in the sickle cell trait individuals protects from malaria, 
when it is reduced due to co-inheritance with a-thalassaemia, it follows that the 
protective effect will be reduced. Similarly, the observation that there is epistasis 
between a-thalassaemia and haptoglobin (Atkinson et al., 2014) led to inferences on 
the mechanism o f the interaction between a-thalassaemia and the haptoglobin 2-2 
molecule. These include the following:
(i) Hp2-2 is less able to quench the unmatched globins in a-thalassaemia 
leading to increased oxidative stress and therefore reducing the protection 
afforded by a-thalassaemia to malaria.
(ii) Both a-thalassaemia and haptoglobin lead to increased methemoglobin. 
Since methemoglobin, is an endothelial cell activator, the effect o f excess 
methemoglobin may reduce protection from severe effects o f malaria.
(iii) Hp2-2 increases pro-inflammatory response thus discounting any 
protection by a-thalassaemia.
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Studies of epistasis can thus lead to possible new avenues o f inquiry into the 
mechanisms o f malaria protection afforded by malaria protective genes.
The current study investigates malaria epidemiology and the effect of malaria 
candidate genes and gene interactions on malaria incidence in Asembo, western 
Kenya.
1.2.4.6 Entomological profile and malaria transmission in Asembo
Historical trends of EIR in Asembo are associated with changes in vector populations, 
proportions and their species-specific EIRs. In the late 1990s, following a large scale 
randomized trial which distributed insecticide treated nets (ITNs) to residents, 
populations o f vector species diminished, and sporozoite rates declined by 
approximately 90% (Gimnig et al., 2003). Whereas An. gambiae and An. funestus were 
the dominant vectors before the ITN intervention (Gimnig et al., 2003), in the mid to 
late 2000s, An. arabiensis became the predominant vector while low proportions o f 
An. gambiae and An. funestus were reported (Bayoh et al., 2010). However, the An. 
funestus population has resurged recently (McCann et al., 2014).
Measures o f EIR have changed over the same period. Compared to data collected
before the large scale distribution of ITNs, daily EIRs have shown a consistent
reduction for An. gambiae sensu latu (indoor EIR = 0.432 in 1985-1988, 0.458 in
1989-1990, 0.023 in 2011). An. arabiensis, a member of the An. gambiae sensu latu
complex (the other being An. gambiae ss) has shown an even more marked reduction
(indoor EIR = 0.532 in 1989-1990, 0.039 in 2009, 0.006 in 2011). However, An.
funestus has shown an overall increase in EIR (indoor EIR = 0.029 in 1985-1988,
0.147 in 1989-1990, 0.010 in 2009 and 0.103 in 2011) (Adazu et al., 2005; Bayoh et
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al., 2014) Malaria transmission occurs year round but EIR peaks in May during the 
wet season each year (Amek et al., 2012).
1.2.4.7 Parasite prevalence reported in Asembo
P. falciparum prevalence in Asembo reduced from a high o f >80% in the 1990s 
(Bloland et al., 1999) to <30% in 2008, and are currently at about 40% since 2009 
(Hamel et al., 2011). The overall reduction from the 1990s prevalence followed the 
introduction o f insecticide treated nets (ITN) scale up and a policy shift from SP to 
artemisinin based combination therapy (Amin etal., 2007). Parasite prevalence within 
the KEMRICDC HDSS is not uniform, with recent reports showing that the 5-14 year 
age category has the highest parasite prevalence o f 58% compared to the <5 years and 
the >15 years (KEMRI CDC unpublished data, referenced in (Desai et al., 2014)). 
According to a model-based map (Noor et al., 2009), P. falciparum malaria 
transmission in Asembo is among the highest in the country, with parasite prevalence 
recorded at >40% in children aged 2-10 years. However, such surveys use rapid 
diagnostic tests (RDTs) for the diagnosis of malaria, which has the potential to 
overestimate the malaria positive rate, as reported by Aydin-Schmidt and colleagues 
(Aydin-Schmidt et al., 2013). This is because RDTs target the parasite antigen 
histidine rich protein 2 (HRP2), which persists in the blood even after successful 
treatment. RDTs are often favoured for malaria surveys because they are logistically 
easier to deploy. However, recent data has shown that polymerase chain reaction 
(PCR) based methods have the ability to detect parasites at much lower levels than 
those detected by microscopy or RDT (Kipanga et al., 2014), while avoiding the false 
positive rates associated with persisting parasite antigens in some RDT methods.
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1.2.4.8 Aims and objectives of the hum an genetic study in Asembo, western 
Kenya
Through this thesis, I aim to investigate the epidemiology of malaria in a birth and age 
cohort of children stratified by genetic polymorphisms including the HbAS, G6PD 
deficiency, CR1 and a-thalassaemia. These polymorphisms are expected to exist at 
high frequencies in the study area since previous studies conducted locally found 
frequencies o f 17% for HbAS (Aidoo et al., 2002), 44% for a+thalassaemia 
heterozygotes (Kifude & Waitumbi, 2007) and 10% for G6PD deficiency (A-) (Hunja, 
2006). The CR1 genotypes associated with protection, Swain Langley 2/2 and McCoy 
a/b were each found at 45% frequency (Thathy et al., 2005). ABO blood groups will 
also be typed as possible confounders in malaria association analyses. In addition, the 
effect of co-inheritance o f these genes, which is rarely analysed in such genetic 
epidemiology studies, will be investigated. Other genes involved in malaria protection 
will also be investigated by typing for Single Nucleotide Polymorphisms (SNPs) in 34 
malaria candidate genes (see Appendix III).
The specific objectives o f this thesis are:
i) To describe the epidemiology o f malaria in comparison with common
infectious childhood illnesses in Asembo, western Kenya.
ii) To investigate the effect o f haemoglobinopathies (HbAS, G6PD
deficiency, a-thalassaemia) and common red blood cell polymorphisms 
(ABO, SI and McC blood groups) on malaria incidence.
iii) To investigate the effect o f polymorphisms in 34 additional malaria
candidate genes on malaria incidence.
iv) To show the effect o f interactions between genes on malaria incidence.
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The proceeding chapters describe the methods used and gives results from 
investigations o f each o f these objectives. These chapters are therefore organized as 
follows:
Chapter 2 outlines the materials and methods employed for the above investigations.
Chapter 3 describes the epidemiology o f malaria in Asembo, western Kenya, in the 
context o f other infectious disease syndromes detected in the area.
Chapter 4 investigates the effect o f red blood cell polymorphisms on malaria 
incidence.
Chapter 5 investigates the effect o f polymorphisms in 34 additional malaria candidate 
genes on malaria.
Chapter 6 investigates possible interactions between genes and their effect on malaria 
incidence.
Chapter 7 presents a discussion and conclusion of findings from the above 
investigations and suggests future directions for further work.
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CHAPTER 2: Materials and Methods
2.1 Study site
The study was conducted in Asembo, part of the Rarieda Sub-County of Siaya County. 
Asembo borders Lake Victoria to the West, and covers an area o f approximately 225 
km2. The population is culturally and ethnically homogenous, more than 95% being of 
the Luo ethnic group and living in dispersed rural settlements (Adazu et al., 2005). 
The main economic activities are agriculture, fishing and small-scale businesses. The 
Sub-County is one of the poorest in Kenya, 70% of the population living on <1 USD 
/ day (Bigogo et a l, 2010).
The Asembo area is one o f the areas covered by a Health and Demographic 
Surveillance System (HDSS) that has been run by the Kenya Medical Research 
Institute (KEMRI) and Centres for Disease Control and Prevention (CDC) since 2001 
(Figure 2.1). Within the Asembo HDSS area, the International Emerging Infections 
Program (IEIP) established an infectious disease surveillance system in 2005. The 
study participants for the current study were drawn from this surveillance area. The 
IEIP surveillance system is described in further detail in section 2.3 below.
2.2 Study population
The study population is predominantly of the Luo ethnic group. The Luo are classified
linguistically as Nilotes, and further sub-classified as River-Lake Nilotes because o f
their historically intimate association with rivers and with Lake Victoria. Originating
from Sudan, a historically malaria endemic area, their migratory path along the river
Nile and subsequent settlement on the shores o f Lake Victoria in East Africa (Ogot,
1967) implies exposure to malaria in the lowlands for several millennia. In the absence
31
of aggressive and large-scale interventions against malaria except in the last century, 
the only survival advantage against malaria in this community is likely to be related to 
their behaviour or to human genetic factors that confer protection from malaria. 
Enrichment for frequencies o f such factors would thus be expected among the Luo and 
as such, they are an excellent group to study for malaria-protective genetic factors.
2.3 International Emerging Infections Program (IEIP) on surveillance.
The IEIP has a programme o f surveillance called PBIDS (Population Based Infectious 
Disease Surveillance), embedded within the KEMRI/CDC Health and Demographic 
Surveillance System (HDSS) (see figure 2.1). It is in the Asembo area o f the HDSS, 
and covers an area o f approximately 100km2 in villages within a 5km radius o f Lwak 
Mission hospital (Figure 2.2).
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Figure 2. 1 The Asembo study areas in relation to Nyanza Province and Kenya.
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Map adapted from Amek and colleagues (Amek et al., 2012).
Figure 2. 2 Map of IEIP area of Asembo, part of the KEMRI/CDC HDSS
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Adapted from (Bigogo et al., 2010). The brown area is the IEIP surveillance area, whereas the yellow area is the 
HDSS area that is outside the IEIP.
33
PBIDS is mainly focussed on three infectious disease syndromes, namely acute 
respiratory infections, diarrhoeal diseases, and febrile illnesses. The catchment 
population included in PBIDS includes 33 villages in which at least 50% of the 
population live within a 5 km radius of Lwak Mission Hospital, the designated referral 
health facility. For a participant to be eligible for inclusion in the PBIDS, they had to 
be registered as residents o f the HDSS run by KEMRI and CDC. HDSS residency is 
defined as being resident in the area for 4 continuous months i.e. not having moved 
from the study area for the previous 4 months.
Such surveillance may give useful data on disease syndromes in the area. An example 
is that home surveillance records between 2006 and 2008 indicated that health seeking 
for symptoms such as fever, diarrhoea and respiratory illness among children under-5 
years ranged from 14-20% (Bigogo et al., 2010).
2.3.1 Syndromic health and morbidity surveillance
As part of the main PBIDS platform, study participants are visited in their homes every 
two weeks and are interviewed to determine whether they are suffering from any one 
o f a range o f syndromes including respiratory illnesses, diarrhoea and fever. Those 
presenting with such symptoms are referred to Lwak Mission Hospital, where 
treatment is offered free o f charge. The syndrome definitions used in the household 
visits are summarised in Table 2.1 below.
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Table 2 .1  Definitions of syndromes used in the home morbidity surveillance 
conducted every two weeks.
Syndrome Definition
Febrile illness Illness in which subjective or 
documented fever was reported.
Diarrhoeal illness An illness in which at least three looser 
than normal stools were reported during 
a 24-h period.
Acute Respiratory Illness (ARI) Presence o f a cough or difficulty in 
breathing.
Acute Lower Respiratory Illness (ALRI) Presence o f cough or difficulty in
in children: breathing and either elevated respiratory 
rate for age or chest in-drawing on exam 
by trained field workers.
Acute Lower Respiratory Illness (ALRI) Presence o f subjective or documented
in adults fever with cough, difficulty in breathing, 
or chest pain.
2.3.2 Passive clinic surveillance
Participants from within the study area are seen during inter-current episodes o f illness 
at the designated surveillance hospital, the Lwak Mission Hospital. Details o f the 
clinical procedures performed at the hospital have been published previously (Feikin 
et a l, 2011). Briefly, vital signs and symptoms are recorded by trained health facility 
recorders or nurses. These include axillary temperatures, respiratory rates (measured 
for 1 minute using an audible countdown timer) and oxygen saturation (measured 
using a fingertip pulse oximeter: NONIN Medical, Minnesota).
Blood smears are prepared for malaria diagnosis on participants presenting with a 
history of fever or who have a documented axillary temperature o f >=38°C. Qualitative
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slide reading is done at the hospital to facilitate malaria case management. As such 
slides are declared either positive or negative and no quantitative malaria slide reading 
is done on routine visits. For particular ALRI patients who meet clinical indications, 
combined nasopharyngeal and oropharyngeal swabs are taken for PCR. Stool and 
blood samples are also collected for culture from patients meeting specific clinical 
indications. Structured questionnaires are used by clinicians to record details of 
sickness episodes including demographic data, case history and a summary o f any 
drugs that may have been taken prior to the hospital visit. Between 2006 and 2013, 
scan-able paper forms (TeleForm® software, Cardiff ™, Vista, CA) were used at 
Lwak to record clinical details (See Appendix VII). However, a patient care system 
was adopted in 2013 in which data are entered directly into a custom-designed 
computerized system with internal quality control checks.
2.4 Hum an genetic factors and childhood disease study 
Through this study I aimed to investigate the following questions:
• Does the incidence of malaria and other childhood infections differ across 
children of different genotypes?
• Do interactions between different genotypes affect the incidence rate o f 
malaria and other childhood diseases?
The study design that was best suited to capture rates o f malaria was a longitudinal 
cohort study, since the cohort may then be stratified into genotypes to give the 
genotype-specific rates o f malarial and common childhood illness. This was satisfied 
by having a birth cohort which would allow observation o f episodes from the youngest 
age, whereas an age cohort involving individuals o f a wider age range allowing 
stratification over wider age bands. The final cohort recruited therefore consisted of
individuals followed up since birth, referred to as the birth cohort and older individuals 
who had follow-up data available since the year 2008, referred to as an age cohort.
My study was therefore conducted in a sequence o f four steps as follows:
(i) Recruitment o f study participants.
(ii) Genotyping for different malaria candidate genes.
(iii) Follow up for malarial and other childhood disease events.
(iv) Analysis for the effect o f genotype on the incidence of disease events.
Since a parasitological case definition o f clinical malaria was required, a cross 
sectional survey involving members o f both cohorts was conducted in June-August 
2013.
The design of my study is summarised in Figure 2.3 below.
37
Figure 2. 3 Schematic summary of the study design.
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Schematic representation o f  the study design. The sampling frame was the emerging infections program hospital 
and surveillance study. From among members o f  the hospital and home surveillance study, a genetic birth cohort 
was recruited prospectively from February 2012 to December 2013. A genetic age cohort consisting o f  siblings o f  
the birth cohort members was recruited in June 2013 to August 2013. The age cohort had two components o f  
surveillance information: a prospective component (red forward arrow) and a retrospective component (green 
backward arrow). A nested cross sectional survey was conducted among birth cohort and sibling members between 
June-August 2013.
The major programme was the IEIP study as described in section 2.3 above. The
genetic cohort was nested within this programme. It consisted of members followed
since birth from February 2012 to December 2013, and a wider variety o f ages, termed
an age cohort, which was recruited from among the members of the IEIP health and
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morbidity surveillance during a cross-sectional survey conducted between June- 
August 2013. In effect, the data for this study came from the morbidity surveillance, 
the prospective birth cohort, the cross-sectional survey and the retrospective and 
prospective age cohort.
The availability o f a population-based health and morbidity surveillance system in a 
population with stable year-round malaria transmission provided me with an excellent 
opportunity to study the effect o f human genetic factors on the incidence o f malaria 
and common childhood illnesses.
2. 4.1 Preparation for the study
Before the study could be initiated, I held a number o f meetings to assess the feasibility 
o f the study in the area. These included securing support for the study within the HDSS 
and enlisting the support o f key investigators who were already participating in the 
health and morbidity surveillance study. These discussions allowed me to develop a 
protocol detailing the study including the background, aims, study objectives, 
justification, required budgetary resources, coordination plans, data management, 
genotyping, data analysis and a publication plan. I then developed a protocol for 
submission to relevant Scientific and Ethical committees. I was primarily responsible 
for correspondence between the investigation team and the Scientific and Ethical 
Committees - copies o f these communications are presented in Appendix V.
A series o f meetings were held with influential community members including
political and religious leaders and workers within the community as follows: meeting
the chiefs and provincial administration, Community Advisory Board (CAB), opinion
leaders, village reporters and community interviewers. During these meetings, I
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presented the aims o f the study, the participation o f the community, benefits and risks 
of the study. I received feedback from community members on whether they thought 
the study would be beneficial to the community and suggestions on how best to 
conduct the study to mutually benefit the study team and the community.
The study protocol was approved by the KEMRI Scientific Steering Committee in 
October 2011. Study staff with desired skills in informed consenting, sample 
collection, laboratory sample processing and reporting were recruited. A number of 
staff were shared with the main morbidity study, in which case a time sharing 
agreement was entered into to allow both this genetic study and the main cohort study 
to proceed concurrently. I trained the study team members according to the protocol 
and sub protocols regarding the particular procedures in which they would be involved.
Consent forms explaining the purpose o f the study, the risks and benefits were 
prepared in English and then translated into the local languages, Dholuo and Kiswahili. 
A sample is found in Appendix I. Having prepared the site for the study, recruitment 
began in February 2012. The major study procedures, including recruitment, 
genotyping, follow-up and analysis are explained in further detail below.
2.4.2 Recruitment
2.4.2.1 Prospective birth cohort
The birth cohort study targeted all children born within the health and morbidity 
surveillance area of the Asembo HDSS between 22nd February 2012 and 31st 
December 2013. The mothers or guardians o f these children were approached with a 
view to recruitment into the study. The objective o f the study was explained and where
40
families were willing informed consent was sought. Eligibility was determined 
according to the following inclusion and exclusion criteria.
(a) Inclusion criteria
The study included all children who fulfilled the following inclusion criteria:
(i) All children bom to mothers participating in the HDSS and IEIP population 
study.
(ii) Bom between 22nd February 2012 and 31st December 2013.
(iii) Less than 6 months old at the time o f recruitment.
(iv) Consent obtained from one or both parents or a legal guardian.
(b) Exclusion criteria
(i) Refusal to participate in the study.
(ii) Those who had not enrolled in the IEIP/HDSS study.
(iii) Bom before the commencement of the study.
(iv) Bom before 22nd February 2012 or after 31st December 2013.
2.4.2.2 Age cohort of siblings
The effect o f age on the incidence of malaria was also a key factor under investigation. 
While it would be possible to capture age-specific events during the first 2 years o f 
life within the birth cohort, this cohort alone would not have allowed me to investigate 
the genotype-specific incidence of malaria over a wider age range. To complement 
age effects investigated in the birth cohort, an age cohort covering a wider age range 
was recruited. Since the age-specific incidence o f malaria is a proxy for naturally
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acquired immunity (NAI), the upper age limit o f 12 years was chosen as an 
approximate age by which NAI would be presumed to have developed.
I considered a number o f approaches to the recruitment o f an age cohort covering the 
age range 0-12 years, including:
• Inviting all children in the HDSS <12 years of age.
• Recruitment o f older children for each birth cohort member recruited, matched 
by area.
• Recruitment of siblings of birth cohort members under the age o f 12 years.
The approach chosen would have to be the best for effective control o f confounding. 
In genetic predisposition analyses, confounding would come from two sources; 
environmental factors and genetic factors. The best method would be one that 
minimizes the confounding which arises from these sources. Environmental factors 
may best be controlled by grouping participants who share a common environment in 
a scale as small as possible. The unit o f analysis in HDSS settings is commonly the 
household, where members share the same socio economic status including sanitation 
facilities, income and food among other factors, which are likely to be related with the 
risk o f illness. Genetic factors may be controlled for in the analysis if  a measure o f 
genetic relatedness among individuals is used. A random sample drawn from the study 
area would have related individuals by chance, and getting measures of genetic relation 
between individuals would be a complex task. However, it is known that siblings 
would share approximately 1/2 of their genes, first cousins about 1/4 o f their genes, 
second cousins 1/8 and so on. Since the study was conducted in a small area (within 
5km radius o f Lwak hospital) o f a typical rural setting where related individuals are 
found within short distances, failure to adjust for genetic relatedness would potentially
overestimate or underestimate effect sizes seen. From the foregoing, a sibling cohort 
would be the best approach because it allows for effective control for environmental 
confounding by having members from the same household, and control for genetic 
confounding since relationships between siblings would be explicitly captured at 
recruitment.
This sibling recruitment approach also had practical benefits in the field as it was easier 
to recruit siblings since their parents had been taken through the study procedures and 
were more likely to welcome the study team to conduct sibling sampling. In addition, 
overall, pooling of the samples o f children from the younger ages and older siblings 
would allow the final cohort to attain the power required to detect small effects of 
genes on malaria incidence. The sampling frame for the sibling cohort was the same 
as that for the cohort studies, i.e. the Asembo area population within a 5km radius of 
Lwak hospital and who are already enrolled in the PBIDS study.
Sibling recruitment
Siblings of birth cohort children were recruited during the June-August malaria 
transmission season of 2013. This was done in the context o f malaria cross sectional 
survey. The same inclusion and exclusion criteria as those for recruiting the birth 
cohort members as described above were applied for the siblings with the major 
difference being that the siblings had to be 12 years o f age or less at the time o f cross 
sectional survey. Genotyping and disease surveillance follow up was also done for the 
siblings. The cross-sectional survey is described in more detail below.
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2.5. C ross-sectional genetic and m alaria survey
2.5.1 Justification
As described in section 1.2.4.8 above, one o f my principal aims in this study was to 
investigate the age- and genotype-specific incidence o f malaria among children with a 
range of inherited red blood cell disorders through a cohort study o f children living 
within the Asembo area. A cross-sectional survey was complementary to these 
objectives, as it would (i) show the parasite prevalence in the area and (ii) assist in 
determining the case definition o f malaria through a comparison o f symptom, fever 
survey and parasite densities. I therefore conducted a cross-sectional survey of all 
enrolled and genotyped cohort members to investigate the prevalence and density o f 
malaria parasites along with clinical data on fever.
2.5.2 Conduct of the cross sectional survey: June-August 2013
Scientific and ethical permission were sought from the KEMRI Scientific Steering 
Committee (SSC) and Ethics Review Committee (ERC) respectively. Once these were 
secured, I developed a community entry strategy through meetings with the provincial 
administration and chiefs, followed by meetings with religious leaders and opinion 
leaders, the community advisory board and finally some o f the study workers including 
village reporters and community interviewers.
Parents o f all eligible children were approached in their homes by village reporters and
community interviewers and given basic information concerning the study. They were
also given invitation cards for each eligible child to come to Lwak hospital on
particular days within the survey period. Heeding to the invitation was voluntary. On
the designated days between June and August 2013, parents accompanied their
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children to Lwak hospital to learn more about the study and if convinced of its’ 
benefits, enrol for the study. On arrival at Lwak hospital, study staff confirmed the 
eligibility o f study participants by checking against a register o f all targeted index 
children and their siblings. Among the eligible members, study staff explained the 
rationale o f the study, i.e. to investigate the link between malaria infection and a range 
o f specific genetic variants.
Each parent who agreed to participate in the study gave written informed consent for 
participation in the study by signing the informed consent forms. After consenting, 
parents o f the children answered a questionnaire on malaria risk factors separately for 
each child to distinguish unique risk-factors which may predispose particular children 
to malaria more than others. Temperature measurements were then taken for each child 
to record the temperature on the day of the survey, compared to reports o f fever during 
the week. Thermoscan™ digital thermometers were used to record axillary 
temperatures.
A blood sample was collected using a finger prick procedure for children >1 year o f 
age and heel prick for those children <1 year old. Thick and thin malaria blood films 
were made for diagnosis of malaria by microscopy. The malaria slides were then left 
for air-drying before staining with 10% Giemsa stain. Due to logistical constraints, 
slides were not read immediately but stored appropriately for speciation and parasite 
density readings. Slides were examined at xlOOO magnification for asexual P. 
falciparum parasites. 100 fields were examined before slides could be considered 
negative.
45
During the cross sectional survey, the diagnostic test used for case management was a 
rapid diagnostic test (RDT) Carestart™ PfHRP2 (American Access Bio Company) 
kit. In addition, dry blood spots (DBS) were collected as a back up to the whole blood 
collected from each individual.
All children found with RDT positive results were treated with a combination of 
Artemether and Lumefantrine (AL), the first line treatment for uncomplicated malaria 
in Kenya. Dosage o f AL was based on the weight o f the child for maximum 
effectiveness. Weighing of children was done to confirm the weight o f the child before 
administration of AL. In accordance with World Health Organization and National 
guidelines, the administration o f the AL was done in Lwak hospital and the child 
observed to confirm that they took the first dose. For those who vomited within 30 
minutes, a repeat administration was done to ensure the correct dose of the drug was 
taken. Their parents were also advised to monitor them for vomiting o f dosages taken 
at home, in which case they would re-administer the drug.
During the cross sectional survey only siblings had an EDTA sample o f about 200pl 
collected from the finger prick for genotyping for red cell genetics and other malaria 
susceptibility genes. EDTA samples were not collected for index children as these had 
already been collected earlier for genotyping and ABO blood grouping by serology. 
Serological typing for ABO blood groups was additionally done for siblings. During 
the survey period, the samples were kept in -20°C freezers awaiting full genotyping 
later in the study before being transported to the KEMRI/CDC Kisian laboratories. 
Stained slides were kept in slide boxes pending later reading at the KEMRI Centre for 
Geographic Medicine Research-Coast (CGMRC) in Kilifi.
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2.6 Surveillance for clinical m alaria episodes in the longitudinal cohort study
Surveillance for clinical malaria episodes during the cohort follow-up was done 
through the IEIP system as described above in section 2.3.2.
2.6.1 Case definition of m alaria in the cohort study
Malaria may either be uncomplicated or complicated. Uncomplicated malaria is 
defined as symptomatic infection with malaria parasitaemia but without signs of 
severity. Severity may or may not include vital organ dysfunction (WHO, 2010). 
Complicated malaria, also described as severe malaria refers to syndromes o f malaria 
that cannot be explained by other aetiologies in a child positive for malaria slides. 
These include severe anaemia, respiratory distress and cerebral malaria (WHO, 2000), 
as described in section 1.2.3.2.2 above. Since fevers are common in endemic areas, 
parasite density above a certain threshold would be required for a more specific 
diagnosis o f malaria. During the cohort follow-up in Lwak hospital, data were 
available regarding Giemsa-stained blood-slide positivity, inability to breastfeed, 
lethargy and convulsion, difficulty in breathing and data on a comma scale, the AVPU 
response scale, in which the letters refer to whether the patient is Alert, responds to 
Voice, responds to Pain or is Unconscious. From these data, a pragmatic case 
definition o f malaria was adopted as follows.
Uncomplicated malaria was defined as fever in the presence of a asexual parasite 
positive Giemsa-stained slide, in a child who wafr not admitted to hospital, was alert 
(A) or responding to voice (V) on the AVPU scale, who lacked any o f the severe 
symptoms listed above and did not have an alternative bacterial cause for their fever.
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Complicated malaria was defined as fever in the presence o f a malaria-positive blood 
film in a child admitted to hospital or referred for care who also presented with severe 
disease symptoms such as inability to breastfeed, convulsions, difficulty in breathing 
or unconsciousness (U) on the AVPU scale. Table 2.2 below gives the definition for 
uncomplicated and severe malaria that were used in the current study, as derived from 
the WHO definitions.
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Table 2. 2 Data available from the Lwak hospital IEIP clinic surveillance 
corresponding to WHO definition o f uncomplicated and severe malaria.
Case definition 
used
WHO definition 
uncomplicated 
malaria (WHO, 
2010)
WHO severe malaria 
definition (World 
Health Organization, 
2000)
Data available in Lwak 
hospital questionnaire (ref 
Appendix)
Fever or history of 
fever in last 48 
hours
Fever Symptoms include 
headache, lassitude, 
fatigue, abdominal 
discomfort,
and muscle and joint 
aches, usually followed 
by fever, chills, 
perspiration, anorexia,
vomiting and worsening 
malaise (WHO, 2010)
Q. 3.1.0 presenting with 
fever
Q 5.4 history of fever
Q 6.0 Case definition of 
fever met
Blood film positive 
for malaria 
parasites
Blood film 
positive on 10% 
Giemsa stain
Parasite species 
identification
Lacks any of the 
severe signs of 
vital organ 
function below
P. falciparum asexual 
parasitaemia
Any one or more of 
these severe 
malaria syndromes
Has any of the severe 
signs identified below
Prostration
Impaired consciousness
6.3b Giemsa stain results 
(Positive/N egative)
6.3c Parasite species?
See below for questionnaire 
indications
Q. 5.1a Able to breastfeed 
(Yes/No)
Q 5.13 Unconscious 
(Yes/No)
Respiratory distress Q 5.2 Difficult breathing 
(Yes/No)
Multiple convulsions Q5.14 Convulsion or 
History of convulsion 
(Yes/No)
Severe anaemia 5.33 Clinical signs of
anaemia e.g. paleness of 
palms, nail bed or 
conjunctiva (Yes/No)
6.1 Haemoglobin g/dl
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2.6.2 Definition o f other childhood infectious disease syndromes
Definitions o f syndromes used were adapted from the IEIP as follows.
Respiratory illness was defined for those <5 years as cough or difficulty 
breathing and one o f the following: convulsions, unable to drink fluids or 
unable to breastfeed, lethargic, chest in drawing, vomiting everything, stridor, 
oxygen saturation <90%; and for persons >5 years old as cough or difficulty 
breathing or chest pain and one of the following: temperature >38°C and 
oxygen saturation <90%.
Non malarial fever: documented axillary temperature >38°C without an 
obvious cause, defined as cough, difficulty breathing, chest pain, signs of 
meningitis, or bloody diarrhoea. Presenting with symptom o f fever together 
with no diagnosis o f malaria and a slide negative for malaria parasites by the 
Giemsa stain.
Diarrhoea or gastroenteritis: Those with a diagnosis or discharge diagnosis of 
diarrhoea or gastroenteritis or dysentery. Diarrhoea was defined as at least 3 
looser than normal stools reported in a 24 hour period (Feikin et a l , 2011).
2.7 Host genotyping
Recruitment blood samples from all cohort members were typed for a range o f 
candidate malaria-associated genes by a variety o f methods.
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H aem oglobin  phenotyping
Haemoglobin (Hb) typing for normal (HbAA), carrier (HbAS) or sickle cell anaemia 
(HbSS) status was done by cellulose acetate electrophoresis using the Helena systems 
kit according to the manufacturer’s instructions (Laboratories). Briefly, 
electrophoresis consisted o f a lane with a mix o f controls for normal haemoglobin 
(HbA), foetal haemoglobin (HbF) sickle haemoglobin (HbS) and haemoglobin C 
(HbC), which was run alongside sample lanes. On completion o f the electrophoresis 
run, sample bands corresponding to the control band positions for haemoglobin A, F, 
S, C were interpreted as either A, F, S or C. It was then possible to have phenotypes 
as AA, FF, SS, CC, AF, AS, AC, FS, FC, SC as follows:
Table 2. 3 Interpretation of results for haemoglobin electrophoresis.
Sample band corresponding to control 
band a t position
Phenotype
A only H bA A
F only Hb FF
S only H bSS
C only Hb CC
A and F Hb AF
A and S Hb AS
A and C Hb AC
F a n d S Hb FS
F and C Hb FC
S and C Hb SC
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ABO phenotyping
To type each sample for ABO blood groups, 3 separate drops o f whole blood were 
dropped onto a microscopy slide. Using a dropper, drops of antisera for blood group 
A, B and Rhesus blood group were used to spot the blood drops in turn. Blood was 
mixed with antisera using a rod and the slides were checked for agglutination and 
interpreted as per table 2.4 below.
Table 2.4. Serological phenotyping for the ABO blood groups.
Reaction with anti sera Interpretation
A Blood group A
B Blood group B
A and B Blood group AB
D Rhesus positive +
No reaction with either anti 
A or anti B Blood group 0
It was then possible to discern Rhesus positive blood groups A+, B+, AB+, 0 +  or 
Rhesus negative blood groups A-, B-, AB- and 0 -.
2.6.1 DNA-based genotyping for o ther candidate genes
Molecular DNA based methods were used to confirm phenotypes for haemoglobin
electrophoresis and ABO blood groups. CR1, G6PD deficiency and 59 additional
SNPs chosen from a review o f literature for malaria candidate genes by the malaria
genetic epidemiology network, MalariaGEN (http://www.malariagen.net/). were also
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typed using molecular methods. These SNPs, which are in immunity and inflammation 
genes, cytokine genes, red blood cell conformation and metabolism genes among 
others, are listed in full in Appendix III.
2.6.1.1 DNA extraction
With the help o f colleagues in the laboratories at the KEMRI-CDC Programme in 
Kisumu, and the KEMRI-Wellcome Trust Programme in Kilifi, I extracted genomic 
DNA from whole blood using the QIAamp DNA Blood Mini Kit (Qiagen) according 
to manufacturer’s instructions. DBS samples from the same individuals which had 
been collected were used as a back-up sample to allow re-extraction in case the whole 
blood sample was damaged. The whole blood sample extraction is briefly described. 
20pL of proteinase K was pipetted into a micro centrifuge tube. 200pL o f whole blood 
was then added to the tube. Where the sample was less than 200pL it was topped up 
to a volume of200pL using phosphate buffered saline (PBS). 200pL o f buffer AL was 
then added to the sample, and pulse vortexing used to mix the sample for 15 seconds. 
The mixture was incubated at 56°C for 10 minutes to allow lysis o f cells to release 
DNA into the mixture. The tube was then centrifuged to remove drops from the inside 
o f the lid. DNA was precipitated by adding 200pL o f ethanol (96-100%) to the micro­
centrifuge tube. Pulse vortexing was done for 15 seconds to allow thorough 
precipitation and the tube was spun briefly to remove drops from the inside o f the lid. 
The mixture containing the precipitate was then pipetted onto a spin column with a 
collection tube underneath. It was centrifuged at 6000g (8000 revolutions per minute 
(rpm)) for 1 minute to allow the DNA to be trapped in the spin column and the rest of 
the mixture to be collected into the collection tube. The collection tube containing the 
non-DNA mixture was then discarded and the spin column washed twice with wash
buffer 1 (AW1) and wash buffer 2 (AW2) respectively to further purify the DNA.
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Wash 1 was done by adding the wash buffer (AW1) to the spin column and 
centrifuging at 8000rpm for 1 minute before placing the spin column in a new 
collection tube. Wash 2 was done by adding the wash buffer (AW2) to the spin column 
and centrifuging at 20,000g (14,000rpm) for 3 minutes. After the wash steps above, 
the spin column was placed onto a 1.5ml micro-centrifuge tube. DNA was eluted from 
the spin column by adding 200pL o f the elution buffer (Buffer AE, or distilled water). 
The spin column was incubated for 1 minute at room temperature (23-25°C) and then 
centrifuged at 6000g (8000rpm) for 1 minute. The spin column was discarded and the 
eluted DNA in the micro-centrifuge tube was then stored for further DNA analysis. In 
order to type for SNPs using multiplex technology, DNA was shipped frozen to 
Oxford, where the remaining genotyping was conducted by collaborators.
2.6.1.2 Typing for the a+thalassaemia deletion
The 3.7kb gene deletion in the a-globin gene resulting in a+thalassaemia was typed 
separately by a specific PCR reaction (Chong et a l , 2000). A Qiagen PCR kit was 
used to make a PCR master mix volume of 10.05 pL per reaction, consisting o f 2pL o f 
RNase free water, 2pL o f 5X Q-Solution, 3 pL o f 2X fast cycling PCR master mix, 1 
pL o f 10X Coral load cycling dye and ofthalassaemia specific primers (10 pM) as 
follows: 0.375 pL of Primer 376, 0.375 pL of Primer 377, 0.1 pL o f primer 378, 0.6 
pL o f LIS1-F and 0.1 pL o f LIS1-R.
The primer sequences were as below:
Primer LIS I F  (GTCGTCACTGGCAGCGTAGATC)
Primer LIS 1 -R (GATTCCAGGTTGTAGACGGACTG)
376 (a2F, -3.7F) (CCCCTCGCCAAGTCCACCC)
54
378 (a2R) (AGACCAGGAAGGGCCGGTG)
377 (-3.7R) (AAAGCACTCTAGGGTCCAGCG)
The master mix was plated into wells containing 2pL of control (homozygous 
a+thalassaemia control, heterozygous control, normal control and a no template 
control) or sample DNA. The plate was carefully capped and cycling was done 
according to the following profile: 95°C 5:00 min, 30 cycles of (97°C 0:45 min, 60°C 
1:15 min, 72°C 2:30 min) and a final extension o f 72°C for 5:00 min. After PCR, 2 pL 
o f the amplicon was run on a 1% agarose gel at 95 V for 2hours and 30minutes. The 
gel was then exposed to an ultraviolet ray trans-illuminator (GelDoc), where a single 
1.8Kb band was interpreted as aa /aa  (normal), a 2.1 Kb band was interpreted as '3 7a/' 
3 7a  (homozygote) and two bands consisting of 2.1Kb and 1.8Kb was interpreted as aa  
A3,7a  (heterozygote).
2.6.1.3 Sequenom Mass A rray™  genotyping
At the Wellcome Trust Centre for Human Genetics (WTCHG), Sequenom Mass 
Array™ genotyping was used to confirm genotypes for sickle and ABO blood groups 
and to assay for a total o f 65 SNPs in malaria candidate genes as follows. Genomic 
DNA samples were used to conduct whole genome amplification using the primer 
extension pre-amplification technique as described by Zhang and colleagues (Zhang 
et a l, 1992). The whole genome amplicons were then genotyped using the Sequenom 
Mass Array™ genotyping platform (P. Ross et a l, 1998; Wilson et a l,  2005). The 
platform consists o f specific PCR amplification using sets o f primers, which are able 
to distinguish between different SNPs since the size or base composition o f the 
amplicon is different according to the SNP present. Mass spectrometry o f the PCR
products allows the resolution o f the mass of the PCR product, decoding the masses 
of particular bases. Each mass window is unique to a particular primer’s target 
amplicon. It is therefore possible to have a multiplex system where several targets are 
amplified as long as the mass windows of their amplicons are different. Different mass 
windows are assured by two methods, either having different lengths o f amplicons or 
using different base composition of amplicons. A more detailed description o f the 
method is included in Appendix IV.
2.7 Statistical analyses
The incidence of malaria over time was assumed to follow a Poisson distribution, as 
previously published (Williams, Mwangi, Roberts, et a l, 2005). A univariate model 
predicting malaria incidence by genotype was fitted for the 65 SNPs assayed and for 
oCthalassaemia genotypes. All genotypes which had P<0.1 in the univariate model 
were fitted in a multivariate model to predict malaria incidence. The multivariate 
model in addition to adjusting for effects o f other genes adjusted for covariates o f 
malaria including age, gender, socio-economic status (SES), mothers/household 
head’s education level, year, season and distance to Lwak hospital. The estimates were 
also adjusted for clustering by household and genetic relationship using sib-ship 
information. Estimates were further refined using the sandwich estimator (Armitage 
P, 2001), which inflates confidence intervals to account for correlation between 
observations events on the same child.
Variable descriptions
Gender: A categorical variable consisting o f 2 levels, male or female.
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Age: A continuous variable, converted to categorical age bands o f 3 months up to 2 
years, and 2 year age bands up to 10 years of age.
Mothers’ or household head’s education level: This was a categorical variable which 
could be; no education, primary, secondary or post-secondary.
Distance to Lwak hospital: The straight line distance from the participants household 
to Lwak hospital, calculated using geographical coordinates of the household and the 
hospital.
Socio-economic status: Defined in wealth quintiles with 1 being the most poor and 5 
being the least poor.
Season: A binary categorical variable, with high season being during the long rains 
and low season being during the dry season and short rains.
Testing for interactions: I used the likelihood ratio method to compare Poisson 
models with and without interaction terms to test for interactions between exposure 
variables including genetic polymorphisms. Where multiple SNPs were tested (see 
Chapter 5), the p-value for significance was adjusted using the Bonferroni correction 
method.
M odel of inheritance
An additive model o f inheritance was assumed for these analyses. This model performs 
well in detecting effects o f SNPs that are inherited in an additive or co-dominant 
fashion. However, this model does not maximize power for those genes where 
recessive effects contribute to the disease being studied (Lettre et a l , 2007).
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CHAPTER 3: The epidemiology of malaria and other 
childhood infectious syndromes in Asembo
In this chapter I present a summary o f the epidemiology of malaria and o f other 
common diseases o f childhood within the context o f my cohort study. Epidemiological 
risk factors predicting malaria incidence were investigated using two approaches, a 
longitudinal approach and a cross sectional survey. The risk factors investigated 
included demographic, seasonal, socio-economic and health seeking behaviour. In the 
longitudinal approach, since the disease rates presented here were calculated from data 
collected in Lwak hospital, the rate o f health seeking for potential malaria fevers was 
investigated and the results are presented. In addition, the parasitological case 
definition for malaria was explored through a cross-sectional survey o f malaria fevers 
confirmed by blood films. The rates o f infectious syndromes such as respiratory tract 
infections, diarrhoea and non-malarial fevers are presented in comparison with the rate 
o f malaria so as to position the malaria burden in relation to other causes o f childhood 
morbidity in the area.
3.1 Objectives
The specific objectives o f this chapter are as follows:
1. To investigate the epidemiology o f malaria in children living in the IEIP area 
through a longitudinal cohort study.
2. To further investigate the epidemiology o f malaria in the same area through a cross 
sectional study.
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3. To investigate the parasite density threshold associated with malaria fever.
4. To compare the incidence o f malaria with that o f other infectious syndromes 
detected through the IEIP system.
Two approaches were used to define the epidemiological risk factors for malaria; a 
cohort approach and a cross sectional survey approach. The cohort approach was 
better suited to evaluate time changing variables such as season, calendar year and age, 
whereas the malaria cross sectional survey approach was useful in delineating specific 
factors related to malaria including bed net use, anti-malarial use and level of 
education of the household head. The following sections give determinants o f malaria 
in both cohort and cross sectional designs.
3.2 The epidemiology of malaria in the genetic cohort: Longitudinal 
study
3.2.1 Incidence o f uncomplicated malaria within the cohort
Over a period o f 6 years (January 2008- December 2013), 2431 disease episodes of
malaria were recorded in 4936.3 child years o f follow-up, resulting in a rate o f 0.49
(95% Cl 0.47-0.51) malaria episodes/child year of follow up (cyfu). The cohort
consisted o f 1462 children, index children were 659 and siblings were 803. The
calculation of person time discounted the loss o f follow up time due to being away
from the study area. Two considerations were used to determine time away: residency
in the area and the time to malaria symptoms once infected. Residency was defined
as being present during HDSS census rounds every 4 months. Only those who had an
exit event were noted, as such the absence o f an exit event from the HDSS indicated
the presence o f the individual during the census round. The second consideration; time
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to malaria symptoms while infected, would be the pre-patent (incubation) periods for 
the species o f plasmodia prevalent in the study area. The periods for the two species 
present are; 7 days for P. falciparum and 30 days for P. malariae. The time period of 
7 days was considered as too sensitive and may have resulted in an overestimation of 
the loss to follow up time, and therefore a 30 day period was chosen as defining time 
away from the study area.
Since the current study had access to both HDSS follow-up data (every 4 months) and 
home and morbidity surveillance data (every 2 weeks), a more stringent definition o f 
follow-up time could be made from these two data sources. For HDSS data, time away 
was defined as the difference between an exit event and an entry HDSS event. The 
same individuals were further assessed for time away using household morbidity 
surveillance (HMS) data. For HMS data, time away was defined as a difference 
between consecutive HMS interview dates o f more than 30 days, considering the 
incubation period as described above.
Among the birth cohort members, 45 individuals had 5.7 years discounted which 
consisted o f a difference between consecutive HMS visits. Among the sibling cohort 
members, 699 individuals had 224 years discounted consisting o f 43.6 years between 
an exit and entry event and 180.2 years due to differences of more than 30 days 
between consecutive HMS visits.
No follow-up time could occur after death, so the data were checked to ensure this was 
the case for all the deaths recorded. There were 18 deaths in the birth cohort and only 
1 death recorded in the age cohort. The lower number o f deaths in the age cohort
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indicates a selection bias, the survivor effect, since the sibling death events could not 
be observed among the sibling cohort members retrospectively. In summary after 
consideration of all HDSS events, including deaths, outmigration, exit and HMS loss 
o f follow-up time, the total person time accumulated was 4936.3 years. Factors likely 
to affect the rate detected include health-seeking behaviour for disease symptoms and 
the case definitions used for malaria in the hospital. Health seeking will be addressed 
in the discussion section. Malaria illness was defined as described in Table 2.2 in the 
hospital. In brief, a malaria episode was defined as a positive slide in the presence of 
fever, with accompanying symptoms such as muscle and joint aches, malaise and 
headache. This rate is lower than the rates reported in the area by the RTS, S malaria 
vaccine trials (Agnandji et al., 2012), o f about 4 episodes per child per year. Personal 
communication with the Siaya study team was used to confirm the site specific rates 
o f malaria recorded during the RTS, S study. Differences in follow up procedures 
between the current study and the RTS, S study may account for differences in the 
rates o f malaria recorded. In the RTS, S trial parents or guardians were encouraged 
were informed to look out for signs of illness and transportation was facilitated. In 
addition, all participants presenting to an RTS, S trial facility with a reported or 
documented fever during the previous 24 hours had evaluations done for malaria. In 
the current study, parents reported to health facilities at their discretion and 
transportation was not provided. In addition, not all participants with 24 hour reported 
fever had evaluations done for malaria.
The incidence of malaria by age
The incidence o f malaria was low in children <2 years, increased thereafter through to 
a peak at 2-4 years then showed a reduction in all the older age groups (Figure 3.1).
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Figure 3 .1 The incidence o f  malaria within the cohort by age.
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Children were followed from 2008-2013. Incidence data was calculated in age strata, therefore one child could 
contribute data to several age strata during the study period. The number o f  children contributing data per age strata 
are as follows: <2 years N=1454 cyfu=1691.7; 2<4 years N=845 cyfu=l 095.1; 4<6 years N=697 cyfu=915.2, 6<8 
years N=480 cyfu=692.2; 8<10 N=289, cyfu=388.4; 10< 12 N=151 cyfu=153.7 The blue bars represent the crude 
incidence, error bars represent the 95% confidence interval.
T he incidence o f m a la ria  by  ca le n d a r y e a r
Incidences of malaria by year are summarised in Table 3.1 below. The adjusted 
incidence of malaria was similar during 2008 and 2009, after which a marked increase 
was seen in 2010. After this, a significant decline was observed in 2011, with similar 
rates of malaria for the years 2011, 2012 and 2013 being observed in the cohort.
T he  effect o f season
The seasonal indicator most relevant to malaria transmission in this area is the amount
of rainfall since it affects the abundance of malaria vector breeding sites. The major
rainy season in Asembo occurs between April-July while a shorter rainy season may
occur in November or December. To study the effect of season, therefore, the months
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u n d er2yrs  2< 4yrs 4< 6yrs 6< 8yrs 8 < 1 0 y rs  10< 12yrs
throughout the year were divided into two: April to September, which includes the 
long rains season and October to March, which includes the short rains season. The 
incidence rates o f malaria in these two seasons were compared. Higher incidence of 
malaria was observed in the long rains season. Using season as a dependent variable, 
a Poisson regression model was fitted to the data to predict malaria incidence, with 
age, year and distance to hospital as covariates. The short rainy season was used as the 
reference group in the analysis. The adjusted incidence rate ratio for malaria incidence 
in the rainy season was 1.24 (95% Cl 1.14-1.35; PO.OOOl). Season is therefore an 
important variable to adjust for in further investigations o f malaria by risk factors such 
as genetics.
Effect of gender, mother’s education and socioeconomic status (SES)
Gender significantly affected the likelihood of having a malaria episode. Compared to 
boys, girls had a higher incidence of malaria, 1.17 (95% Cl 1.07-1.27; P=0.01). This 
may be due to societal values o f boys and higher health seeking behaviour for them. 
Mother’s education also had a significant effect. Compared to primary educated 
mothers, secondary educated mother’s children had a reduced incidence o f malaria, 
0.64 (95% Cl 0.56-0.73; PO.OOOl). There was no significant effect o f tertiary 
education, although the trend showed a higher incidence o f malaria. This could be due 
to the low number (n=13) of tertiary educated mothers in the sample.
Regarding socioeconomic status, less poor SES had a higher incidence o f hospital 
diagnosed malaria compared to the poorest (see table 3.1). This finding appears 
counter-intuitive since malaria is expected to affect the poor the most. However, since
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the current study was a hospital based study, this may reflect better health seeking 
among higher socioeconomic classes.
The effects of age, year, season, gender, distance to hospital, mother’s education, and 
socioeconomic status on longitudinal incidence o f malaria are summarized in Table
3.1
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Effect of distance to Lwak hospital
Since this study relied on passive case detection, I hypothesized that health seeking 
behaviour might play a major role in the rates of malaria reported. A previous study in 
the area (Bigogo et a l, 2010) showed that residents sought care at Lwak hospital for only 
10% of the fevers reported through the fortnightly home visits. Therefore, it may be 
expected that the ‘true’ incidence o f malaria that would be captured at home visits might 
be many times higher than that detected through this surveillance approach. For our study, 
we observed a malaria incidence o f 0.49 episodes per child per year, and the therefore the 
true community incidence rate might actually be as high as 4-5 episodes per child per 
year, similar to that estimated in the RTS, S trial (Agnandji et al., 2011) o f 4 to 4.5 
episodes per child per year.
Self-reported care-seeking at Lwak hospital from the home morbidity surveillance was 
analysed by a logistic regression to determine the odds o f seeking care at the hospital. 
The results are presented in Figure 3.2 below.
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Figure 3. 2 Odds of  seeking care for fever stratified by distance from the hospital.
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The blue bars represent the crude estimate o f  the odds ratio for care seeking at the hospital for different 
distances, while the error bars represent the 95% confidence interval. The reference group is the odds o f  care 
seeking for cohort members living within half a kilometre from Lwak hospital (O R=l), compared to individuals 
living in successive distances o f  500m up to 5 kilometres and over 5 kilometres from Lwak hospital.
These results show a significant difference in the odds of seeking care in Lwak between 
those who are less than 2km from the hospital, those 2-4km from the hospital and those 
4km and over from the hospital. Distance is therefore be an important factor to adjust for 
in studies investigating the incidence of disease within the study framework.
3.2.2 Incidence o f severe o r com plica ted  m a la ria
A total of 41 episodes of severe malaria were recorded within the cohort during a follow- 
up period of 4936.3 years, giving a rate of severe malaria o f 8 episodes per 1000 child 
years of follow-up. As expected the rate of severe malaria was considerably lower than 
that of uncomplicated disease. Comparison of complicated and uncomplicated disease 
shows that approximately 2% of disease episodes progressed to become severe. Since
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mild malaria cases were underestimated by a factor of 10, severe malaria cases could also 
have been underestimated by the same factor.
3.3 The epidemiology of malaria in the genetic cohort: cross-sectional 
survey
A cross-sectional survey was conducted between June 2013 and August 2013 with the 
aim o f gaining an understanding of the probability o f having malaria parasites in this 
community. A questionnaire, which included questions on factors that might possibly 
affect the probability of having malaria parasites, was designed and administered to the 
study participants (see Appendix VI).
The list o f possible risk factors investigated included:
i) Level o f education of household head.
ii) Age o f participant.
iii) Socioeconomic indicators of the household such as wall type, roof type and 
floor type.
iv) Influence of malaria control efforts such as e.g. IRS (indoor residual spraying) 
and the use of mosquito coils and spray repellent.
v) Bed-net use.
vi) Gender.
vii) Sought care or not.
viii) Anti-malaria drugs taken recently.
Complete parasitological, risk factor and genotype data was collected on a total o f 1044 
individuals. The risk o f malaria was assessed using a malaria case definition o f fever in 
the presence of a positive malaria blood film.
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Factors with a significant effect on malaria in the crude analysis included higher level of 
education of the household head, use of at least one antimalarial and seeking any sort of 
care. However, in the adjusted analysis only age (older participants at 6-8 years had a 
higher risk o f malaria compared to the youngest group o f 0-2 years) and whether the 
participant sought care remained significant. Other factors were not associated with 
protection of susceptibility to malaria. These factors included gender, bed-net quality, 
indoor residual spraying in the last 12 months and repellent use. House type indicators, 
which were used as a proxy for socio-economic indicators, did not show any effect on 
any case definition.
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3.4 Parasitological case definition of malaria
All individuals presenting for the cross-sectional survey were assessed for the presence 
o f fever or a history o f fever before a malaria blood slide was prepared. This data would 
assist in distinguishing between malarial fevers and non-malaria fevers. In endemic areas, 
asymptomatic carriage o f malarial parasites is common, and apparently healthy 
individuals may carry parasites asymptomatically. Under such circumstances, it can be 
difficult to determine whether febrile episodes are attributable to malaria or other 
diseases. However, the likelihood that the symptoms experienced are due to malarial 
parasites increases with the density o f parasites observed on thin blood films by 
microscopy. Clinical malaria can therefore be defined on the basis o f fever in the presence 
of parasites at a density above a defined threshold value. This threshold can be determined 
using a logistic regression approach that estimates the probability o f having fever as the 
dependent parameter and parasite density as the independent parameter (Smith et a l, 
1994). Candidate threshold values are evaluated in the model to find one that gives the 
highest specificity and sensitivity. This value is then adopted as the threshold value that 
defines clinical malaria from asymptomatic malaria. The threshold also helps to 
distinguish if  the fever symptom experienced can be attributed to malaria parasites or 
other possible aetiologies such as viral or bacterial agents.
Some o f the questions I hoped to resolve in this study were therefore:
(i) Is malaria case definition affected by genotype?
From the foregoing, it is evident that the threshold value used as a cut-off for malaria 
fevers is a population average value. It is possible that the threshold may be different in 
particular subsets of the population, such as different genotypes or age groups. This is an
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important distinction to make, as measures o f protection from disease by genotypes 
assume a homogenous exposure. Parasite density thresholds for malaria fever were 
compared for significant differences across genotype and age categories.
(ii) Is the malaria attributable fraction the same across different genotypes?
If there are significant differences in the threshold of malaria, it follows that the 
proportion o f fevers due to malaria (the malaria attributable fraction o f fever, MAF) may 
also be different in the various ages and genotypes. Proportions of malaria attributable 
fever were compared for significant differences by genotype and age categories.
To answer these questions, parasitological data was available from 1035 individuals with 
parasite counts ranging from 0 to 35,000 parasites / pL. The data included all the children 
in the age range from 0 to 12 years, of which 222 had positive slides for malaria parasites. 
Sections 3.4.1 onwards address these questions.
3.4.1 Distribution of slide densities
Approximately 80% of the participants had a negative malaria slide, whereas only 0.05% 
of the participants had a parasite density >10,000 parasites / pL. Figure 3.3 below shows 
a plot o f the proportions o f parasite density values for slide-positive individuals. O f those 
with non-zero values for parasite density, the majority (60%) had parasite densities less 
than or equal to 2,500.
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Figure 3. 3 The distribution o f  different parasite density values
in
10000 20000 30000 40000
nParasitesPer uL
The parasite density values are plotted in the x-axis in incremental bands o f  200 parasites per pL. 
nParasitesPer_uL= number o f  parasites per pi. The y-axis represents the percentage o f  individuals 
with a particular parasite density value.
Given the skewed parasite density values, the data were transformed into natural 
logarithms as shown in Figure 3.4 below.
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Figure 3. 4 Proportions of  log transformed parasite density (logpar)
L O
logpar
10
The x-axis represents different log o f  parasite density values whereas the y-axis is the percentage o f  individuals with a 
particular log o f  parasite density.
14.3% (163 individuals) had either a current fever or a fever in the last 48 hours, whereas 
a total of 300 individuals had a history of fever in the previous two weeks.
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3.4.2 Age o f  m alaria cross sectional survey participants
Many participants in the survey were under five years of age as shown in Figure 3.5 
below.
Figure 3. 5 Age distribution of participants in cross sectional malaria survey 
m
o
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The x-axis denotes the age in one year age categories. The y axis shows the percentages o f  individuals in each age 
category.
3.5 Malaria attributable fraction of fever (MAF)
Fever episodes may be dichotomized into those of malarial aetiology and those that are
not of malarial aetiology. The proportion o f fevers due to malaria is termed the malaria
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attributable fraction of fever. Determination of MAF is complicated by the fact that not 
all fevers in malaria parasite positive individuals are due to malaria. A plot of parasite 
density thresholds and their sensitivity/specificity in defining malaria fever episodes helps 
to determine which cut off to use. The malaria-attributable fraction at that cut-off is then 
determined to be the malaria attributable fraction of fever. The method employed for these 
calculations is described by Smith and colleagues (Smith et al., 1994). Results are 
presented in section 3.3.3 below.
3.5.1 A ttr ib u ta b le  frac tio n s  o f fever a t d iffe ren t th resh o ld s  o f  p a ra s ite  
density
Attributable fractions are tabulated in table 3.3 below.
Table 3.3 Attributable fractions of fever at defined parasite thresholds. Sensitivity and 
specificity refer to the ability of the cut off definition to define a fever.
Parasite density threshold 
(parasites/pL)
Sensitivity Specificity Attributable
fraction
0 100.00 0.00 0.35
500 68.43 86.52 0.73
1000 64.45 87.33 0.73
1500 56.44 88.94 0.73
2000 56.44 88.94 0.73
2500 52.43 89.74 0.73
3000 44.39 91.34 0.73
3500 44.39 91.34 0.73
4000 44.39 91.34 0.73
5000 24.26 95.30 0.73
5500 20.23 96.09 0.74
6000 20.23 96.09 0.74
6500 20.23 96.09 0.74
7000 16.19 96.88 0.74
10000 8.11 98.44 0.74
15000 8.11 98.44 0.74
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From Table 3.3, it can be seen that 35% of fevers were not due to malaria parasites (AF 
at parasite density=0). Increase in parasite density to 500 resulted in an increase in the 
attributable fraction to 73%. Beyond 500 parasites / pi there was no significant difference 
in the attributable fraction of malaria fever, with 74% at 15,000 parasites per pi. Parasite 
densities were therefore investigated using a receiver operating characteristic (ROC) 
curve to check for a threshold that best predicts a malaria fever as shown in Figure 3.6 
below. Table 3.4 shows the corresponding sensitivity and specificity at each threshold.
Figure 3.6. ROC curve showing the performance of parasite density in predicting fever 
episodes.
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Area under ROC curve = 0.6185
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Table 3.4. Sensitivity and specificity of predicted fevers at thresholds of parasite 
density.
Threshold Sensitivity % Specificity % Correctly classified %
>=0 100 0 4.04
>=500 38.64 82.79 81.01
>=1000 36.36 87.76 85.69
>=2000 31.82 91.2 88.81
>=3000 25 93.59 90.83
>=6000 11.36 96.08 92.66
>=9000 9.09 97.99 94.4
>=12000 4.55 99.04 95.23
>12000 0 100 95.96
The ROC curve tested the ability of parasite density to predict a fever, defined as 
temperature > 37.5°C. The area under the ROC curve was 0.61 (0.53-0.68), meaning that 
the level of parasite density did not discriminate well individuals with malaria fever from 
individuals without a malaria fever. As such, these data did not show a distinct threshold 
that was predictive of a malaria episode. These results were consistent with the MAF 
calculations that did not show a difference in MAF of fever beyond a parasite density of 
500. These results were unexpected since as it is commonly held in the literature that the 
likelihood of having malaria symptoms increases above a defined threshold of parasite 
density. Our results could be because there were few fever or parasitaemia episodes. 
Smith and colleagues (Smith et al., 1994) used data collected every two months for two 
years from children living in an endemic area, while the current dataset was generated 
from a single cross sectional survey of malaria. A cross tabulation of fever and absence 
of fever in some indicative parasite densities is shown in Table 3.5 below. The table shows 
that above 2500 parasites, there were less only 13 individuals who had fever in the cohort.
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This could have led to the low discriminatory ability of the ROC test to predict malaria 
fevers.
Table 3.5 Number of fever episodes in different parasite density cut-offs.
Parasite cut offs Fever No fever
>=100 19 203
< 100 27 866
>=500 17 180
<500 29 889
>= 1500 14 108
< 1500 32 961
>=2500 13 78
<2500 33 991
>=3500 11 58
< 3500 35 1011
>=5000 6 47
< 5000 40 1022
>=7500 4 31
< 7500 42 1038
>=10000 2 15
<10000 44 1054
3.6 Relative burden of malaria compared with other infectious 
syndromes
The relative burden of malaria compared to other infectious diseases in the area was 
investigated by comparing the rates of malaria to the rates of other infectious disease 
syndromes detected in Lwak hospital. These syndromes included respiratory infections, 
non-malarial fevers and diarrhoea/gastroenteritis. Case definition of these syndromes was 
based on clinician diagnosis at presentation and the discharge diagnosis at the hospital.
Rates of uncomplicated and severe malaria were compared with respiratory rates, non- 
malarial fevers and diarrhoea/gastroenteritis. These are shown in Table 3.6 below.
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Table 3.6 Incidence of malaria compared to non-malarial illnesses diagnosed in Lwak 
hospital
Number of
Cyfu Number
Crude Incidence
individuals of events (events/cyfu)* (95% Cl)
Malaria 1522 5115.9 2601 0.51 (0.49-0.53)
Severe malaria 1522 5115.9 47 0.009 (0.007-0.012)
Non malarial fever 1522 5099.4 587 0.12(0.11-0.12)
Respiratory syndromes 1524 5099.5 3643 0.71 (0.69-0.74)
Diarrhoea/Gastroenteritis 1518 5098.8 548 0.11 (0.10-0.12)
Note: Definitions o f  Respiratory illness, non-malaria fever and diarrhoea/gastroenteritis are explained in section 2.6.2 
above.
The crude incidence rates of the infectious syndromes above were compared with crude 
rates of malaria in a pie-chart, as seen in Figure 3.7 below. Clinical malaria episodes 
accounted for about 35% of the infectious syndromes evaluated in by this study.
Figure 3.7 Malaria in comparison with infectious syndromes.
■ Malaria ■  Severe m alaria
■ Non malarial fever ■  Respiratory syndrom es
■ D iarrhoea/gastroenteritis
Five infectious syndromes were considered, o f  which uncomplicated malaria (in light blue) accounted for 35%, 
respiratory syndromes (orange) accounted for 49%, diarrhoea/gastroenteritis accounted for 7%, other non-malarial 
fever (grey) accounted for 8% and severe malaria(red) accounted for 1%.
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3.6.1 Laboratory confirmation of other infectious illnesses among cohort 
members
3.6.1.1 Blood culture
Blood culture was performed for a subset o f the cohort members to investigate the 
aetiology o f defined clinical syndromes. Blood for culture was collected from patients 
who met respiratory and febrile illness case definitions. Fever was defined as an axillary 
temperature o f >38°C. Due to the expected high incidence of febrile illness in this malaria 
endemic area, blood for culture due to the fever criterion was only collected from the first 
two patients <5 years old and first two persons >5 years old presenting to the hospital 
with fever each day.
Respiratory illness was defined as described in section 2.6.2. Occasional individuals who 
did not meet these criteria had blood collected if  the clinician suspected sepsis. Collection 
was not restricted to this genetic cohort, but to the larger PBIDS cohort o f Asembo. 
Among the genetic cohort members, 532 individuals had blood investigations done on 
them. These investigations included the use o f a BACTEC™ 9050 system (to detect 
growth o f microorganisms), a Gram stain or a microbiological blood culture. A total o f 
1043 samples were collected during the period. Results were available for 1041 o f the 
samples. Since individuals could be seen more than once, the total number o f blood 
samples are more than the number of individuals contributing to the blood samples. Table 
3.7 below presents results o f cohort members.
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Table 3.7 Blood microbiology investigation results of cohort members.
MICRO-ORGANISM No. %
No growth 951 91.35
Gram positive bacteria
Streptococcus pneumoniae 5 0.48
Staphylococcus species# 12 1.15
Gram positive bacilli ** 46 4.42
Gram negative bacteria
Haemophilus influenza 1 0.10
Klebsiella oxytoca 2 0.19
Pseudomonas oryzihabitants 1 0.10
Salmonella group H 1 0.10
Salmonella group B 12 1.15
Salmonella group D 8 0.77
Serratia rubidae 1 0.10
Escherichia coli 1 0.10
Total blood samples 1,041 100
# No distinction between pathogenic and non-pathogenic Staphylococci was made for these samples 
*** Gram positive bacilli were not further delineated into specific bacteria
3.6.1.2 Stool culture
Patients meeting the case definition of diarrhoea of more than 3 looser than normal stools 
in a day, as defined in section 2.6.2, had a stool sample collected for culture. A previous 
study in the study area found an incidence of diarrhoea of 0.40 episodes per year for 
children <5 years and 0.09 for persons >5 years (Feikin et al., 2011). However, among 
the cohort members, only 36 stool samples were collected. The results were as follows:
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Table 3.8 Stool culture results.
MICRO-ORGANISM No. % Rotavirus result No. %
Gram negative bacteria
Campylobacter coli 3 8.33 Negative 27 75.00
Campylobacter jejuni o3 8.33 Positive 8 22.22
Salmonella Group B i 2.78 Not tested 1 2.78
Salmonella species i 2.78
Shigella flexneri 4 11.11
Shigella sonnei 2 5.56
Vibrio cholera 2 5.56
Gram positive bacteria 0 0
No pathogen detected 22 61.11
Total 36 100 Total 36 100
Percentages represent the proportion o f  samples that grew the microorganism out o f  the total number o f  samples tested. 
The total is greater than 100% because two participants had more than one microorganism isolated. One had Shigella 
Sonnei and Campylobacter Coli whereas another individual had Salmonella species and Campylobacter Coli.
No pathogen detected consists o f  normal human gut flora.
3.6.1.3 Nasopharyngeal and oropharyngeal swab tests
Upper and lower respiratory tract infections may result from several aetiologies, including 
Influenza viruses. Among the cohort members, it was possible to capture the data for 
nasopharyngeal oropharyngeal swabs tested for Influenza A and B. The results are 
presented in Table 3.9 below. Of 608 samples collected, there were 29 positive for 
Influenza A (4.8%), whereas 14 (2.5%) were positive for Influenza B.
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Table 3.9 Results for Nasopharyngeal oropharyngeal swabs.
Flu A Result No. % Flu B Result No. %
Not determined 2 0.33 Negative 593 97.5
Negative 565 92.93 Positive 15 2.5
Positive 41 6.74
Positive Sub typed 29 4.77
HI 3 0.49
H3 8 1.32
NH1 14 2.30
SUB INC* 4 0.66
Total 608 608 100
Hl=Haemagglutinin 1 
H3=Haemagglutinin 3 
NHl=Neuraminidase Haemagglutinin 1 
SUB INC= subtype not confirmed
Sections 3.6.1.1 through 3.6.1.3 above show that individually each aetiological agent 
contributed only a small portion to the disease incidence recorded. However, together, 
the various aetiological agents contributed to the infectious disease syndromes such as 
respiratory illness and diarrhoea in this cohort. Since not all individuals presenting with 
illness were sampled, incidence due to a particular aetiological agent could not be 
estimated without adjusting for the individuals that were not sampled. Going forward, 
investigation of these other syndromes were not investigated as a blood sample was not 
available systematically from these cohort members. The information on which 
aetiological agents cause the infectious syndromes was nevertheless useful to show the 
relative importance of the various aetiological agents in causing illness in the study area 
compared to P. falciparum malaria.
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3.7 Discussion
As expected, the malaria incidence within the cohort study area increased by age from 
birth up to 6 years, after which it declined, an observation that almost certainly reflects 
the acquisition o f malaria-specific immunity. Younger children are expected to have low 
immunity, and therefore malaria affects them more. It appears that beyond 5 years the 
immunity is well developed and consequently less malaria is experienced by the children.
Since this was a hospital-based study, the rates reported are likely to be representative o f 
only those individuals who sought care at the hospital. One o f the major factors which 
may affect the decision to seek care at a hospital is the distance from the patient’s home 
to the hospital. A previous study in the area had found that rates o f fever in the home were 
approximately 10 times higher than in those seen in the hospital. This may explain the 
low rates seen in this study o f about 0.5 episodes / cyfu, compared to the rates recently 
reported during the RTS,S malaria vaccine study that took place approximately within 
the same period (2009-2013) which reported rates approximately 10 times higher, o f 4-5 
episodes / cyfu.
Recent declines in malaria have been reported globally. The rates o f malaria in the study
area over the period appeared to be constant compared to the reference year, 2008.
However, 2 years stand out as having different rates, an increase as seen in 2010 and a
decline reported in 2013. A nested cross sectional cohort study was conducted during the
study for two reasons - to derive a parasitological definition and to investigate risk factors
for having malaria parasite. While it was possible to define a number of risk factors, such
as age and effect of care seeking on malaria, a clear cut-off defining fever was not evident.
This could have been due to the low number o f measured fever events during the cross
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sectional survey. In addition, a review of fever and malaria has shown that fevers due to 
malaria are declining, especially in East Africa (D'Acremont et al., 2010). This has 
implications for presumptive treatment o f fevers in areas classified as endemic, where 
treatment should be guided by evidence of a malaria parasite positive slide.
3.5 Summary
1. Malaria is among the major of infectious illnesses reported in Lwak hospital in this 
study area, representing a significant health burden.
2. Major infectious disease syndromes in the study area include respiratory tract 
infections, diarrhoea and non-malarial fevers. Data was only available in some children 
for definitive diagnosis o f aetiological agents in these syndromes, and therefore 
conclusive analysis o f incidence by aetiological agent was not done.
3. Risk factors for malaria illness has been investigated through a longitudinal approach, 
showing the that time-changing variables such as season, age, calendar year, season and 
distance to hospital affect rates o f malaria reported. Investigation through a cross 
sectional survey showed a significant effect for participants age and whether the 
participant sought care, whereas condition o f bed net, house type, gender and distance 
from hospital did not affect the odds o f having malaria.
4. The parasitological case definition of malaria was investigated in this population using 
cross sectional malaria survey o f malaria symptoms such as fever compared with parasite 
density o f malaria. From the data analysis, a clear threshold was not seen.
5. The rates calculated in this study were significantly influenced by distance to the health 
facility. The odds o f attending the surveillance hospital was found to change significantly 
for every 2km.
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CHAPTER 4: Red blood cell genes and malaria incidence in
Asembo
4.1 Background
The classical genes associated with protection from malaria are related to the red blood 
cell. These polymorphisms include the sickle cell trait, a-thalassaemia, the ABO blood 
groups system, G6PD deficiency and polymorphisms in the CR1 Knops blood group 
system, particularly at the Swain Langley and McCoy loci. However, from a survey of 
the literature (see Chapter 1), there is no consensus on the effects of some o f these genes, 
such as G6PD deficiency and CR1 polymorphisms. While several studies have focused 
on the effects o f these genes on severe malaria, their effect on uncomplicated malaria has 
only been reported in relatively few studies. In this chapter, variants o f these common red 
blood cell gene polymorphisms are investigated for their effect on malaria incidence in 
the children o f Asembo. Incidence data is further stratified by gene variant and age to 
give indications o f the rate o f development o f naturally acquired immunity in the various 
variants. The investigations in this chapter will therefore aim to answer the following 
questions:
1. Do polymorphisms in the classical red blood cell genes affect the incidence o f 
uncomplicated clinical malaria?
2. Do the age-specific rates provide evidence for a difference in the rate o f 
acquisition o f naturally acquired immunity in the different genotypes?
3. Do red blood cell polymorphisms affect the parasitological case definition o f 
malaria?
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4.2 Objectives
Specific objectives were as follows:
1. To investigate protection conferred against malaria incidence by red blood cell 
genes in Asembo.
2. To investigate the age specific malaria incidence patterns o f the red blood cell 
polymorphisms in order to infer associations with naturally acquired immunity.
3. To investigate the role o f common red blood cell genes in predicting malaria 
fevers.
4.3 Summary of methods
Methods for surveillance, case definitions for malaria and the statistical methods have 
been described in detail in Chapter 2, summarised briefly as follows. Passive hospital 
based surveillance in Lwak hospital was employed to follow up enrolled children for 
incident malaria episodes between 2008 and 2013. Crude and adjusted incidence rates 
were calculated by Poisson regression. Crude incidence rates were calculated by dividing 
the diseases episodes by the follow-up time. Adjusted rates were calculated by adding to 
the Poisson model other variables found to significantly affect the incidence o f malaria 
on univariate analysis. These variables were season, year, distance to Lwak hospital, age, 
gender, mother’s education and socio-economic status. An additional adjustment was 
using the sandwich estimator to account for repeated observations on the same individual. 
This adjustment reduces the p-values and inflates the corresponding confidence intervals. 
Age and genotype specific incidence rates and incidence rate ratios were calculated by 
restricting the model to individuals of particular ages and genotypes respectively.
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Likelihood ratio test for effect of age on genotype specific rates
To further investigate if  the interaction between genotype and age is important in 
predicting malaria episodes, I conducted a likelihood ratio test to check for a statistically 
significant interaction between genotype and age. I reasoned that if the interaction 
between genotype and age is important, then it should significantly improve a Poisson 
model which predicts malaria from its covariates. I therefore compared two models for 
each red blood cell genetic polymorphism:
Model (i) a Poisson regression model with a red blood cell genotype, age category and 
the covariates season, year, distance to Lwak hospital, age, gender, mother’s education 
and socio-economic status.
Model (ii) Poisson regression model similar to model (i) but in addition having an 
interaction term for age category and sickle genotype among the independent variables. 
A likelihood ratio test comparing the likelihood estimates from the two models was 
applied, and significance for differences between the estimates was evaluated at the 
P<0.05 level.
4.4 Results
4.4.1 Sickle
4.4.1.1 Effect of sickle on incidence of uncomplicated malaria
Out of 1444 participants, 1132 (78%) had HbAA, 289 (20%) had HbAS and 23 (1.6%) 
had HbSS. The overall incidence rate ratio for malaria in children with HbAS compared 
to HbAA among children 0-12 years old was 0.83 (0.75-0.92; p<0.001). This reduction
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was significant both on crude analysis and on adjustment for season, year, distance (km) 
to Lwak hospital, age, gender, mother’s education and socio-economic status. However, 
upon additional adjustment of p-values and confidence intervals using the sandwich 
estimator, the protective effect was not evident, with IRR 0.85 (0.69-1.04; p=0.12).
4.4.1.2 Age-specific incidence of m alaria by sickle cell genotypes
Differences in the malaria age-incidence curves were investigated by comparing the age- 
specific incidence rates in normal children, HbAA, compared children with HbAS (Table 
4.1). The incidence of malaria by genotype and age is presented in Figure 4.1 below. The 
rates in the stratified age categories were not significantly different compared to the 
overall effect in all the age categories combined.
Figure 4.1 Rates of uncomplicated malaria in HbAA compared to HbAS individuals 
stratified by age categories.
0 .9
<2 2 <4 4< 6  6< 8  8< 1 0  10< 12
Age in years
■  H b A A  « H b A S
The y-axis represents the episodes o f  malaria per child per year o f  follow-up, whereas the x- 
axis represents the age-bands o f  the children in 2 year age categories. Error bars represent the 
95% confidence interval for the estimate o f  malaria episodes per child per year. The blue bars 
represent children who are normal at the sickle cell locus (HbAA), while the red bars represent 
children who are carriers for the sickle cell trait, HbAS.
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Malaria incidence for HbAA formed a clear peak incidence at the 2<4 year category, 
compared to the preceding 0<2 years, and the next age category, the 4<6 year category. 
By contrast, the HbAS peak incidence at 2<4 years appears to be significantly different 
from only the preceding age category’s (0<2) and but not the other age categories above 
4 years. Malaria incidence also declines more sharply for older age groups of HbAA 
compared to HbAS. Interestingly, there is a higher incidence of malaria in AS children 
compared to AA children in the 8-10 and >10 year age categories, although the difference 
did not reach statistical significance. These two phenomena, the peak shift and apparent 
shift in malaria protection in the older age groups suggest that there may be a difference 
in the acquisition rate o f naturally acquired immunity in the HbAA compared to the HbAS 
children.
A likelihood ratio test comparing the age interaction model and the non-age interaction 
model gave a p-value o f 0.045, indicating marginal significance at the <0.05 threshold. 
This suggests that age interacts with genotype to predict rates o f malaria. Since the effect 
o f age may be heterogeneous across the age categories, the rates o f malaria were presented 
in each age category in Table 4.1 along with the number o f malaria episodes, number o f 
individuals per genotype in each age category, the child years of follow up and incidence 
rate ratio adjusted for the covariates.
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4.4.2 Alpha thalassaemia
4.4.2.1 Effect of a—thalassaemia on incidence of malaria
Genotyping for a+thalassaemia was completed for 1299 individuals. There were 616 
(47.4%) normal (aa/aa) individuals, 547 (42.1%) heterozygotes (-a/aa) and 136 (10.5%) 
homozygotes (-a/-a). The frequency o f the a '3 7 allele was 0.32. The crude malaria 
incidence rate ratio in a+thalassaemia homozygotes compared to normal individuals was 
significantly higher, with IRR 1.20 (1.05-1.36; p<0.01). However, upon adjustment for 
covariates and the sandwich estimator, the significant effect was lost, with IRR 1.01 
(0.76-1.35; p=0.92). Heterozygous individuals showed no differences in either the crude 
analysis (IRR 0.94 Cl 0.86-1.03, p=0.17) or the adjusted analysis (IRR 1.02, Cl 0.85- 
1.23, p=0.83).
4.4.2.2 Age-specific incidence of malaria by a-thalassaemia genotype
The age-stratified effects o f a-thalassaemia are shown in Figure 4.2 and Table 4.2 below. 
The adjusted analyses did not show an effect o f a-thalassaemia specific to any age 
category, as seen in Table 4.2.
95
Figure 4.2 Rates of uncomplicated malaria in a -thalassaemia genotypes stratified by age 
categories.
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The y-axis represents the episodes o f  malaria per cyfu, whereas the x-axis represents the age-bands o f  the children in 2 
year age categories. Error bars represent the 95% confidence interval for the estimate o f  malaria episodes per child per 
year. The blue bars represent children who normal at the alpha thalassaemia locus (aa/aa), orange bars represent 
children who are heterozygous (-a/aa) whereas the grey bars represent children who are homozygous (-a/-u).
A likelihood ratio test comparing the a-thalassaemia genotype and age interaction model 
with the non-age interaction model gave a p-value of 0.0083. Age therefore interacts with 
thalassaemia genotypes to predict malaria incidence rates. The age-specific incidence of 
malaria by a-thalassaemia genotype is presented in Table 4.2 below.
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4.4.3 ABO blood groups
4.4.3.1 The effect of ABO blood groups on incidence of uncomplicated malaria
Compared to blood group O, the incidence of malaria in children with blood groups A, B 
and AB was higher on the crude analyses. Blood group A gave marginal evidence of 
increase in malaria incidence with an IRR o f 1.10 (1.00-1.22; p=0.06). Blood group B 
was associated with an IRR o f 1.27 (1.15-1.40; p<0.0001), while the IRR in blood group 
AB children was 1.47 (1.22-1.77; p<0.0001). However, none o f these blood groups 
maintained significance for effect after adjustment for covariates and robust analysis 
using the sandwich estimator.
Blood group O compared to the non-0 blood groups had a reduced malaria incidence, 
with IRR 0.88 (0.80-0.96; p=0.003) when adjusted for covariates. However, when an 
additional adjustment was made using the sandwich estimator, the protective effect was 
not evident (0.74-1.04; p=0.13).
4.4.3.2 Age specific incidence of malaria by ABO blood groups genotypes
ABO blood groups affect the age-specific incidence o f malaria. Above the age o f 6 years
there was a significant difference between blood group O and blood group A in all age
categories considered in the crude analysis. However, in the adjusted analyses, there was
a protective effect o f blood group O only in children above 8 years o f age when compared
to particular ABO genotypes. The IRR in blood group B compared to O was 2.30 (95%
Cl 1.2-4.4; P=0.01). Among children >10, the blood group A individuals had an IRR of
5.65 (95% Cl 1.42-22.5; P=0.01), whereas blood group B had an IRR o f 5.02 (95% Cl
1.34-18.87; P=0.02). However, these findings should be interpreted cautiously given the
low number o f individuals in these age categories. The effect o f age on malaria incidence
98
is shown in Figure 4.3 and Table 4.3 below. Note that Figure 4.3 plots the crude age 
effects unadjusted for covariates.
Figure 4.3. Rates of uncomplicated malaria in ABO blood groups stratified by age 
categories.
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The y-axis represents the episodes o f  malaria per cyfu, whereas the x-axis represents the age-bands o f  the children in 2 
year age categories. Error bars represent the 95% confidence interval for the estimate o f  malaria episodes per child per 
year. The blue bars represent children with blood group O, red bars represent children with blood group A, green bars 
represent blood group B, whereas the purple bars represent children with blood group AB.
A likelihood ratio test comparing the ABO genotype and age interaction model with the 
non-age interaction model gave a p-value o f <0.0001. Age therefore interacts with ABO 
blood groups to predict malaria incidence rates. Age specific incidence rates o f malaria 
by ABO blood groups are presented in Table 4.3 below.
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4.4.4 G6PD deficiency
4.4.4.1 Effect of G6PD deficiency on incidence of m alaria in males
There was no effect of G6PD genotypes on malaria incidence, since neither the crude or 
adjusted analysis gave an effect. In the adjusted analysis, G6PD A individuals had an IRR 
o f 1.02 (0.79-1.32; p=0.89) while G6PD A- individuals had an IRR o f 0.86 (0.57-1.30; 
p=0.46).
4.4.4.2 Age specific incidence of m alaria by G6PD genotypes in males
Age stratified analyses did not show any significant effect o f G6PD genotypes on malaria 
incidence in any age category considered in the adjusted analyses. These effects are 
shown in Figure 4.4 and Table 4.4 below. The crude analyses had suggested a marginal 
effect of G6PD A (376) in the 0-2 year old children. Crude analyses had also indicated 
an effect for G6PD A (376) in children >10 years, but the low number o f children in this 
age category indicate that this result should be cautiously interpreted.
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Figure 4.4. Rates of uncomplicated malaria in G6PD genotypes of males stratified by age 
categories.
1.2
<2 2 <4 4< 6  6< 8  8 < 1 0  1CX12
A g e  in y e a r s
■  G6PD m ale g e n o ty p e  B (N orm al non  d efic ien t)
■  G6PD m ale g en o ty p e  A ("85% activ ity , n on  d efic ien t)
■  G6PD m ale g en o ty p e  A- ("40%  activ ity ,d efic ien t)
The y-axis represents the episodes o f  malaria per cyfu, whereas the x-axis represents the age-bands o f  the children in 2 
year age categories. Error bars represent the 95% confidence interval for the estimate o f  malaria episodes per child per 
year. The blue bars represent children with G6PD genotype B, orange bars represent children with G6PD genotype A, 
while grey bars represent children with G6PD genotype A-.
The LRT comparing the interaction between G6PD male genotypes and age with the non- 
genotype-age interaction model resulted in a p-value of 0.03. This suggests that age 
interacts with G6PD genotype in males to predict malaria incidence rates.
Age specific incidence rates of malaria by G6PD genotypes are presented in Table 4.4 
below.
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4.4.4.3 Effect of G6PD deficiency on incidence of m alaria in females
When all age categories were analysed in combination, no effect o f G6PD deficiency was 
seen in females. Heterozygous deficient individuals AA- and BA- were grouped together. 
Compared with the non-deficient group (BB, BA and AA), the IRR for malaria in the 
heterozygous deficient group was 0.94 (0.70-1.25; p=0.66). When the deficient group (A- 
A-) was compared to the non-deficient group, the IRR was 0.82 (0.44-1.53; p=0.54).
4.4.4.4 Age specific incidence of m alaria by G6PD genotypes in females
When the results were analysed by age categories, a significant increase in malaria 
incidence was seen among the youngest A-A- (deficient) children 0-2 years old. The IRR 
was 5.22 (1.95-13.97; p<0.01). However, this finding may not be generalizable as only 
3 participants had A-A- in this age category, and therefore any malaria incident easily 
inflates the IRR compared to the AA wild type. In the 8-10 years category, A-A- 
individuals also had a higher IRR 2.76 (95% Cl 1.19-6.64) compared to non-deficient 
(BB, BA and AA) individuals. Only 5 individuals were in the 8-10 year category and 
therefore the finding should be interpreted with caution. The effect o f G6PD female 
genotypes on malaria are shown in Table 4.5 and Figure 4.5 below.
Overall, comparing the trends of malaria incidence according to G6PD deficient 
genotypes among males and the females (Table 4.4 for males and Table 4.5 for females), 
it appears the deficient genotype increases malaria incidence in some age groups among 
females but not in males. Considering the low numbers o f individuals as discussed above, 
this finding may not be generalizable and would need to be confirmed in adequately 
powered studies.
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Figure 4.5. Rates of uncomplicated malaria by G6PD genotype in females stratified by 
age categories.
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■  G6PD fem ale  p h en otyp es BA- AA- (H eterozygote deficient)
■  G6PD fem ale  p h en otyp es  A-A- (deficien t)
The y-axis represents the episodes o f  malaria per cyfu, whereas the x-axis represents the age-bands o f  the children in 2 
year age categories. Error bars represent the 95% confidence interval for the estimate o f  malaria episodes per child per 
year. The blue bars represent children with G6PD genotype AA, AB, BB (termed non-deficient). Red bars represent 
heterozygote deficient individuals with genotypes BA- and AA-. Green bars represent children with G6PD genotype 
A-A-(deficient).
The LRT comparing the interaction between G6PD genotypes and age with the non­
genotype-age interaction model had a p-value of 0.07. There was therefore no evidence 
that age interacts with G6PD phenotypes in females to predict malaria incidence rates. 
Age specific incidence of malaria stratified by G6PD genotypes are presented in Table 
4.5 below.
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4 .4 .5  C R 1  M c C o y
4.4.5.1 Effect of McCoy blood groups on incidence of m alaria
McCoy genotypes consist of McC a/a, McC a/b and McC b/b. They result in McCoy 
blood groups. The effect of McCoy genotypes on malaria incidence is shown in Table 
4.6. There was no significant effect of McCoy genotypes on malaria incidence. McCoy 
a/a was used as the reference group. McC a/b was associated with an IRR of 1.17 (0.98- 
1.40; p=0.08) whereas McC b/b individuals had IRR 1.04 (Cl 0.82-1.32; p=0.74).
4.4.5.2 Age specific incidence of m alaria by McCoy blood groups genotypes
McCoy rates were not sensitive to differences in age as shown in figure 4.6 and table 4.6 
below.
Figure 4.6. Rates of uncomplicated malaria in McCoy genotypes stratified by age 
categories.
1.2
<2 2 <4 4<6 6<8 8<10 1(X12
A ge  in  ye a rs
■  M cCoy g e n o ty p e  McC a /a  ■  M cCoy g e n o ty p e  McC a /b  ■  M cCoy g e n o ty p e  McC b /b
The y-axis represents the episodes o f  malaria per cyfu, whereas the x-axis represents the age-bands o f  the children in 2 
year age categories. Error bars represent the 95% confidence interval for the estimate o f  malaria episodes per child per 
year. The blue bars represent children with McC a/a genotype, red bars represent McC a/b genotype whereas green bars 
represent children McC b/b genotype.
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The LRT comparing the interaction between McCoy genotypes and age with the non- 
genotype-age interaction model had a p-value of 0.17. There was no evidence that age 
interacts with McCoy genotypes to predict malaria incidence rates.
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4.4.6 CR1 Swain Langley
4.4.6.1 Effect of Swain-Langley blood groups on incidence of malaria
SI genotypes can either be SI 1/1 (normal), SI 1/2 (heterozygotes) or SI 2/2 homozygotes. 
Crude analyses indicated that SI 1/2 and 2/2 variants increased the incidence o f malaria. 
However, upon adjustment, the rates o f malaria detected were the same with the reference 
group, SI 1/1. The IRR for SI 1/2 was 1.19 (0.86-1.64; p=0.29). SI 2/2 had IRR 1.23 (0.90- 
1.70; p=0.20).
4.4.6.2 Age specific incidence of malaria by Swain-Langley genotypes
When the results were stratified by age, there was no difference with the pooled age 
results. The age stratified results are shown in figure 4.7 and table 4.7 below.
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Figure 4.7. Rates of uncomplicated malaria in Swain Langley genotypes stratified by age 
categories.
Malaria rates by Swain Langley g e n o t y p e s
0.7
<2 2<4 4< 6  6< 8  8 < 1 0
A g e  in y e a r s
■  Sw ain Langley g e n o ty p e  SI 1 /1  ■  Sw ain Langley g e n o ty p e  SI 1 /2  ■  Swain L angley g e n o ty p e  SI 2 /2
The y-axis represents the episodes o f  malaria per cyfu, whereas the x-axis represents the age-bands o f  the children in 2 
year age categories. Error bars represent the 95% confidence interval for the estimate o f  malaria episodes per child per 
year. The blue bars represent children with SI 1/1 genotype, red bars represent SI 2/2 genotype whereas green bars 
represent children with SI 2/2 genotype.
The P value comparing the Swain Langley-age interaction model with the non-age 
interaction model was 0.19, indicating a non-significant interaction with age in Swain 
Langley genotypes. Age specific rates are tabulated in Table 4.7
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4.5 Does red blood cell genotype affect the parasitological case definition of
malaria?
Using cross-sectional survey data (see section 2.5), the effect of genotypes on how parasite 
densities predict fever was investigated. This was done by conducting a likelihood ratio test 
comparing the logistic model with an interaction term between parasite density and genotype 
to a model without the genotype interaction term. If the two models are significantly 
different, then genotype affects the likelihood of having a malaria fever, and the parasite 
densities predicting fever should be reported in each genotype. The test was done for sickle, 
a-thalassaemia, ABO and G6PD genotypes and the results are reported in Table 3.11.
Table 4.8. Likelihood ratio test of red blood cell genotype interactions with parasite density 
in predicting fever compared with a model without interaction.
Interaction model LRT p-value
Sickle genotype:
model (i) logit fever'- sicklegenotypes parasite density
model (ii)logit fever ~' sickle genotypes parasite density
sickle_genotypes#parasite density 0.95
a+thalassaemia
model (i) logit fever'- a+thal_genotypes parasite density
model (ii)logit fever -' a+thal_genotypes parasite density
a+thal_genotypes #parasite density 0.63
ABO blood group
model (i) logit fever -- abogenotypes parasitedensity
model (ii) logit fever -- abo genotypes parasite density
abo_genotypes#parasite density 0.02
G6PD genotypes
model (i) logit fever -' g6pd_genotypes parasite density
model (ii)logit fever -J g6pd_genotypes parasite density
g6pd_genotypes#parasite density 0.79
*G6PD genotype models were for the 202 genotype in males
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There was no difference in the ability of the logistic model to predict a malaria fever based 
on interaction with parasite density for sickle, thalassaemia and G6PD genotypes. However, 
the ABO interaction model predicted fevers better than the non-interaction model. I 
hypothesized that this interaction effect may result from higher parasite densities in some 
blood groups of ABO. However, I found that the difference was not due to a difference in 
parasite densities in the ABO blood groups as shown in Figure 4.8.
Figure 4.8. Graph comparing parasite densities in ABO blood groups.
CM
oo ■ ©
CDO
s _
10 2A 3AB 4B
Key 1 0 = B lo o d  group O 2A =B lood group A 3A B =B lood  group AB 4B =B lood  group B
t_ l=  best transformation o f  parasite density that predicts malaria fevers. For our model this transformation was 
(parasites per pL *0.01). There was no difference in parasite densities predicting a fever episode in the different 
blood groups.
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4.6 Discussion and conclusions
Protective effects were shown in crude analysis of sickle cell trait, increased incidence of 
malaria in alpha thalassaemia homozygotes, increased incidence in non O blood groups, 
increased incidence in McCoy a/b blood groups and increased incidence in SI 1/2 and S12/2 
blood groups. However, adjustment for covariates and repeated episodes in the same 
individual led to a loss of effect. Using the LRT test, there was evidence suggesting that age 
interacts with some red blood cell genotypes such as sickle cell trait, a-thalassaemia, ABO 
blood groups and G6PD deficiency in males. However, there was no evidence of age and 
genotype interactions in predicting malaria rates among G6PD deficient females, McCoy and 
Swain Langley genotypes in males.
Age-specific incidence by genotypes and relation with naturally acquired immunity
Age as a proxy for malaria immunity: In many epidemiological studies of malaria, incidence 
varies with age, which is measure of exposure and therefore immunity to malaria. Age 
specific malaria incidence would therefore be a measure of immunity to malaria. This is a 
pragmatic approach especially because there is no reliable gold standard used as a measure 
of immunity. Including genotypes in this analysis showed whether genes affect rates of 
acquiring naturally acquired immunity to malaria, as described in a previous study (Williams, 
Mwangi, Roberts, et al., 2005).
Age interactions affect naturally acquired immunity (Aponte et al., 2007). It can be shown 
from malaria incidence rates stratified by genes which genes are protective from malaria 
infection. However, by conducting an age stratification analysis to show it was possible to
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investigate if the effect is constant throughout the ages, or whether age affects the level of 
protection afforded by these genes.
Previous studies assessing evidence of acquired immunity include the study by Gong and 
colleagues (Gong et al., 2012), who recruited a cohort of 601 children, 1-10 years of age in 
Kampala, Uganda, and followed them for 18 months for symptomatic malaria and 
asymptomatic parasitaemia. The molecular force of infection, a measure of establishment of 
parasitaemia was reduced in HbAS children 9 years of age (IRR 0.50; 0.28-0.87; P=0.01) 
compared to children at 2 years of age (IRR 1.16; 0.62-2.19; P=0.6). Similarly, protection 
from development of disease was more evident in older HbAS children at 9 years of age (RR
0.68; 0.51-0.91; P=0.008) compared to younger children at 2 years of age (RR 0.92; 0.77- 
1.10; P=0.3).
Le Hesran and colleagues (Le Hesran et al., 1999) conducted a longitudinal study of P. 
falciparum infection and immunity. The prevalence of cellular responders to P. falciparum 
PH55/RESA antigen was similar in AA and AS children less than 2 years but was higher in 
AS children who were older. This implies that immunity to malaria develops at a higher rate 
among older children compared to infants.
If an immune basis to the protection exists, what might be its mechanism of action?
For HbAS
• Higher lympho-proliferative responses to P. falciparum soluble antigens in children 
with HbAS compared with normal children (Abu-Zeid et al., 1992; Bayoumi, 1987).
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• Higher titres of antibodies in HbAS compared with normal individuals(Marsh et al., 
1989).
• Interactive effect of HbAS in antibody-mediated immune protection (Achidi et al., 
1996).
For G6PD
• Courtin and colleagues (Courtin et al., 2011) found that G6PD A- reduced the 
antibody response to P. falciparum antigens. However, it is still is still not clear if G6PD A- 
actually reduces the incidence of malaria in a prospective cohort.
Three important conclusions have resulted from this study. First, in the face of changing 
malaria epidemiology in the last few years, variants of red cell genes still provide varying 
levels protection from malaria incidence. Secondly, red cell genetic variants affect the rate 
of acquisition of naturally acquired immunity. The mechanisms through which red cell genes 
interact with immune genes to accelerate acquisition of naturally acquired immunity is an 
area requiring further investigations. Finally, the likelihood of having malaria fevers may be 
dependent on red cell genotypes, for example in ABO blood groups.
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CHAPTER 5: The effect of other human candidate
polymorphisms on malaria incidence
5.1 Introduction
Background: Apart from the classical red cell genetic polymorphisms, many other candidate 
malaria-protective polymorphisms have been proposed. In this chapter, I investigate the 
association between a range of additional SNPs in multiple genes and the incidence of 
uncomplicated malaria.
Methods: The methods used have been described in detail in the materials and methods 
section. In summary, DNA was extracted from blood samples contributed by 1462 study 
participants and typed for 67 SNPs in 38 genes using a multiplex Mass Array™ method, as 
described in section 2.6.1.3 and Appendix IV. In addition samples were typed for 
a+thalassaemia by PCR (as described in section 2.6.1.2) to give a total of 68 genetic variant 
sets in 39 genes.
Statistical analysis: The effect of the each polymorphism on malaria incidence was 
investigated by Poisson regression. The outcome variable was uncomplicated malaria 
incidence. Predictor variables included genotypes of the candidate genes and other covariates 
including age, gender, year, season, socio-economic status, the education level of the 
caregiver and distance to Lwak hospital. Each SNP was fitted with the covariates alone and 
the results reported. The results of a multivariate analysis including significant confounders 
are also reported.
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Inferences: Since these SNPs are in malaria candidate genes, this investigation of their 
associations with incidence of malaria may be indicative of the role of the corresponding 
genes in malaria pathology. In addition, the results of these analyses are discussed in the 
context of the results from other studies that have investigated the effect on malaria of the 
same SNPs.
5.2 Objectives
1. To investigate allele frequencies and Hardy Weinberg equilibrium of SNPs in malaria 
candidate genes.
2. To investigate the effect of SNP markers in malaria candidate genes on incidence of 
malaria.
5.3 Results
5.3.1 Allele frequency, genotype frequency and Hardy Weinberg Equilibrium
Eleven SNPs were removed from further malaria incidence association analysis for the 
following reasons:
• Six were monomorphic in the study population: rs33930165, rs33950507, rs5743611, 
rs5743810, hcd36_gl439c and rsl799969.
• Two (rs2814778, rsl800482) had minor allele frequencies of less than 1%.
• Two alleles (rs461645 and rs7935564) deviated significantly (p<0.01) from Hardy 
Weinberg equilibrium.
• One allele, rsl 800750 was not successfully genotyped by the multiplex assay.
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As a quality control measure, 58 individuals were excluded because their self-reported gender 
was different from genetic markers in the amelogenin genes for gender (Eng et al., 1994). 
Therefore, 56 SNPs were investigated for associations with uncomplicated malaria in 1462 
individuals and the results are reported below. Deviations from Hardy Weinberg equilibrium 
were calculated using Pearson’s %2 test. The allele frequencies and Hardy-Weinberg 
equilibrium tests are presented in Table 5.1 below.
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5.3.2 A ssociation o f SNPs w ith  uncom plicated  m a laria
The association was investigated by determining a model and significance threshold as 
defined in section 5.3.2.1. The effect of SNPs on autosomal genes is reported in section
5.3.2.2 whereas the effect of SNPs on X linked genes is reported in section 5.3.2.3.
5.3.2.1 Model description and determination of a significance threshold
Associations between SNPs and malaria were studied using a Poisson model with the 
covariates age, gender, education, socio-economic status, year, season and distance to Lwak 
hospital (km). All the SNPs that yielded a p-value of <0.1 were fitted into a multi-gene SNP 
model with covariates as listed above. Since multiple statistical testing inflates the 
occurrence of false positives, an adjustment for multiple testing was required. Bonferroni 
correction was used to adjust for multiple testing by dividing the conventional type I error p- 
value (0.05) by the number of SNPs tested. However, since Bonferroni correction is a 
conservative adjustment method, a number of promising SNPs did not attain the statistical 
significance cut-off. Some of these will be discussed in the results as gene markers that 
potentially influence malaria incidence.
5.3.2.2 Autosomal genes: Effect of 50 SNPs on m alaria incidence
Each gene was tested individually for its malaria protective effect, with and without 
adjustment for the confounding variables such as the distance to hospital, age, year, season, 
education, socio-economic status and gender. Significant results of at least one gene variant 
are presented in Table 5.2 below.
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Table 5. 2 Genotypes that significantly affect the incidence of malaria in Poisson 
regression analyses.
rsnumber Gene_name genotype IRR min95 max95 p_value
rsl7411697 Interleukin 1A TT 2.19 1.31 3.66 <0.01
rs352140 Toll like receptor 9 AG 1.19 1 1.42 0.05
rs5743809 Toll like receptor 6 CC 0.26 0.15 0.45 <0.0001
rsl801033 Complement 6 AC 0.68 0.53 0.88 <0.01
rsl801033 Complement 6 CC 0.75 0.58 0.98 0.04
rs20541 Interleukin 13 TT 1.67 1.16 2.41 0.01
rs2243250 Interleukin 4 CT 1.45 1.01 2.08 0.04
rs2243250 Interleukin 4 CC 1.56 1.09 2.21 0.01
rsl800629 Tumor Necrosis Factor AG 1.24 1 1.53 0.05
rs361525 Tumor Necrosis Factor AA 0.49 0.29 0.84 0.01
rs3093662 Tumor Necrosis Factor GG 0.56 0.36 0.86 0.01
rsl7140229 CFTR CT 1.25 1.05 1.49 0.01
rs4986790 TLR4 GG 0.28 0.16 0.51 <0.0001
rs7935564 TRIM5 AG 0.83 0.69 0.99 0.04
rs2227507 IL22 CC 0 0 0 <0.0001
rs2230739 ADCY9 GG 3.59 1.88 6.82 <0.0001
rsl805015 IL4R CT 1.25 1.03 1.52 0.02
rs8078340 NOS2A TT 1.58 1.01 2.46 0.04
rs373533 EMR1 TT 0.77 0.61 0.97 0.02
Considering only the above genes, a simple model of innate immunity may be that pathogens 
are recognized through toll like receptors, innate immune effector mechanisms are recruited 
into action through production of TNF and interleukins, this process may be affected by cell 
signalling and membrane receptors and finally infected cells are killed by the complement 
system or through the action of species such as NO and TRIM-5. The presence of mutations 
affecting the incidence of malaria along this pathway are discussed below.
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5.3.2.2.1 Toll like receptors affect uncom plicated malaria incidence
(i) TLR-9 rs352140 G>A mutation is associated with an increased incidence of 
uncomplicated malaria.
Toll like receptors are innate immune receptors that recognize pathogen associated molecular 
patterns and trigger activation of immune cell responses. The current study used GG 
genotype of the rs352140 SNP as the reference group to compare malaria incidence across 
genotypes. Heterozygosity for AG was associated with a higher incidence of uncomplicated 
malaria (IRR 1.19; 1.00-1.42; p<0.05 but no significant association was seen with 
homozygosity of the A allele (IRR 1.15; 0.84-1.57; p=0.39). In keeping with these findings, 
TLR9 rs352140 GG was associated with a reduced risk of symptomatic malaria (RR 0.34; 
p=0.048) in a cohort study conducted in Ghanaian children (Omar et al., 2012). This mutation 
has also been associated with gene interactions which control parasite infection levels (Basu 
et al., 2012).
(ii) Toll like receptor 6 rs5743809 T>C mutation reduces the incidence o f uncomplicated 
malaria
Using the TT genotype as the reference, homozygosity for the C allele was associated with a
lower incidence of uncomplicated malaria (IRR 0.26; 0.15-0.45; p<0.0001). No association
was seen with heterozygosity (IRR 0.94; 0.0.76-1.16; p=0.54). 68% of these genotypes were
successfully genotyped. However, this finding is similar to that by Leorratti and colleagues,
who reported that the TT homozygotes were over represented in individuals with
asymptomatic infections (Leoratti et al., 2008). Although the function of the rs5743809 T>C
polymorphism is unknown, TLR 6 forms heterodimers with TLR2, a molecule that
recognizes P. falciparum glycosylphosphatidylinositol (GPI) to recruit the innate immune
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system to eliminate the parasite. It is likely that a disruption of any of these molecules affects 
the role of TLR2 in clearance of the parasite from the system (Leoratti et al., 2008).
iii) TLR-4 rs4986790 A>G mutation reduces the incidence of uncomplicated malaria
TLR-4 also recognises P. falciparum glycosylphosphatidylinositol, and primes the innate 
immunity for clearance of the parasites from the body (Krishnegowda et al., 2005). The TLR- 
4 gene carries the rs4986790 SNP also known as Asp299Gly (or 896A/G). Compared to the 
AA genotype, incidence of malaria was significantly reduced in GG homozygotes (IRR 0.28; 
0.16-0.51; p<0.0001) but not in AG heterozygotes (IRR 0.89; 0.71-1.1; p=0.27). The GG 
homozygote frequency was 1%, therefore the power was low to detect an effect. In a study 
in Burundi, genotype frequencies were similar between severe and uncomplicated malaria 
cases (Esposito et al., 2012).
5.3.2.2.2 Interleukin gene mutations and their receptors affect uncomplicated malaria 
incidence
i) Interleukin-1 a  rsi 7411697 G>T mutation increases the incidence o f uncomplicated
malaria.
This SNP in IL-1 a is also known in other notations as rsl7561. It codes for a non­
conservative amino acid change from alanine to serine at codon 114 of the interleukin 1-a 
protein. In this study, the GG genotype was used as the reference group. Homozygosity for 
the T allele was associated with raised incidence of malaria (IRR 2.19; 1.31-3.66; p <0.01). 
No effect was seen in GT heterozygotes (IRR 1.13; 0.95-1.34; p=0.17). My findings are 
similar to a previous study reporting an association between this polymorphism and
uncomplicated malaria in Gambian children (Walley et al., 2004). However, a second study
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has reported an association between this SNP and severe malaria in Vietnamese adults 
(Dunstan et al., 2012). As discussed by Dunstan and colleagues (Dunstan et al., 2012) the 
disparity in results might be explained by differences in case definitions, demographics of 
the malarial populations or to differences in transmission. At the time the Gambian study was 
conducted, The Gambia was a high transmission area, where most of the population had 
acquired immunity to malaria and would be expected to show only mild symptoms of the 
disease. As in most immune populations, clinical disease commonly affects children who 
have not fully developed immunity to malaria. However, in Vietnam low transmission results 
in a non-immune population, resulting in the disease affecting all age categories, and 
therefore disease presentation may be severe in the affected adults. The finding of association 
with mild malarial disease does not preclude association with severe disease. In the current 
study, this association could not be tested due the low number of severe disease episodes.
ii) IL-13: rs20541 C>T mutation increases the incidence of uncomplicated malaria. 
Interleukin 13 is a Th2 cytokine that has about 30% sequence similarity with IL-4 and has 
similar functions (Zurawski & de Vries, 1994). It activates B cells and monocytes, promotes 
IgE class switching and inhibits the production of pro-inflammatory cytokines. In the current 
study, CC genotype individuals were the reference group. Homozygosity for the T allele 
(IRR 1.67; 1.16-2.41; p< 0.01) was associated with higher incidence of malaria. 
Heterozygous CT individuals (IRR 0.95; 0.80-1.13; p=0.54) did not show a difference 
compared to the reference group. The C allele frequency was 0.78 whereas the T allele 
frequency was 0.22. The role of the mutation is well defined for severe disease compared to 
uncomplicated malaria. In a case control study conducted among Vietnamese, this mutation 
was associated with protection from severe malaria (Dunstan et al., 2012). A mutation in the
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same locus, the IL13 promoter -1055 C to T has also been associated with severe malaria 
protection in a case control study in Thailand (Ohashi et a l, 2003). More recently, a 
Tanzanian case-control study found that the rs20541 TT children were twice as likely to 
develop cerebral malaria compared to the CT children (Manjurano et al., 2012). Taken 
together, the higher incidence of uncomplicated malaria in the TT genotype reported in this 
study and more severe disease in the TT genotype from previous studies are consistent with 
a role of IL-13 in susceptibility to mild malaria and progression from mild to severe malarial 
disease.
iii) IL-4 rs2243250 T>C mutation increases the incidence of uncomplicated malaria. 
Interleukin-4 is a cytokine that activates T-cells from naive forms to T-helper 2 (Th2) cells. 
Th2 cells are important host immune effectors which stimulate proliferation of B-cells, 
increase production of neutralizing antibodies and induce the switch between antibody 
classes. The IL-4 rs2243250T variant is associated with increased transcriptional activity of 
the IL4 gene. Conversely, the C variant would be associated with lower levels o f IL-4. Using 
the TT as the reference, both the CT heterozygotes (IRR 1.45; 1.01-2.08; p=0.04) and CC 
homozygotes (IRR 1.56; 1.09-2.21; p<0.01) had a significantly higher incidence of mild 
malaria. However, the relationship between this variant and malaria is not the same between 
different studies. In family based pedigree studies in Tanzania, no association was reported 
between this locus and clinical episodes of malaria (Carpenter et a l, 2009). A study 
conducted in the Burkina Faso found that the mutation was not associated with P. falciparum- 
specific immunoglobulin E (IgE) in severe malaria or uncomplicated malaria. However, total 
IgE in IL-4 rs2243250 T individuals was significantly elevated among children with severe 
malaria (Verra et a l, 2004). The authors proposed there could be an association between IgE
and severe malaria, and that this relationship may be investigated in other settings. Another 
study in Ghanaian children with cerebral malaria found that the T variant appears at higher 
frequency in children with cerebral malaria compared with children with mild malaria (Gyan 
et al., 2004). Since cerebral malaria normally manifests in children with lower exposure to 
malaria, it would appear that the C variant protects from severe disease by predisposing 
children to higher mild malaria disease episodes.
iv) IL4R rsi 805015 T>C mutation increases the incidence of uncomplicated malaria.
The importance o f IL-4 in malaria incidence is further reinforced by the fact that the IL4 
receptor was also associated with malaria incidence. Compared to the TT genotype, incidence 
of malaria was significantly reduced in CT heterozygotes (IRR 1.25; 1.03-1.52; p<0.02) but 
not in CC homozygotes (IRR 1.14; 0.88-1.47; p=0.31). A study in Gabonese patients with 
severe malaria found high levels of soluble IL-4 receptor in serum (Perkmann et a l , 2005), 
suggesting a role of interleukin 4 in severe disease.
v) IL-22 rs2227507 T>C mutation may reduce the incidence of uncomplicated malaria in 
homozygotes.
IL-22 modulates tissue responses during inflammation, and is produced in response to IL-12, 
IL-18 and IL-13 by natural killer cells (Zenewicz & Flavell, 2011). The current study used 
the TT genotype of rs2227507 as the reference, and found that the incidence of malaria 
appeared to be reduced in the rare CC homozygotes (p<0.0001). However, there were only 3 
CC homozygotes (genotype frequency <1%)  and therefore the data could not allow for an 
estimate of the IRR or confidence intervals. As such, the result should be interpreted with 
caution. There was no effect of AG heterozygosity (IRR 1.15; 0.95-1.4; p=0.16). A study in 
West Africa identified two haplotypes in IL22, one containing the rs2227491 (+708) that was
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associated with protection against severe anaemia and another containing the rs2227478 (- 
1394) that was weakly associated with cerebral malaria. Since these SNPs could exist in 
different haplotype permutations with the one in the current study, the haplotypes need to be 
further investigated to delineate the causal allele for the reduced incidence reported in this 
study.
5.3.2.2.3 Effect of polymorphisms in TNF on malaria incidence
i) TNF rs 1800629 G>A mutation is protective against the incidence o f uncomplicated 
malaria.
TNF is a cytotoxin, produced by monocytes as part o f the innate immune response. Compared 
to the GG genotype, incidence of malaria was significantly reduced in AG heterozygotes 
(IRR 1.24; 1.00-1.53; p<0.05) but not in AA homozygotes (IRR 0.88; 0.43-1.8; p=0.73). 
Higher plasma levels of TNF have been linked with cerebral malaria and malarial fatality 
(Kwiatkowski et al., 1990). In another study conducted in the Solomon Islands, serum TNF 
levels were found to be correlated with malarial parasite density and patient’s temperatures 
(Butcher et al., 1990). Thus SNPs which may affect TNF function or production are expected 
to have an effect on malaria symptoms.
ii) TNF rs361525 G>A mutation reduces the incidence of uncomplicated malaria.
Compared to the GG genotype, incidence of malaria was significantly reduced in AA 
homozygotes (IRR 0.49; 0.29-0.84; p<0.01) but not in AG heterozygotes (IRR 1.08; 0.84- 
1.4; p=0.54). However, the significant reduction in AA homozygotes should be interpreted 
with caution as the AA genotype frequency was only 1%.
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iii) TNF rs3093662 A>G mutation reduces the incidence of uncomplicated malaria. 
Compared to the AA genotype, incidence of malaria was significantly reduced in GG 
homozygotes (IRR 0.56; 0.36-0.86; p<0.01) but not in AG heterozygotes (IRR 1.15; 0.95- 
1.4; p=0.16). The GG homozygote frequency was 2%, therefore the result should be 
interpreted with caution.
5.3.2.2.4 Mutations in membrane receptors and cell signalling pathway receptors 
affect mild malaria incidence
i) EMR1 rs373533 G>T mutation is protective against incidence of uncomplicated malaria. 
Epidermal growth factor module-containing mucin-like hormone receptor (EMR) 1 is a 
hormone receptor which belongs to the 7 trans-membrane superfamily of receptors. 
Compared to the GG genotype, incidence of malaria was significantly reduced in TT 
homozygotes (IRR 0.77; 0.61-0.97; p=0.02) but not in GT heterozygotes (IRR 0.92; 0.75- 
1.12; p=0.4). The rs373533 mutation has been associated with malaria-associated seizures 
in a case control study conducted in Kumasi (Kariuki et al., 2013). In a Cameroonian study 
of patients admitted with malaria, the GT individuals were found to have a significantly 
higher risk of hyperpyrexia compared to the GG and TT individuals (Apinjoh et al., 2014).
ii) CFTR rs 17140229 T>C mutation increases the incidence of uncomplicated malaria. 
CFTR is a chloride channel in epithelial cell membranes. Mutations in CFTR have previously 
been associated with protection from Salmonella typhi infection (van de Vosse et al., 2005). 
The current study used the TT genotype as the reference group and found that the incidence 
of malaria was significantly increased in CT heterozygotes (IRR 1.25; 1.05-1.49; p<0.01) but 
not in CC homozygotes (IRR 1.31; 0.96-1.78; p=0.08). A previous study in Cameroon 
comparing the TT with the CT and CC variants has associated the latter 2 variants with a
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protective effect from malarial anaemia in Cameroonian patients (Apinjoh et al., 2014). This 
SNP has also been associated with repetitive malaria associated seizures in a pooled analysis 
of data from Kenya, Malawi, Tanzania and Ghana (Kariuki et al., 2013).
iii) ADCY9 rs2230739 A>G mutation may increases the incidence of uncomplicated 
malaria.
Adenylate cyclase 9 is a stimulatory G protein signal transduction protein that is membrane 
bound. Compared to the AA genotype, incidence of malaria was significantly increased in 
GG homozygotes (IRR 3.59; 1.88-6.82, p<0.0001) but not in AG heterozygotes (IRR 0.89; 
0.68-1.17; p=0.41). The GG homozygote frequency was 0.4%, therefore the result should be 
interpreted with caution. However, Auburn and colleagues did not identify any association 
between this allele and severe malaria (Auburn et a l, 2010).
5.3.2.2.5 Mutations in genes involved in clearing pathogens from the body affect mild 
malaria incidence
i) Complement 6 rs 1801033 A>C mutation is protective from incidence of uncomplicated 
malaria.
Complement 6 is part o f the innate complement system, involved in the classical pathway of 
complement activation, which complements the ability of phagocytic cells and antibodies to 
clear foreign antigens from the body. This protein constitutes a part of the membrane attack 
complex, which usually causes cells that are infected with pathogens to lyse. Using the AA 
genotype as the reference group, both AC heterozygotes (IRR 0.68; 0.53-0.88; p<0.01) and 
CC homozygotes (IRR 0.75; 0.58-0.98; p=0.04) were found to have a lower incidence of 
uncomplicated malaria. The rsl801033 A>C SNP may lead to more efficient action of
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complement 6 and therefore lead to less occurrence of clinical malaria in individuals carrying 
this mutation, as observed in this study.
ii) NOS2A rs8078340 C>T mutation increases the incidence of uncomplicated malaria. 
Compared to the CC genotype, incidence of malaria was significantly reduced in TT 
homozygotes (IRR 1.58; 1.01-2.46; p=0.04) but not in CT heterozygotes (IRR 0.99; 0.83- 
1.19; p=0.96). The TT homozygote frequency was 4%, therefore the result should be 
interpreted with caution. In contrast, a study in Vietnam (Dunstan et a l , 2012) did not find a 
polymorphism at rs8078340. However, nitric oxide species have previously been reported to 
have an inverse relationship to severe malaria outcomes (Anstey et a l, 1996), with higher 
levels in asymptomatic individuals and the lowest levels in children who had cerebral 
malaria. Mutations in genes such as NOS2A involved in production of nitric oxide are 
therefore expected to have an effect on malaria outcomes.
iii) TRIM-5 rs7935564 G>A mutation reduces the incidence of uncomplicated malaria. 
Mutations in TRIM 5 have been associated with susceptibility to HIV (Nakayama & Shioda, 
2012) possibly because the molecule binds to HIV virions and targets them for removal from 
the body (Lukic et a l, 2011). Compared to the GG genotype, incidence of malaria was 
significantly reduced in AG heterozygotes (IRR 0.83; 0.69-0.99; p=0.04) but not in AA 
homozygotes (IRR 1.16; 0.88-1.54; p=0.3. This SNP has previously been recognized as a 
risk factor for severe malaria (additive A, OR= 1.273; 1.042-1.555; p=0.02) in Tanzania 
(Manjurano et a l, 2012). In a study in Vietnam, this SNP was associated with death from 
severe malaria when the severe malaria episodes were compared with cases that recovered 
from the disease (Dunstan et a l, 2012).
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Full results for all variants of the genes tested are presented in Figure 5.1 (a)-(d) and Table
5.3 below.
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5.3.2.3 Sex-linked genes: Effect o f  4 SNPs on malaria incidence
SNPs from sex linked genes were analysed separately from autosomal gene SNPs. In this 
study, these SNPs were in two genes, the G6PD deficiency SNPs (amino-acid positions 376 
and 202 mutations) and the CD40LG SNPs rs3092945 and rsl 7424229. Incidence rate ratios 
for G6PD deficiency mutation have been reported in Chapter 4 (see section 4.4.4). CD40LG 
analyses are reported here. The data were stratified by gender and analysed for the effect in 
the respective SNPs, rs3092945 and rs l7424229.
The rs3092945 affects malaria incidence in boys but not in girls: Among boys, using the 
TT genotype as the reference, CC individuals had a higher incidence of malaria (IRR 1.39; 
1.10-1.76; p<0.01). However, there was no difference in girls, where neither the CT 
individuals (IRR 0.99; 0.77-1.26; p=0.91) nor the CC individuals (IRR 0.96; 0.68-1.35; 
p=0.81) gave evidence of a difference with the TT reference group.
The rsl7424229 does not affect m alaria incidence in boys or girls: The TT genotype was 
used as the reference genotype. Among boys, there was no difference in incidence o f malaria 
in the CC individuals (IRR 0.76; 0.54-1.06; p=0.11). Among girls, neither the CT individuals 
(IRR 0.93; 0.73-1.18; p=0.53) nor the CC individuals (IRR 0.96; 0.38-2.46; p=0.93) gave 
evidence of a difference with the TT reference group.
148
5.3.2.4 Effect o f m ultivariate SNPs on malaria incidence
All genes with p-value less than 0.1 in the univariate analysis were used as predictors in a 
multivariate model, in addition to covariates. 3 genetic polymorphisms were found to be 
significantly related to malaria incidence.
i) EMR1 rs373533: Compared to the GG group, TT individuals were protected against 
clinical malaria (IRR 0.67; 0.53-0.84; p<0.001). The genotype frequencies were 28%, 51% 
and 21% for GG, GT and TT respectively. The role of EMR1 and comparison to other studies 
was described in section 5.3.2.2.4 above.
ii) TLR_6 rs5743809: Compared to the TT group, the rare CC genotype individuals were 
protected against clinical malaria (IRR 0.31; 0.16-0.6; p<0.001). The genotype frequencies 
were 82%, 17% and 1% for TT, CT and CC respectively. The role of TLR-6 and comparison 
with other studies was discussed in section 5.3.2.2.1 above.
iii) ADCY9 rs2230739: Compared to the AA group, rare GG genotype individuals had 
increased susceptibility to malaria (IRR 5.12; 2.23-11.75; p<0.001) incidence of clinical 
malaria episodes. The genotype frequencies were 87%, 12% and 1% for TT, CT and CC 
respectively. The role of ADCY9 has been described in section 5.3.2.2.4 above.
Among the genes above, the EMRlrs373533 variant had a protective variant (TT) with a 
high frequency. This suggests it is not deleterious, and may in fact be selected because of the 
protection it provides against malaria incidence. I therefore further investigated the age 
specific incidence of this gene in a Poisson-adjusted model, with and without covariates, as 
described in Table 5.4 below. Crude malaria incidence was also plotted according to 
genotype and age categories as shown in Figure 5.2
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Overall, the rs373533 TT variant reduced the incidence of uncomplicated malaria on both 
crude and adjusted analyses. The IRR for the adjusted analyses was 0.77 (95% C.I. 0.62-
0.97; P<0.05). The other genes were not included in this analysis, hence the difference in the 
effect sizes seen between this model and the multi-gene model (see section 5.3.2.4). The 
current single gene analysis shows that the TT genotype was still significantly associated 
with a lower incidence of malaria, similar to the multigene model. Age specific investigation 
revealed significant protection at 4-6 years, but this effect appeared to be reversed for those 
over 10 years of age. However, the number of individuals over 10 years was low and therefore 
lacked sufficient power to conclude that the TT gene variant increases the incidence of 
malaria in this age group.
5.4 Discussion
This study investigated the protective effect that may arise from candidate malaria protective 
genes in a population of Lwak, Asembo. The major hypothesis under consideration was that 
variants of these malaria candidate genes significantly affect the incidence rate of malaria. I 
found that markers in 17 genes were related to malaria (see Table 5.2 above). However, some 
of these findings should be interpreted with caution, as the protective genotype frequency is 
<5%. Few studies consider susceptibility to uncomplicated malaria as a major outcome in 
malarial disease susceptibility studies. In contrast, this study contributes to the discourse on 
malaria susceptibility genes by focussing on susceptibility to mild malaria. One of the major 
results is that the same genes involved in susceptibility to severe malaria also implicated in 
susceptibility to mild malaria. These findings could be interpreted in at least two ways; first, 
that children at higher susceptibility to mild malaria are also much more likely to come down
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with severe malaria. Alternatively, it may be that malaria progresses from asymptomatic to 
mild and eventually severe in a particular subset of children who carry a subset of genetic 
variants. These possibilities remain to be proved in mechanistic studies. However, there are 
important differences between this study and previous studies showing the risk of malaria in 
these gene variants. These previous studies were case-control studies in severe malaria 
susceptibility (Dunstan et a l, 2012; Kariuki et al., 2013; Manjurano et a l, 2012), whereas 
this study was an observational cohort study whose main outcome was mild malaria.
The current study also considered potential sources of bias and confounding. Covariates of 
malaria incidence, a possible source of confounding, were identified through univariate 
analysis and adjusted for in the multivariate model. However, not all individuals had data on 
all the covariates, and therefore only the ones which had complete data for were included in 
the adjusted rates. Bias may arise in the conclusion of this study due to correlation of 
outcome measures from the same individual and relationships between the children studied. 
I used the sandwich estimator to account for possible bias due to the same individual 
contributing to multiple episodes. I sought to add an additional adjustment factor for 
household level clusters which approximate genetic relationships since I studied siblings, but 
the data showed that adjustment using the sandwich estimator was not significantly different 
from analyses using both the sandwich estimator and household cluster. The data were 
therefore only adjusted using the sandwich estimator.
The current approach used may also add value to genome wide association studies (GWAS). 
Although a candidate gene approach was used, several of the genes showing an appreciable
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effect on univariate analysis were also analysed together in one Poisson regression model. 
However, the emphasis in GWAS studies is usually to identify new markers of resistance, 
and the complexity of GWAS means that complex statistical procedures are employed to 
choose the markers of significance (Jallow et a l , 2009). By comparing a few marker genes 
in a candidate gene approach, this study hopes to increase the chances of finding a true 
relation between the gene and malaria, un-confounded by the many SNP variations that may 
occur randomly in genome wide association comparisons.
Another important finding of the current study was that without controlling for effect of other 
genes, variants of thalassaemia and sickle both appear to significantly affect the incidence of 
uncomplicated malaria. However, when other candidate genes were controlled for, sickle and 
thalassaemia did not show a statistically significant effect on mild malaria. This may be due 
to interactions between the various genes. This possibility is considered in chapter 6.
It is clear from the list of significant genes that immuno-genetics plays a crucial role in 
protection from malaria. A review of malaria immunity was considered in order to set in 
context the findings in the current chapter. Immunity to malaria is complex; however, a few 
key features of malaria immunity are worth noting. Firstly, anti-malarial immunity is not 
sterile i.e. individuals may still fall ill to malaria when exposed (Marsh & Kinyanjui, 2006). 
Moreover, individuals who reside in malaria endemic areas appear to lose immunity when 
they travel to a non endemic site and subsequently fall ill more often when they return to 
their original endemic area. This suggests that constant exposure to the malaria parasite 
affords some immunity in the patients, and the phenomenon is termed as premunition (Smith
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etal., 1999).
Secondly, anti-malarial immunity may further be divided into two components: anti-disease 
immunity, which is immunity to symptomatic effects of parasite infection and anti-parasite 
immunity, which is immunity that results in lower levels of parasitaemia (Marsh & 
Kinyanjui, 2006). Observations from endemic areas have shown that individuals develop 
tolerance to the malaria parasite, and therefore anti-disease immunity before the more 
specific anti-parasite immunity. Such anti-malarial immunity may be species and strain 
specific (Jeffery, 1966).
Finally, the mechanisms of immunity to malaria may explain premunition, anti-disease 
immunity, anti-parasite immunity and the observations in the current chapter. Malaria 
immune mechanisms have been broadly classified according to the components of the hosts’ 
immunity or according to the parasite stages affected by the immune response. The host 
immune response involves both the cell mediated and humoral immune components. Cell 
mediated immunity is characterized by CD8+ T cells, CD4+ T cells, natural killer cells(NK), 
natural killer T cells (NKT), yST cells and macrophages, whereas humoral immunity is 
mediated by antibodies produced by plasma cells and memory B cells. In a mouse model, 
within 48 hours of sporozoite inoculation, Plasmodium specific CD8+ T cells are detectable 
in lymph nodes that drain the skin (Chakravarty et al., 2007). Such T cells produce IFN-y, 
which induces innate nitric oxide, a toxic radical which has been shown to limit the 
development or replication of malaria parasites (Schofield & Mueller, 2006).
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In the liver, sporozoite inoculation studies have highlighted the importance of cell mediated 
immune (CMI) responses, where sterilizing immunity to infection by irradiated sporozoites 
has been achieved by inducing diverse CMI responses. The initial response is thought to 
result from innate recognition of the pathogen and reaction through natural killer and natural 
killer T cell mediated killing of infected cells. Adaptive responses result when the antigens 
from the parasites are processed and presented on MHC molecules, leading to CD8+ T cells 
acting as cytotoxic T lymphocytes (CTL) by recognizing parasite infected cells and killing 
them. Dendritic cells may be crucial to this process, as they can act as an antigen presenting 
cells by phagocytizing sporozoite antigen and presenting peptides from parasites on MHC 
class I to CD8+ T cells (Cockbum et al., 2011). CD4+ T cells also produce IFN-y, which 
promotes NK activity.
In the blood stages, the innate response is characterized by induction of macrophages, NK 
and NKT cells producing NO through the inducible nitric oxide synthase( iNOS), which are 
toxic to malaria infected cells (Schofield & Mueller, 2006). However, antibody responses are 
the most important at this stage in reducing parasitaemia and relieving symptoms of malaria, 
as shown in the classical immune antibody transfer from protected adults to sick children 
(Cohen et al., 1961). Such antibodies are produced by plasma B cells and form the plasma 
antibodies that protect against malaria in endemic areas. However, such antibodies are known 
to decline rapidly in the absence of constant exposure (Weiss et al., 2012). Memory B cells 
are also produced as a result of exposure to malaria parasites, and are generally more long 
lasting than circulating antibodies. In the absence of exposure, such memory B cells can 
induce rapid boosting of the antibody response when the host is re-exposed to malaria
antigens after several years (Wipasa et a l, 2010) and (Ndungu et al., 2012). Repeated 
infections have also been implicated in the expansion of the memory B cell compartment of 
human immunity to malaria (Weiss et al., 2012).
CD4+ T cells produce Thl inflammatory cytokines, and later Th2 regulatory cytokines. Thl 
pro-inflammatory cytokines and chemokines are associated with fever and other malarial 
symptoms (Collins & Jeffery, 1999). These include IFN-y, TNF, IL-ip, IL-6, IL-12(p70) and 
IL-8 (Lyke et al., 2004; Walther et al., 2006). Inflammation results from interaction parasite 
derived products or by products interacting with immune cells, for example, haemozoin 
which binds to activating TLR9 (Parroche et al., 2007) and GPI anchors to TLR2 
(Krishnegowda et al., 2005) trigger inflammation. Inflammation may also result from an 
interaction with host receptors, for example, some PfEMPl variants bind endothelial protein 
C receptor in the brain(EPCR), thus blocking the protective function of the receptor in 
binding activated protein C and resulting in cerebral malaria (Turner et al., 2013).
Since excessive inflammation can lead to severe and fatal malaria (Grau et al., 1989), Th2 
regulatory cytokines are also produced by the host. Work in mouse models has shown that 
regulatory cytokines TGF-p (Omer & Riley, 1998) and IL-10 (Li et al., 1999) counter the 
production of pro-inflammatory cytokines -IFN  y and TNF. In humans, higher ratios of pro 
to anti-inflammatory cytokines in serum during acute malaria have been associated with more 
severe disease in some studies (Day, 1999; Dodoo et a l, 2002) but another study found a 
different result (Walther et al., 2009). It has been argued that the key distinction of survival 
from life threatening malaria in early life may be linked to the ability to control excessive P.
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falciparum-induced inflammation, since antibodies are only reliably acquired after many 
years of P. falciparum exposure (Portugal et al., 2013).
The lack of sterilizing immunity in human malaria is likely to be due to many factors, which 
may include the high immuno-regulatory environment of the skin and the liver, (Honda et 
al, 2011), the high levels of intra-hepatic response required to kill intra-hepatic parasites 
immunity and initiate sterilizing immunity (Schmidt et a l, 2010). In addition, studies show 
that the magnitude of vaccine-induced CD8+ specific for pre-erythrocytic antigens is 
correlated to protection (Webster et a l, 2005), and therefore sterilizing immunity is likely to 
be associated with responses above a high threshold which has not been achieved to date in 
natural infections.
Based on an understanding of the immune response in malaria, various vaccines have been 
formulated and studied for the protection they afford against malaria. The vaccine candidates 
target different stages of the life cycle of the parasites, as reviewed by Schwartz and 
colleagues (Schwartz et a l, 2012). Many of these target the blood stage as it produces 
symptoms of malaria, whereas some target the sporozoite based on the early promise of 
whole cell irradiated sporozoite induced protection (Nussenzweig et a l, 1967). The most 
advanced vaccine candidate to date is the circumsporozoite based P. falciparum RTS,S 
vaccine which confers sterile protection to than more half o f malaria naive adults (Casares et 
al, 2010). In endemic populations, the vaccine reduces incidence of malaria by 
approximately 50% in children 5-17 months old (Agnandji et a l, 2011) and 30% in infants 
6-12 weeks old (Agnandji et a l, 2012). Since the current study has shown genetic variants
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that affect malaria incidence, evaluation of the impact of the vaccine may benefit from an 
analysis of the genetic variants of children in the various randomization arms.
5.5 Summary
This study found that 17 SNPs (see Table 5.2 above) made a significant difference in 
incidence rate ratio of malaria. In multivariate analysis, a polymorphism in EMRI-1 gave a 
significant result for protection from malaria. SNPs in two other genes, ADCY9 and TLR-6, 
had low numbers of protective or susceptibility loci. These findings should therefore be 
interpreted with caution since the power of the study was reduced by the low numbers of 
genotypes of variants affecting malaria incidence. The role of the genes has been identified 
from the literature, showing biological plausibility for why they could be related to malaria 
incidence. Interventions seeking to reduce malaria incidence, such as malaria vaccine studies, 
may benefit from an evaluation of the gene frequencies of some of these protective variants 
among study participants. Interactions between the various genes could be one reason why 
fewer genetic effects were seen in the multiple gene analysis. This possibility is investigated 
further in the next section, Chapter 6.
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CHAPTER 6: Effect of interactions between malaria candidate 
genes on malaria incidence
6.1 Introduction
Background: Apart from the effect of individual genes, gene interaction is likely to be an 
important factor influencing malaria outcomes. Such genetic interaction, termed epistasis 
may play a role in complex trait outcomes (Carlborg & Haley, 2004), such as malaria. In 
recent years, examples of the effect of gene epistatic interactions on malaria outcomes have 
been shown in malaria endemic populations (Atkinson et al., 2014; Williams, Mwangi, 
Wambua, Peto, et al., 2005). These examples involve genes related to the red blood cell 
metabolism which interact to increase or reduce malaria severity. A brief overview of the 
role of epistasis in malaria incidence was presented in chapter 1 (section 1.2.4.5). In this 
chapter, I investigate two way genetic interactions, first between loci in red blood cell genes 
and second between loci in other malaria candidate genes in the Asembo genetic cohort.
Methods: I recruited a paediatric cohort of 1462 children from Asembo in western Kenya, 
and followed them up for incidence of malaria episodes by passive surveillance at Lwak 
mission hospital between 2008 and 2013. Detailed descriptions of the cohort, the study area 
and recruitment methods are outlined in Chapter 2. A multiplex mass array method was used
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to type for all the genes tested for interaction, as described in section 2.6.1.3 and Appendix 
IV. In addition a+thalassaemia was typed by PCR (as described in section 2.6.1.2) and added 
to this set for a final set of 68 genetic variant sets in 39 genes. I conducted analyses for the 
effect o f interactions between variants of the typed genes as described below.
Statistical analysis: I fitted two models to genotype and malaria incidence data as follows:
1. A non-interaction Poisson model (Model I). This model predicts malaria incidence 
using, as dependent variables, a pair of genes and covariates such as age, distance to hospital, 
year, season, education, gender and socio-economic status.
2. An interaction Poisson model (Model II). It is similar to model I, but in addition has 
an interaction term representing the interaction between the pair of genes.
I used a likelihood ratio test (LRT) to compare the likelihood estimates of Model I and Model 
II. I inferred a significant interaction effect when the LRT p-value was < 0.05 or when the p- 
value was less than a Bonferroni correction of this p-value when multiple tests were 
performed.
Inferences: Models which showed a statistical significance were assessed for biological 
plausibility by checking biological databases of protein interactions and literature on the 
interacting pair of genes. Some hypotheses on why an interaction between the genes may 
affect malaria incidence were proposed.
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6.2 Specific objectives
1. To investigate how co-inheritance of common red blood cell genes variants affect 
malaria incidence
2. To investigate the effect of co-inheritance at 68 malaria candidate gene loci on 
malaria incidence
Definitions:
1. Statistical significance thresholds: The threshold used to determine significantly 
interacting genes from the likelihood ratio test. Thresholds for objective 1 and 2, plus their 
justifications, are presented below.
Threshold considerations for objective 1: Significant interactions were assumed for those that 
had an LRT p-value < 0.05 since these interactions had been hypothesized a priori.
Threshold considerations for objective 2: Testing for multiple interactions is likely to 
introduce false positives. Therefore, a Bonferroni correction was used on the p-value by 
dividing it by the number of tests. In this comparison I did 56 tests on each of 57 SNPs, a 
total of 3192 tests. Therefore the significance p-value threshold was < 0.05/3192= 0.000016
2. Interaction terms: A term denoting occurrence of two variants together, added to 
the Poisson model to check the effect of interaction. Examples of interaction terms are shown 
in table 6.1 for red blood cell genes. For example, for interaction between sickle and a 
thalassaemia, the interaction term ‘a’ in table 6.1 was used, whereas for interaction between 
sickle and CR1 Swain Langley, interaction term T  was used and so on.
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Table 6.1 Interaction terms for Sickle, ABO blood groups, G6PD deficiency in males, 
G6PD deficiency in females, CR1 McCoy blood groups and Swain Langley blood groups.
a
th a la s s a e m ia
A B O
G 6P D  d e f. 
m a le
G 6P D  d e f. 
fe m a le
CR1
M c C o y
CR1
S. L a n g le y
S ick le
Interaction term 
a
Interaction 
term b
Interaction 
term c
Interaction 
term d
Interaction 
term e
Interaction 
term f
A lp h a
th a la s s a e m ia
Interaction 
term g
Interaction 
term h
Interaction 
term i
Interaction 
term j
Interaction 
term k
A B O
Interaction 
term I
Interaction 
term m
Interaction 
term n
Interaction 
term o
G 6P D  d e f ic ie n c y  
m a le
Interaction 
term p
Interaction 
term q
G 6P D  d e f ic ie n c y  
fe m a le
Interaction 
term r
Interaction 
term s
M c C o y
Interaction 
term t
def. =  deficiency
6.3 Results
QC procedures. Since multiple testing using the LRT may give ‘false positives’ for 
interaction, stringent quality control procedures were applied on the resulting output. As 
outlined in chapter 5 (section 5.3.1), 11 SNPs were excluded from further analysis because 
they were either monomorphic (rs33930165, rs33950507, rs5743611, rs5743810, 
hcd36_gl439c and rs l799969), had minor allele frequencies less than 5% (rs2227507, 
rs9282799 and rs4986791) or showed a more significant deviation from Hardy-Weinberg 
equilibrium pO.OOl likely due to genotyping error (rs4986791 rs7935564 rs2814778).
To allow for biologically meaningful interpretations, RBC polymorphism interactions for 
which more is known are presented first (section 6.3.1). Once confidence in these results was
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established, interactions between other genes in the same cohort were investigated (section 
6.3.2) and possible promising pairs of interacting genes were proposed.
6.3.1 Red blood cell gene in teractions
The results of interaction tests for red blood cell genes are reported in table 6.2 below.
Table 6. 2 Likelihood ratio test p-values comparing a non-interaction models (model I) and 
a model with interaction (model II) for common genotypes of red blood cells.
a
A B O
G 6P D  d e f. G 6P D  d e f. CR1 CR1
th a la s s a e m ia m a le fe m a le M c C o y S. L a n g le y
S ick le 0.003 0.032 0.016 0.001 0.109 0.019
a - th a la s s a e m ia <0.001 0.003 0.182 <0.001 0.008
A B O 0.015 <0.001 <0.001 <0.001
G 6P D  d e f ic ie n c y  
m a le
0.021 <0.001
G 6P D  d e f ic ie n c y  
fe m a le
0.086 0.031
M c C o y 0.026
def. = deficiency
For the common red blood cell genes, there is evidence for interaction at the p<0.05 level. 
Results are presented to 3 decimal places to compare the relative evidence for interaction 
between the various gene pairs.
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Figure 6. 1 Forest plot showing the interaction between sickle and thalassaemia
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The effect o f  thalassaemia homozygotes in increasing the rate o f malaria appears to be reversed in the background o f  sickle 
cell trait, such that homozygotes instead reduce the rate o f malaria.
Table 6. 3 Incidence rate ratio (IRR), 95% lower class limit (LCL) and upper class limit 
(UCL) of various co-inheritance patterns of sickle and thalassaemia genotypes.
S ick le
g e n o ty p e s
T h a la s s a e m ia
g e n o ty p e s
IRR LCL UCL
A A aa/aa 1
-a/aa 1 .0 1 0 .8 2 1 .2 4
-a/-a 1 .1 3 0 .8 4 1 .5 2
AS aa/aa 0 .8 6 0 .6 3 1 .1 6
-a/aa 0 .8 7 0 .6 3 1 .2 2
-a/-a 0 .6 4 0 .3 4 1 .2 0
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6.3.2 Interactions in 57 malaria candidate gene loci
Interaction tests were conducted between pairs of candidate gene loci, except the loci 
interacting with itself, resulting in a total of 57*56=3192 tests. The p-values for these tests 
were assessed if they were lower than the Bonferroni corrected value of 0.000016. Figure 6.2 
is a Manhattan plot of all the p-values in the test, showing the ones above and below 
threshold.
Figure 6. 2 Manhattan plot of -log 10 p-values for SNP interactions.
gene variant
In the figure, values less than the threshold (0.000016 after Bonferroni correction) appear above the threshold value o f  4.8 
(the dashed line) since the p-values are transformed by multiplying by -loglO.
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Most of the p-values did not attain the threshold, but about 180 exceeded the threshold value, 
indicating a high incidence of potential statistical interaction between SNP pairs in 
modulating malaria incidence. The 50 lowest p-values are shown in table 6.4 below. They 
are arranged by the first gene (gene 1) of the interacting pair for ease of comprehending the 
number of gene interactions that one gene is likely to be involved in.
Table 6. 4 The top 50 SNP-pair hits detected using the LRT method. The table shows SNP 
pairs, SNP reference numbers and p-values of the LRT.
Gene 1 genel_rsnum ber Gene2 gene2_rsnumber LRT p-value
CR1 rsl7047660 IL1B rsll43634_2 2.43E-09
CR1 rsl7047660 GNAS rs8386 4.35E-09
CR1 rsl7047660 TNF rsl800629 6.66E-09
CR1 rsl7047661 ADCY9 rs!0775349_2 1.37E-10
CR1 rsl7047661 C6 rsl801033_2 8.14E-09
ILIA rsl7411697 IL13 rs20541 1.05E-10
ILIA rsl7411697 NODI rs2075820_2 2.80E-08
TLR9 rs352140 IL4 rs2243250 2.62E-15
TLR9 rs352140 IL13 rs20541 1.92E-10
TLR9 rs352140 IL20RA rsl555498_2 2.1E-10
TLR9 rs352140 TNF rsl799964 1.26E-09
TLR9 rs352140 CTL4 rs2242665_2 4.57E-08
IL17RD rs6780995 IL4 il4r63011_2 8.38E-17
IL17RD rs6780995 NOS2 rs9282799_2 1.93E-08
TLR1 rs4833095 GNAS rs8386 2.55E-09
TLR1 rs4833095 NOS2 hnos21659_2 3.00E-08
C6 rsl801033 TNF rsl799964 1.35E-10
C6 rsl801033 IL22 rs2227491 2.5E-10
C6 rsl801033 IL22 rsl012356 1.3E-08
IRF1 rs2706384 CD40LG rs3092945_2 4.39E-13
IRF1 rs2706384 IL13 rs20541 8.54E-09
IRF1 rs2706384 EMR1 rs373533 2 2.25E-08
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Gene 1 g e n e lrs n u m b e r Gene2 gene2_rsnumber LRT p-value
IL13 rs20541 SPTB rs229587_2 7.4E-12
IL13 rs20541 IL4 rs2243250 2.60E-08
IL4 rs2243250 DERL3 rs3177244_2 5.74E-11
IL4 rs2243250 NOS2 rs8078340 3.81E-08
LTA rs2239704 LTA rs909253 8.59E-10
LTA rs2239704 CFTR rsl7140229_2 1.31E-09
LTA rs2239704 ADORA2B rs2535611_2 3.02E-08
LTA rs909253 CFTR rsl7140229_2 7.46E-10
LTA rs909253 RTN3 rs542998_2 4.62E-09
TNF rsl800629 CD40LG rs3092945_2 1.31E-09
NODI rs2075820 CD40LG rs3092945_2 2.02E-08
RTN3 rs542998 DERL3 rs3177244_2 4.36E-08
IL22 rs2227491 CD40LG rs3092945_2 3.69E-10
IL22 rs2227478 SPTB rs229587_2 5.17E-11
ADORA2B rs2535611 EMR1 rs373533_2 5.65E-10
ICAM1 rs5498 GNAS rs8386 2.33E-08
GNAS rs8386 CD40LG rs3092945_2 1.55E-08
ABO inferred_bg RTN3 rs542998_2 8.55E-12
ABO inferred_bg IL4 rsl805015 8.53E-09
IL10 rsl800896 LTA rs909253 1.01E-12
IL10 rsl800896 CFTR rsl7140229_2 3.49E-08
IL10 rsl800890 LTA rs909253 1.89E-08
IL10 rs3024500 LTA rs909253 7.79E-12
IL10 rs3024500 IL4 rs2243250 6.63E-09
IL10 rs3024500 TNF rs361525 2.63E-08
GBP7 rs7537937 IL10 rs3024500 4.79E-11
GBP7 rs7537937 IL22 rs2227478 1.96E-10
HBB rs334 LTA rs909253 3.51E-11
Top 50 genetic interactions were those that had the lowest LRT p-value. Genes are arranged by the first gene o f  the 
interacting gene pair to show the various interactions one gene could have. SNPs highlighted in bold match the network o f  
interactions identified using a biological database o f interacting genes, the STRING database (see figure 6.3).
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I expected a lower number of interaction signals. At least two reasons could account for the 
higher than expected significant p-values detected in this study (i) A high number of residual 
false positives (ii) Higher number of actual gene interactions than expected. These 
possibilities are considered in turn below.
(i) The analysis may reflect a high number of residual false positives
I used two approaches to address the possibility that the p-values detected were indeed false 
positives. The first was to compare the p-values detected with a known interaction which 
affects severe malaria incidence, the sickle cell trait and a-thalassaemia interaction. One 
important consideration is that the current study addresses uncomplicated malaria incidence. 
As such, the p-value for sickle and a-thalassaemia interaction as detected in this study for 
mild malaria was used as a comparator to any potentially significant interactions between 
genes that may affect mild malaria. The LRT p-value interaction was reported in section 6.3.1 
above and yielded a p-value of 0.003 in this dataset (see section above). This was significant 
at the p<0.05 level. The p-values detected by the LRT were several orders o f magnitude 
smaller than this p-value, ranging from 0.003 to 8.38E-17. It was possible that p-values much 
lower than 0.003 were spurious interaction effects. However, at the p<0.003 significance 
level, about 30% of the tests gave a signal for interaction, which I considered to be an unlikely 
possibility.
The second approach was to check if interactions between genes reported from this analysis
had evidence from literature and biological databases. The tool used for this was the Search
Tool for Retrieval of Interacting genes/proteins, STRING database, version 10. I submitted
169
31 protein names to the database for construction of a protein interaction network as seen in 
figure 6.3. The parameters used in the STRING database for the construction of the network 
were: medium confidence score of 0.4, evidence from all active prediction methods including 
neighbourhood, gene fusion, co-occurrence, co-expression, experiments, databases and text 
mining. Given its well documented role in malaria incidence, haptoglobin was included as 
part of the input to the STRING database to check for the proteins it interacts with, even 
though it was not typed in the current study. Interestingly, the STRING network demonstrates 
that haemoglobin related proteins (Haemoglobin beta (HBB), Haemoglobin alpha 1 (HBA1), 
Haemoglobin alpha2 (HBA2) and Haptoglobin (HP)) for which there is evidence of epistatic 
interaction for malaria incidence (Atkinson et a l, 2014; Williams, Mwangi, Wambua, Peto, 
et a l, 2005) cluster together and form a tight 1:1 interaction node of the network. This is 
consistent with the conclusion that the STRING network is an important tool in interpretation 
of statistical data and in validating hypotheses of interaction between genes (Emily et a l,
2009). The top 50 interactions from the LRT as reported in table 6.4 were compared with the 
nodes of the interaction network from the output of STRING (figure 6.3). From this 
comparison, 3 interactions from table 6.4 (in bold) matched interacting nodes from the 
STRING database. These gene interaction pairs are TLR9-IL4, IL4-IL13 and IL10-IL4. 
The presence of these nodes appears to validate the results of some of the LRT analyses. 
However, the vast majority are not supported by evidence from the STRING database and 
may represent statistical but not biologically plausible interaction. Alternatively, the 
STRING database may yet be updated with evidence of these genetic interactions in future.
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A high number of false positives could also be a feature of the Poisson model used. Lettre 
and colleagues (Lettre et al., 2007) have shown that this model performs well in detecting 
effects of SNPs that are inherited in an additive or co-dominant fashion. However, it does not 
maximize power for those genes where recessive effects contribute to the disease being 
studied.
Figure 6. 3 Network of interacting genes from among the 31 being tested for interactions.
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The figure was generated from the STRING database, version 10. Purple lines indicate evidence from experiments, blue 
lines indicate homology o f sequences, green indicates evidence from text-mining, dark green indicate association by 
neighbourhood, Red indicates association by gene fusion whereas blue indicates association in gene and protein databases.
171
(ii) There may be a higher num ber of actual gene interactions than expected.
A review of epistasis has suggested that it may be more common than previously assumed 
(Carlborg & Haley, 2004). However, given that there are potentially a very large number of 
interactions between these genes, the current results should be interpreted with caution. The 
number of associations detected is dependent on the threshold of significance assumed, with 
higher thresholds resulting in higher number of signals. This study used the most 
conservative method of correction, which was expected to yield a very low threshold, and 
consequently, a few plausible epistasis candidate pairs. However, one challenge in the current 
analysis is that Bonferroni correction does not take account of linkages between genes. It 
assumes that the multiple tests are independent from each other, whereas one individual may 
carry several SNPs at the same time, or there could be linkage disequilibrium between SNPs 
and therefore one SNP could be related to several others. In addition, many SNPs would not 
remain significant on application of the most conservative methods such as the Bonferroni 
method. Among the alternative methods, the permutation approaches are currently favoured 
in choosing p-value cut-offs for multiple genetic tests, but they are complex and 
computationally intensive to implement. In addition, they assume independence o f the 
multiple tests. An adaptation of the permutation approach for use in correlated genetic data 
has been described (Gao et al., 2008) and has been used in various data sets which consider 
the same SNPs like this study (Dunstan et a l, 2012; Kariuki et al., 2013; Manjurano et al., 
2012). Since the p-values cut off depends on the genetic SNP variation data, genetic structure 
may be a factor in choosing the correct cut-off. Given the complexity involved in such 
determinations, I considered using a threshold of significance similar to ones used for
previous studies in local populations. A review of the literature identified two studies 
(Kariuki et a l, 2013; Manjurano et a l, 2012) that investigated the association between these 
same SNPs and severe malaria, and in populations that are expected to share the same genetic 
structure as participants in the current study. One study, conducted in Tanzania (Manjurano 
et a l, 2012) used permutation methods to arrive at a cut-off p-value of p<0.02, whereas the 
other, conducted in Kilifi, used the method described by Gao and colleagues (Gao et a l, 
2008) that approximates the permutation method to arrive at a cut-off p-value of p<0.009. 
The average of these (0.0145) was considered as a significance threshold. However, a major 
disadvantage of this approach was that the model specification used in these previous studies 
were different, as all the genes were modelled together in a multivariable model. In addition, 
in these previous studies, a LRT was not performed to check for interaction between loci. 
After all these considerations, I chose to use the Bonferroni correction since it is a 
conservative method and is expected to give the lowest number of false positives.
6.4 Discussion
Gene interactions are important in conditions of complex aetiology such as malaria. Epistasis 
could explain the absence of ‘novel’ genetic associations in studies, apart from classical loci 
such as sickle cell trait or a-thalassaemia as reported by Mackinnon and colleagues 
(Mackinnon et a l, 2005). In addition, genetic interactions may explain differing effects of 
genes on malaria outcomes in different populations. An example is the case of Interleukin 12 
beta gene (IL12B) and lymphotoxin alpha (LTA) where different malaria phenotypes such 
as hyper-parasitaemia, severe malarial anaemia or cerebral malaria are often found to be 
associated with IL12B gene(Marquet et a l, 2008; Ong'echa et a l, 2011; Phawong et a l,
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2010) while the association between parasitaemia with LTA is not consistent between studies 
(Barbier et al., 2008; Clark et al., 2009; Randall et al., 2010).
A review of the effect of haptoglobin in various studies has also shown that the conflicting 
effects of haptoglobin on severe malaria reported in different studies could be explained by 
epistatic effects between the haptoglobin phenotypes and a  thalassaemia(Atkinson et al., 
2014).
A study of genetic interactions may lead to hypothesis on mechanisms of action of the 
interacting genes as shown in studies conducted on the coast of Kenya (Atkinson et al., 2014; 
Williams, Mwangi, Wambua, Peto, et al., 2005). Thus, sickle and a-thalassaemia have been 
hypothesized to have contrasting mechanisms of action (Williams, Mwangi, Wambua, Peto, 
et al., 2005). It has been shown that in populations where both of these conditions occur, the 
percentage of the HbS component of haemoglobin is reduced in individuals with higher a- 
thalassaemia deletions (Mouele et al., 2000). The protective effect of HbS may therefore be 
lost due to having a lower proportion of the HbS component when co-inheritance with a- 
thalassaemia occurs. In populations with high frequency of both HbS and a-thalassaemia, 
interventions to reduce the effect of a-thalassaemia could potentially be used to maintain 
high HbS component among those who co-inherit both, thus reducing malaria incidence or 
severity.
The interaction between haptoglobin and a-thalassaemia (Atkinson et al., 2014) has also led
to proposals of various scenarios of its mechanism of action which could potentially be used
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for interventions. Atkinson and colleagues consider different scenarios which affect the 
haptoglobin and a-thalassaemia genotypes. Co-inheritance of a-thalassaemia and Hp 2-2 
genotype has been associated with higher incidence of severe malaria compared to 
coinheritance with Hp 2-1 or Hp 1-1. One of the mechanisms proposed is that Hp2-2 may 
be less able to quench the high oxidative stress associated with a-thalassaemia. Drugs which 
allow a better management of oxidative stress among a-thalassaemia patients could 
potentially improve severe malaria outcomes in those who co-inherit a-thalassaemia with 
Hp2-2.
The current study proposes that loci in cytokines and genes relevant to innate immunity may 
interact to affect malaria incidence. These are TLR9-IL4, IL4-IL13 and IL10-IL4 
interactions. It is worth noting that each of the SNPs in these interacting gene pairs 
significantly affected the incidence of malaria on univariate analysis (see Table 5.2), with the 
exception of the SNP in interleukin 10 (rs302500) which gave marginal evidence (p=0.06) 
of a significant effect (see Table 5.3). This suggests that a useful strategy of identifying 
possible interacting gene pairs is to select SNPs which show evidence of affecting the malaria 
outcome and considering the effect of their interaction on malaria incidence. The role of TLR 
9 was discussed in Chapter 5 section 5.3.2.2.1 while the role of IL-4 and IL-13 in malaria 
have been discussed in Chapter 5, section 5.3.2.2.2.1 probed for the association between IL- 
4 and IL-13 and found that the genes are closely linked, display high sequence homology and 
have functional similarities (Zurawski & de Vries, 1994), further reinforcing the evidence for 
epistasis between the two genes in predicting uncomplicated malaria incidence. Thus, both 
IL-4 and IL-13 induce differentiation of naive T cells to Th2 cells and affect the balance
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between Thl and Th2 cytokines. This suggests a possible intervention against malaria may 
be to balance cytokine responses as suggested by a previous study (Dodoo et al., 2002).
IL-10, the other gene for which significant interaction was found, is an anti-inflammatory 
cytokine, and low levels have previously been associated with severe malaria among 
Ghanaian children (Kurtzhals et a l, 1998). Another study among Gambian children (Wilson 
et al., 2005) found that children who had a haplotype including the G mutation were protected 
from severe malaria, but no specific polymorphism on its own was associated with severe 
malaria. The finding of particular haplotypes being protective is indicative of protection only 
being seen in a particular combination of IL-10 haplotypes or protection due to a 
polymorphism, not genotyped in that study but that may be in linkage disequilibrium with 
the IL-10 polymorphism. Since the G polymorphism was associated with protection from 
severe malaria but in this study gave evidence of susceptibility to mild malaria, it is consistent 
with the natural vaccine mechanism of protection from severe malaria. In the current study, 
IL-10 was found to interact with IL-4 to affect malaria incidence. Among the many roles of 
IL-4 is a reduction in Thl cells and induction of Th2, while IL-10 also downregulates the 
expression of Thl cells. It is possible that IL4 and IL10 interact positively to complement 
each other in reducing malaria incidence. The mechanisms underlying these interactions are 
yet to be investigated, however, it is possible that they affect processes in the development 
of malarial disease, as shown by a previous study which showed that SNPs in other immune- 
regulatory genes (TNF, IL12B and TLR4) interact epistatically to increase P. falciparum 
parasite growth in vitro (Basu et al., 2012).
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The current study also showed another significant interaction, the IL4-TLR9 interaction. 
Interactions with TLR-9 are potentially important, given its role in the immune recognition 
of malaria parasites. For example, it has been shown that a malaria vaccine candidate using 
the TLR-9 CpG ligands as an adjuvant promotes the acquisition of P. falciparum specific 
memory B cells in malaria naive individuals (Crompton et a l , 2009) but not in semi-immune 
adults (Traore et a l , 2009). Since IL-4 suppresses responses to TLR-9 stimulation (Sriram et 
al, 2014) it may be possible for co-inheritance of various genotypes of IL-4 and TLR-9 to 
significantly affect malaria incidence as suggested in the current study.
The above example demonstrates that interaction studies are useful in identifying key 
pathophysiological processes to target for interventions. Since malaria is a systemic disease 
which induces several immune reactions, deciding which reactions are useful and which ones 
are not is a complex problem. SNP interaction studies may clarify which interactions are 
beneficial and which ones are harmful to malaria outcomes. Beneficial interactions may be 
those that reduce malaria incidence, while harmful interactions may increase malaria 
incidence. As such, studies such as the current one can potentially provide a rationale for 
designing interventions to boost beneficial interactions while suppressing harmful ones.
6.4 Summary and conclusions
The LRT test was used to test how epistasis between gene markers (SNPs) affects malaria
incidence. Results were interpreted by comparing the predicted interacting pairs with those
in a database of known and predicted gene and protein interactions (STRING), and also
comparing the interaction effect prediction strength to that of an expected interacting loci
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pair, a-thalassaemia and sickle. Through such comparisons, 3 new possible interacting pairs 
of genes were identified; TLR9-IL4, IL4-IL13 and IL10-IL4. The importance of epistasis in 
understanding the roles of the genes and the giving clues to the pathogenesis of disease was 
considered in the discussion above.
In conclusion, further studies on the role of epistasis may be conducted, including more 
complex multiple gene epistasis models. The three pairs of candidate genes with epistatic 
interactions identified in this study may be studied in other genetic cohorts to confirm if they 
actually interact to increase or reduce malaria incidence. Validation of the several other 
candidate pairs of epistasis identified in the current study may also be undertaken in future 
studies.
178
CHAPTER 7: GENERAL DISCUSSION AND CONCLUSIONS
Through this thesis, I have used demographic surveillance and infectious disease surveillance 
platforms to study genetic protection from malaria incidence. The major themes investigated 
are the age and genotype-specific incidence of malaria, their relation to naturally acquired 
immunity and the effect of interactions between gene variants by multivariate and interaction 
models. I began by studying the malaria epidemiology in the Asembo population in chapter 
3 by longitudinal and cross sectional approaches, defining a pragmatic definition of malaria 
in the surveillance platform and comparing this to the parasitological case definition 
established in the cross sectional survey.
As a first step in understanding the role of genetic polymorphisms in conditioning malaria 
incidence, I studied the best characterized of such genes-the red blood cell polymorphisms. 
While these genes have been known to affect malaria severity, their effect on mild malaria 
has received less attention, yet mild malaria may be the reservoir of potentially severe malaria 
in populations, especially in non-endemic populations (White, 2008). In contrast, in endemic 
populations, the major reservoir is asymptomatic (Githeko et al., 1992). In the current push 
towards malaria elimination, populations are expected to transition from endemic, where the 
main infection reservoir is asymptomatic, to less endemic populations, where the 
uncomplicated malaria reservoir will be more significant. Anti-malarial use targeting 
symptomatic individuals to reduce the transmission reservoir of malaria (White, 2008) may
179
therefore be influenced by the role o f genetics in differential susceptibility to mild malaria, 
as only individuals susceptible to mild malaria will be targeted. To achieve success, such 
programmes need to target all individuals positive for malaria parasites, regardless of 
symptoms as reported in recent mass screening and treatment campaigns (Tiono et al., 2013).
While the distribution of common malaria protective genes has been modelled at increasingly 
better resolutions globally (Howes et a l, 2011; Howes et al., 2012; Piel et al., 2010), the 
current study makes several important contributions. First, it confirms the effect of these 
classical red blood cell genes on mild malaria incidence, which was subsequently used as a 
benchmark for evaluating the effects of other candidate genes on malaria incidence. 
Secondly, the age specific incidence patterns show that the effect significantly varies with 
age, and therefore interpretation of several studies should distinguish studies conducted 
among children of different ages, since what may be protective in one age group may not be 
protective in another age group (Taylor et a l, 2012). Thirdly, these studies contribute to 
debate on mechanisms of protection, such as the proposed natural vaccine hypothesis 
(Williams et al., 1996) or the immune basis to the protection afforded by non-immune gene 
red blood cell polymorphisms (Williams, Mwangi, Roberts, et al., 2005).
In Chapter 5 ,1 further studied 34 more recently identified red blood cell metabolism, cytokine 
and immune effector genes for which there is evidence in the literature of an effect on 
malaria. From the literature, what is clear is that the effects of candidate malaria genetic 
variants are not universal, what may be protective in one population may lead to susceptibility 
in another as shown by the case of LTA (Barbier et al., 2008; Clark et al., 2009; Randall et
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al., 2010). Such differences may arise because of differences in transmission intensity, 
different background genetics or demographic factors. Thus, a study on genetic factors 
affecting malaria incidence in the Asembo population may be used to compare with effects 
reported in other settings. Further, I modelled them in a multivariate model to come up with 
a model that explains the best predictors of malaria in this population. Compared to the 
univariate models for each gene separately, the multivariate model is a better model of reality 
as it allows the variants to control for each other’s effects while at the same time controlling 
for confounding due to covariates such as season, year, socio-economic status and attrition 
of the participants seen in the hospital due to distance from the hospital.
Incidence data in the various genotypes can be used to predict possible mechanisms of 
protection from severe malaria. Involvement of the same SNP in mild malaria in this study 
compared to severe malaria in other studies was interpreted as meaning the SNPs allow for 
a progression from mild to severe malaria. This could mean that at least the same processes 
leading to mild malaria, given time could lead to severe malaria. However, scenarios where 
one SNP enhances to susceptibility to mild malaria but protects from severe malaria as shown 
by the literature were encountered. This was interpreted as either contrasting mechanisms of 
protection in mild and severe malaria, or protection from severe malaria coming at a cost of 
inducing susceptibility to mild malaria. These mechanisms need not be mutually exclusive, 
as malaria may both be a disease that manifests progressively from mild to severe, and at the 
same time be a disease with alternative pathways of illness depending on the host i.e. 
selecting those patients who once infected may manifest either severe or mild disease 
symptoms. SNP markers associated with discernible changes in malaria risk also give
insights into the pathogenesis of malaria. Most of these markers were in immune mediator 
genes, suggesting the crucial role that these genes play in distinguishing between those who 
develop symptoms and those who are asymptomatic. In the current study, toll like receptors 
4, 6 and 9 polymorphisms were associated with either increased or reduced risk of 
uncomplicated malaria. This highlights the relative importance of these genes in the innate 
response to malaria infection. Likewise, SNP markers in complement 6, IL-4, IL-13 which 
were related to mild malaria incidence indicate the role of immune effector mechanisms in 
determining who displays symptoms of malaria.
Among the reasons for difference in effects may be gene interactions. I investigated this 
possibility in chapter 6 by comparing interaction and non-interaction models to find if there 
was a significant difference. Such significant differences between the two models were 
inferred as a possible interaction between the respective genes in conditioning malaria 
susceptibility. Predictions of interacting alleles in this dataset were further confirmed using 
a literature database o f genetic and protein interactions. Through this, I came up with 3 pairs 
of genes that have evidence both statistically in my dataset and external validation from 
biological databases and literature. These three pairs of genes represent candidates for 
epistatic interaction studies and may be further explored to show their effects in larger 
studies.
There were a number of limitations in this study, including a lack of quantitative parasite
density data at the hospital. During the course of the study, malaria slides were collected
mainly for qualitative determination of malaria status, as such parasite density data were not
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available. A possible way of meeting this challenge going forward would be to collect DBS 
from each patient while making the malaria slides. DBS are easier to store than malaria slides 
and can allow for extraction of parasite DNA later, thus allowing for determination of parasite 
density. Nevertheless, several studies on malaria have used presence of parasites during 
febrile episodes and no other reason detected for hospital visits as a case definition for 
malaria. This definition is the same as the one normally used for clinical management of 
malaria. Thus, protective effects can be directly interpreted as representing a lower burden 
on health facilities, while susceptibility inducing effects show the excess burden that carriers 
o f these polymorphisms present to the health facilities.
Another limitation was the passive follow up at the health facility as opposed to what would 
have been more ideal-active follow-up and diagnosis in the study participant’s homes. 
Retrospective and prospective approaches were used in the current study. The bias this may 
cause may be due to inconsistency in collection of data between both approaches. However, 
I confirmed that the data collection methods were similar during the period, and there were 
no major changes that may impact the current study. However, temporal changes in 
transmission which may occur naturally or through interventions which may have been 
introduced in particular years was accounted for by adjusting for year and season in the 
model.
Recruitment of siblings may have meant the population was more related than would be
found in a random sample. However, this data showed a negligible effect of adjustments for
both clustering by household and then by individual episodes of data in the same individual
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(the sandwich estimator). The results reported here are therefore those for the sandwich 
estimator alone.
Finally, this work forms a baseline for further studies, which may include:
i) Finding the optimal mix of effects which is necessary to provide malaria 
protection, or allow for the design of efficient vaccines. This may include 
haplotype analysis.
ii) Testing the interaction candidates identified in this study in larger studies 
powered to detect the interaction effect.
iii) Confirming the effects o f the SNPs using rigorously defined severe malaria cases 
in this population.
iv) More complex epistatic gene interaction analyses, such as 3 way interactions.
v) Comparison of effects of malaria interventions in children of different genotypes.
vi) Since most of the SNPs involve the innate immune responses, they may not be 
specific to malaria and are likely to have an effect on other diseases. Future studies 
may be designed to test for genetic susceptibility to other diseases detected in the 
area.
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APPENDIX I: Informed consent form for parent/guardian in the study
FK grade level: 8.7
Title: The effect of inherited blood conditions on the risk of malaria.
Consent version number 4.
Original dated 27 September 2011
Investigators:
KEMRI/CDC: Godfrey Bigogo (Principal Investigator), Oscar Nyangiri, Deron Burton, 
Robert Breiman, Simon Kariuki, Meghna Desai, Joel Montgomery, Frank Odhiambo, Kayla 
Laserson, John Vulule
KEMRI/Wellcome Trust: Thomas Williams, Alexander Macharia, Carolyne Ndila 
CDC-Atlanta: Craig Hooper
Purpose of research:
Children inherit some red blood cell conditions, which affect the progress of malaria. One 
example of such conditions is sickle cell anaemia. In this disease, the red blood cells have 
abnormal shapes and do not work properly. This causes anaemia. We would like to find out 
how these blood conditions affect malaria in the children of Asembo. To do this, we would 
like to test for the inherited blood conditions and follow up the children to find out how they 
affect their health. We hope this will help us understand malaria so that we can give 
suggestions for prevention and treatment.
What the research involves:
We are inviting all children less than six months and their siblings up to the age of 12 years, 
who are bom to mothers in the IEIP health study to participate in this study. We will enrol 
infants and their siblings within two years from the start of the study. We would like to ask 
your child to be part of this study. This study will involve two steps: testing for inherited 
blood conditions, and follow up to check for their health effects. To test blood, we will need 
a sample as soon as possible after birth. This will allow us to see the health effects of the 
blood conditions early.
We will make a small prick, like the one normally used to test for malaria on the heel o f the 
child. We will collect less than half a teaspoon of blood from this prick to test for the inherited 
blood conditions. We may collect the sample in one of the following ways:
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1) For those bom in the hospital, the sample may be collected in the hospital at birth.
2) For those bom at home: The sample may be collected through the EMEP pregnancy 
outcome follow up visit at home within a few days of birth. This visit checks the health 
of the child for the women participating in EMEP.
3) A nurse can also visit the home or you can bring the child to Lwak Hospital within 6 
months of birth to give the sample.
4) Some mothers are already participating in the study that monitors effectiveness of 
fansidar in pregnancy, (the IPTp-Mon) study. This study collects blood from the cord 
of the baby when they are bom to test if they have malaria. If you agree, we will test 
this blood for the inherited blood conditions instead of collecting blood from the baby. 
The advantage of this is that the child will not feel any pain for blood collection. If 
you are not participating in the IPTp-Mon study, we may still collect cord blood to test 
for these inherited blood conditions if you agree.
We will test for sickle and other inherited blood conditions at KEMRI and the Wellcome 
Trust Centre for Human Genetics in Oxford, United Kingdom. We may do tests to confirm 
our results at the Centers for Disease Control in the United States. If we find children with 
sickle cell disease, we will provide the test result and health education to their parents.
Follow up: Your child is part of the International Emerging Infections Program (IEIP) health 
follow up. This is a home and clinic health follows up. At home, this follow up collects 
sickness information every two weeks to look for common diseases such as malaria. At Lwak 
health centre, the study records all visits. We will get information about the health of your 
child from this follow up. Follow up will go on until 2015. It may go on for a longer time. 
We will look at this information to find the relation between the blood condition and your 
child’s health.
Some children have malaria parasites but do not show symptoms of illness. To determine 
which level of parasites cause malaria illness, your child will be requested to give blood to 
test for malaria during the forthcoming June/July malaria transmission season in Lwak 
hospital. Siblings of the child up to the age o f 12 years old will also be invited to give a
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sample to test for red cell genetics and malaria during the June/July malaria transmission 
season.
Benefits and risks:
There are some benefits and few risks in this study. The test results will show whether your 
child has sickle cell disease or not. This will allow you to take care of the child properly. 
Children who are found to have sickle cell Anaemia in this study will be offered outpatient 
tests and medicines that prevent some sickle illnesses every 3 months until they are two years 
old. These outpatient tests and medicines will be at Lwak hospital and will consist of standard 
diagnostic, therapeutic and preventive measures such as a full blood count test, folic acid, 
penicillin and palludrin. Their siblings who have the sickle symptoms will also be offered 
diagnosis and treatment for the same period. This study will also pay for health insurance 
with National Hospital Insurance Fund (NHIF) for the family until the affected child attains 
2 years of age. In addition, during the cross sectional survey of June/July, the child will be 
tested for malaria and if found positive treatment will be given.
We will not pay you for being in this study. However, we will refund 200 Kenyan shillings 
as transport for those who bring their children to Lwak health centre to give a blood sample 
for this study within 6 months. During the cross sectional survey, parents who bring their 
children to Lwak hospital will also be reimbursed.
There could be a little pain and bleeding from the heel prick. This is the usual pain felt when 
you give a blood sample in hospital. In rare cases, swelling and infection may occur, which 
we will aim to prevent. If your child has any of these symptoms, they will most likely go 
away by themselves in two weeks.
Privacy and Confidentiality:
There is a rare chance that others will find out about the child’s personal information. The
chances of this are low because the child’s records for this study will have an identification
number, but not the name. Any information or samples that leave the hospital will have only
this number. Your child’s name will not be on it. In case of sickle cell Anaemia, the child
will need treatment. In such a case, only the doctors and nurses treating your child and the
person in charge of the study at the hospital will be able to see your child’s name. We will
only share the results of the study, without names, with others. We will keep the information
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in password-protected computers. Only the study staff will have the password. This will 
reduce the chance of other people finding out the information of your child.
Your Right to Participate, Say No, or Withdraw:
It is up to you to decide if you want to take part. You have the right to refuse. If you decide 
to take part, we will ask you to sign two copies of the consent form. One copy will remain in 
the study file and we will give you the other copy to keep. If you do not want to continue 
with the study, you can stop at any time. To do this, please inform Godfrey Bigogo at 
KEMRI/CDC (phone number: +254-57-2022902/59/83).
Injury as a result of research:
This will be a routine blood draw, so no special injuries are expected. If your child has an 
injury or a bad side effect as a result of being in this study, s/he will receive medical care or 
treatment for the injury, but you will not receive payment or compensation. If you believe 
your child has been injured or have questions about a research-related injury, please contact 
Godfrey Bigogo at KEMRI/CDC (phone number: +254-57-2022902/59/83).”
If you have any questions about this study, please contact:
Godfrey Bigogo at KEMRI/CDC (phone number: +254-57-2022902/59/83).
If you have any questions about your child’s rights in this study, please contact:
The Secretary or Chairman of the KEMRI Ethical Review Committee,
PO Box 54840 00100, Nairobi, Kenya:
Telephone:+254-20-2722541 
Email: ERC@kemri.org.
These phone numbers are not for medical emergencies. If you or your child has a medical 
emergency, please go to the nearest health facility.
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Consent for study participation:
Participation in this study does not mean participation in all studies for mothers and their 
babies. You are free to participate in one activity without participating in another.
I have read or had this consent form read to me. I have had a chance to ask questions. I 
understand that I am free to choose not to be in this study. Saying “No” will have no 
effect on me or my family member’s health care. With my signature or thumbprint 
below, I give my voluntary consent to have my child or family member participate in this 
research study.
Name of Child Child’s Date of Birth
(DD/MM/YY)
Name of Parent/Responsible Adult Relationship to child
Signature/Thumbprint of Parent/Responsible Adult Date (DD/MM/YY)
Signature of Witness (for illiterate parents/guardians) Date (DD/MM/YY)
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Perm ission for Storage, Shipping and future use o f  samples:
We would like to store the samples in this study. This will allow us to do other infectious 
disease genetic tests in future. The samples will be stored indefinitely at KEMRI/CDC in 
Kisumu and KEMRI/Wellcome Trust in Kilifi. If you agree, we will ship samples to KEMRI- 
Wellcome Trust in Kilifi, the Wellcome Trust Centre for Human Genetics in Oxford, UK or 
the CDC in Atlanta for tests.
Guardian/Parent
Name of child Signature/thumbprint Date (DD/MM/YY)
Permission to link information from other KEMRI/CDC surveillance projects:
KEMRI/CDC gathers population and health information regularly in areas near Lwak 
Hospital. You or your family member may already take part in one of these ongoing 
surveillance projects. We will link data about you or your family member that we collect as 
part of this study to data from other KEMRI/CDC projects in your area, if you agree.
Guardian/Parent
Name of child Signature/thumbprint Date (DD/MM/YY)
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I have explained this form to the person above. I have answered any questions about 
this study.
Name of Investigator/Study Staff Date (DD/MM/YY)
Signature of Investigator/Study Staff Date (DD/MM/YY)
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A PPENDIX II: Reagents and solutions
1. Cross sectional survey
10% Giemsa stain
EDTA- Ethylene Diamine Tetra Acetic Acid
2. Haemoglobin phenotyping
Cellulose Acetate electrophoresis- Helena systems Kit
3. ABO phenotyping
Antisera for blood group A, B and Rhesus Blood group
4. DNA extraction
QIA amp Blood Minikit -  Qiagen 
Protein K
Phosphate buffered Saline -  PBS 
Buffer AL 
Ethanol 96-100%
Wash Buffer 1 (AW-1)
Elution Buffer 
Wash Buffer 2 (AW-2)
Elution Buffer (Buffer AE or Distilled water)
5. Typing for the a+ thalassaemia deletion
Qiagen PCR Kit
PCR Master Mix 
RNase free water
5X Q solution
2X fast cycling PCR master mix
lOx coral load cycling dye
Alpha Thalassemia Specific primers 
Primer 376
Primer 377
Primer 378
LIS1-F
LIS1-R
Controls
Homozygous Alpha Thalassemia Control 
Normal Control 
No Template Control
1% Agarose gel
6. Multiplex genotyping
Pico Green® Reagent -  (Invitrogen, Paisley, UK)
PCR Master Final mix Volume 
1:10 Diluted N 15 Primer
8Mm Pooled d NTPS (Sigma -  Aldrich, UK)
50Mm Magnesium Chloride -  Mg C12 (Bioline, UK)
10 x Bio Taq Buffer (Bioline, UK)
5U/pL Biotaq Polymerase (Bioline, UK)
MilliQ Water
Genomic DNA (g DNA)
2 % Agarose gel
7. Sequenom mass array genotyping platform
iPLEX Design -  Universal 10 base 5’ Sequence
20 bases of sequence specific bases 
- CEPH and YRI Hap MAP DNAs
Sample preparation
Phenol red Solution O.lmg/ml
i PLEX primers -  Metabion International AG (Martinsried , Germany)
First Round Reaction Master mix
50 mM Magnesium Chloride (Mgcl2)
dNTPs
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10X Hot Star Taq Buffer (Qiagen)
Hot Star Taq (5 u/pL) Qiagen
Milli Q Water
First Round Reaction 
PCR Master Mix
2% Agarose gel
8. Shrimp-alkaline phosphatase treatment
iPLEX Shrimp Alkaline phosphatase (SAP)
Primer Extension Reaction 
Extension Taq
Extension Buffer
Primers 300 Mm
Ion exchange resin
Milli Q Water
BUFFERS
DNA extraction
1. Wash Buffer 1 (AW-1)
2. Wash Buffer 2 (AW-2)
3. Elution Buffer ( Buffer AE, or distilled water)
4. QIA amp DNA Extraction solution Buffer- AL -  Guanidine Chloride +
5. QIA amp DNA Buffer AE- 50-01-1 Guanidinium Chloride 20-50%
Typing for the a+ thalassaemia deletion
First Round reaction mix 
Hot star Taq Buffer
EQUIPMENT
Glass slides
Care start P f HRP2 KIT- RDT Conduct of cross sectional survey
Rods
Pipettes
Micro centrifuge tubes
Flat Cap Strips (Thermo Fischer Scientific)
Microseal ‘A ’ lids (Bio -  Rad)
Spectrochips
Microscopes
Refrigerators
Centrifuges
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QIA amp DNA blood Mini kit -  (Qiagen )
Ultraviolet Ray Trans illuminator- (Gel Doc)
Mass Spectrometer 
Qiagen PCR kit
384 well - PCR Plate -  Thermo Fischer
96 well plates (Thermo- fast ® 96 -  skirted Thermo Fischer Scientific, UK)
APPENDIX III: SNPs assayed for in the multiplex Sequenom platform
Reference SNP number Gene symbol Strand
Reference
allele
Derived
allele
Single
letter
SNP
code
rsl 803632 GBP7 1 G C S
rs2814778 DARC -1 A G R
rs3024500 IL10 1 A G R
rsl 800896 IL10 1 T C Y
rsl 800890 IL10 1 A T W
rsl 7047660 CR1 1 A G R
rsl 7047661 CR1 1 A G R
rsl7561 ILIA -1 G T K
rsl 143634 IL1B -1 C T Y
rs708567 IL17RE -1 G A R
rs352140 TLR9 -1 A G R
rsl 87084 TLR9 -1 C T Y
rs6780995 IL17RD 1 G A R
rs4833095 TLR1 1 C T Y
rs5743611 TLR1 -1 G C S
rs5743810 TLR6 -1 C T Y
rs5743809 TLR6 -1 T C Y
rsl 801033 C6 -1 A C M
rs2706384 IRF1 -1 C A M
rs20541 IL13 -1 C T Y
rs2243250 IL4 1 c T Y
rs2239704 LTA -1 G T K
rs909253 LTA -1 T C Y
rsl 799964 TNF 1 T C Y
rsl 800750 TNF 1 G A R
rsl 800629 TNF 1 G A R
rs361525 TNF 1 G A R
rs3093662 TNF 1 A G R
rs2242665 CTL4 -1 G A R
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rsl 555498 IL20RA 1 C T Y
rs2075820 NODI -1 G A R
rs3211938 CD36 1 T G K
hCD36_G1439C CD36 1 G C S
rsl 7140229 CFTR 1 T C Y
rs4986790 TLR4 1 A G R
rs4986791 TLR4 1 C T Y
rs8176746 ABO -1 C A M
rs8176719 ABO -1 I D I
rs33950507 HBB -1 G A D
rs334 HBB -1 A T W
rs33930165 HBB 1 G A R
rs7935564 TRIM5 1 G A R
rs542998 RTN3 1 T C Y
rs2227507 IL22 1 T C Y
rsl012356 IL22 1 A T W
rs2227491 IL22 1 T C Y
rs2227485 IL22 1 G A R
rs2227478 IL22 1 G A R
rs229587 SPTB 1 T C Y
rs2230739 ADCY9 -1 A G R
rsl0775349 ADCY9 -1 C G S
rsl 805015 IL4R 1 T C Y
rs2535611 ADORA2B 1 T C Y
rs2297518 NOS2 1 G A R
rsl 800482 NOS2 -1 G C S
rs9282799 NOS2 -1 C T Y
rs8078340 NOS2 -1 C T Y
rs373533 EMR1 -1 G T K
rs461645 EMR1 -1 T C Y
rsl 799969 ICAM1 1 G A R
rs5498 ICAM1 1 A G R
rs8386 GNAS 1 C T Y
rsl 128127 DERL3 1 G A R
rs3092945 CD40LG 1 T C Y
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rsl 126535 CD40LG 1 T C Y
rsl 050829 G6PD 1 T C Y
rsl050828 G6PD 1 C T Y
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APPENDIX IV: Multiplex genotyping at the Wellcome Trust Centre for Human 
Genetics, Oxford
Multiplex genotyping
Genotyping for multiple SNPs in the sample was done using a multiplex method at the 
Wellcome Trust Centre for Human Genetics in Oxford, UK. DNA concentrations were 
measured using the PicoGreen® reagent (Invitrogen, Paisley, UK), which uses fluorophores 
that become fluorescent upon binding to DNA. Fluorescence intensity is directly proportional 
to the amount of DNA in the sample allowing quantification of the amount of DNA in the 
sample. Genomic DNA (gDNA) was then amplified by Primer Extension Pre-amplification 
(PEP) (Zhang et a l, 1992) before genotyping for candidate gene polymorphisms using the 
Sequenom Mass Array™ platform [25,26]. PEP allows the amplification o f whole genomic 
DNA from as little as a single cell and is an important genomic DNA enrichment step before 
Sequenom Mass Array™ genotyping.
Genomic DNA was then diluted to Ing/pL in 96-well plates (Thermo-Fast® 96-skirted, 
Thermo Fisher Scientific, UK), leaving 2 to 3 empty wells for water controls. A PCR master 
mix final volume of 45pL was made consisting of the following: 2.2pL of 1:10 diluted N15 
primers (Genetix Ltd, UK); http://www.genetix.com, 1.25pL 8mM pooled dNTPs (Sigma- 
Aldrich, UK), 2.5 pL 50mM MgCh (Bioline, UK); http://www.bioline.com, 5 pL of 10X 
BioTaq buffer (Bioline, UK), 0.5pL 5U/pL Biotaq polymerase (Bioline) and 33.55pl MilliQ 
water was added to each of the 96 wells. 5pL of gDNA (Ing/pL) was added to the PEP 
master mix in each well before sealing the plates with flat cap strips (Thermo Fisher 
Scientific) and thermo cycling. The PCR thermo cycling programme used was as follows:
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94°C for 3 min; 50 cycles of (94°C for lmin, 37°C for 2 min, Ramp to 55°C at 0.1/sec, 55°C 
for 4 min) and a final extension of 72°C for 5 min, maintain at 4°C.
After amplification, the PEP DNA was stored neat at -20°C until it was required.
Before genotyping on the Sequenom platform, the PEP DNA was tested by selecting 12 
samples at random from the PEP plate, amplifying as described below for Sequenom 
genotyping (with modifications) and running the samples on 2% agarose gels to check band 
intensity and fidelity. Modifications on the Sequenom genotyping are described below:
A final reaction volume of 20pL; 1 pL of neat PEP and a single primer pair designed from a 
current iPLEX assay as follows:
forward primer: ACGTTGGATGTCTGTAGTGATGGAGGGATG 
reverse primer: ACGTTGGATGGTGTCCTCTCCCTTGTAAAC
Sequenom Mass A rray genotyping platform
We used a multiplex genotyping platform (P. Ross et al., 1998; Wilson et al., 2005) to type 
for multiple SNPs simultaneously. The specific kit used was the SEQUENOM®lPLEX® Gold 
which allows up to 40 SNPs to be designed into a single reaction and up to 384 samples to 
be processed on a single chip.
SNP sets: Genotyping was performed for SNP sets chosen from literature searches of SNPs 
showing associations with malaria or infectious diseases. See APPENDIX H for a list o f the
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SNPs and associated literature. In addition, SNPs intended for determination of gender by 
the amelogenin gene differences in the X and Y chromosomes were typed (Eng et al., 1994).
iPLEX design: The SEQUENOM® assay design process (www.sequenom.com) 
requires polymorphism sequences. These were downloaded from Ensembl 
(http://www.ensembl.org) and formatted appropriately for the assay design. 
SEQUENOM® RealSNP™ Assay Database (http://www.realsnp.com) tools ProxSNP and 
PreEXTEND were then used for identification of the target SNPs and in the design of first 
round PCR primers. The MassARRAY® Assay Design v3.1 Software was used for 
Multiplex design. iPLEX methodology was employed where common settings for assay 
design included addition of a universal 10 base 5’ sequence and at least 20 bases o f sequence 
specific bases. The design ensured amplicon sizes ranging between 80 to 120 bases, and on 
average the amplicon size was 100 bases. For universal extension primers, the target mass 
range was 4500 to 10,000Da (~15-mer to ~29-mer oligos). 2 multiplexes were designed as 
above then tested using a panel of CEPH and YRI HapMap DNAs. This allowed 
identification of assays that were either poorly performing or that had poor concordance for 
removal from the multiplex system.
Sample preparation: PEP DNA samples were thawed before dilution at 1:10 using a phenol 
red solution (O.Olmg/ml) to aid tracking into 384-well plates. Diluted PEP for use for the 
assay was kept at 4°C for a maximum of 2 days and was not freeze thawed more than twice. 
All the unused diluted PEP was frozen at -20°C. iPLEX primers were purchased lyophilised 
from Metabion International AG (Martinsried, Germany). First round primers and extension 
primers were hydrated to lOOpM and 300pM respectively before storage at -20°C.
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First-Round reaction m aster mix: For each 384 well plate a master mix comprising of the 
following was prepared, allowing some extra volume:
3.3pL of each first-round primer (lOOmM), 214.5pL MgC12 (50mM), 66pL dNTPs (25mM 
pooled), 412.5pL 10X HotStar Taq buffer (Qiagen), 132pL HotStar Taq (5U/ pL) (Qiagen) 
and milliQ water to make a final volume of 1980pL.
First-Round Reaction: 4.5pL per well of PCR master mix was plated into a 384-well PCR 
plate (Thermo Fisher Scientific). To each well, 3pL of 1:10 diluted PEP DNA was added. 
The plate was sealed using Microseal ‘A’ lids (Bio-Rad) and thermo cycling was done using 
the following conditions: 94°C for 15 min, 44 cycles of (94°C for 20 sec, 56°C for 30 sec, 
72°C for 1 min) and a final extension of 72°C for 3 min before maintenance at 4°C. To 
confirm that PCR was successful a lpL  sample from each well o f a single row was run on a 
2% agarose gel.
Shrimp alkaline phosphatise treatm ent: All dNTP’s that were not incorporated into the 
PCR reaction above were destroyed by adding 2 pL of iPLEX shrimp-alkaline phosphatise 
(SAP) mixture to the first-round PCR reaction mixture and incubating at 37°C for 40 min. 
This was followed by 5 minute denaturation step at 85°C and a cooling step of 15°C for 15 
min.
Prim er extension reaction: Final reaction concentrations for the extension primers were 
dependent on their molecular mass based on SEQUENOM® protocol guidelines as follows:
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< 5800Da 0.84 pM, 5800 to 7000Da 1.04pM, 7000 to 10,000Da 1.25 pM, >10,000Da 
1.5pM.
To allow for primer extension in the sample plate, 2pL of a mixture containing 0.2pL iPLEX 
termination mixture, 0.04 lpL  extension Taq, 0.2pL extension buffer and primers (300mM) 
according to the molecular masses as follows; 0.025pL per primer up to 5800Da, 0.0312 pL 
per primer for 5800 to 7000Da, 0.0375 pL per primer for 7000 to 10,000 Da, 0.045 pL per 
primer for >10,000 Da. The final extension volume was 9pL (5ul first-round reaction, 2ul 
SAP and 2ul of extension mixture).
Extension thermo cycling was performed on an MJ Tetrad as follows:
94°C for 30 sec, 40 cycles of (94°C for 5 sec, 5 cycles of (52°C for 5 sec, 80°C for 5 sec)) 
then 72°C for 3 min and 15°C for 15min.
After the reaction, 6mg ion-exchange resin and 16pL MilliQ water was added per well. The 
plates were sealed, rotated for 30 min and centrifuged to pellet the resin. Samples were then 
‘spotted” onto SpectroCHIPS and run on the Mass-Spectrometer.
Data was checked for consistency and genotypes using the SEQUENOM® Typer 4.03 
software. Data were downloaded and stored on a central database for any further curation. 
Genotype data were maintained with reference to the sequence strand used for the design 
process.
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APPENDIX V: Scientific and Ethical Review Board Approvals
KENYA MEDICAL RESEARCH INSTITUTE
P.O. Box 54640 - 00200 NAIROBI, Konya 
To! (254) (020) 2/22541. 2713349, 0722 205901 0733-400003; Fax. (254) (020) 2720030 
E mail dtr0ctor®kemri.org irtfo@kemfi org Websitewww kemri.org
ESACIPAC/SSC/9521
Godfrey Bigogo
Thro’
Director. CGHR 
KISHMll
REF: SSC: No. 2074 (Revised) Cohort study of human genetic factors and 
childhood malaria in the Asembo area of Western Kenya
ITiunk you for your loiter dated I July, 2011 responding to the comments
raised by the KEMRI SSC,
I am pleased to inform you that your protocol now has formal scientific 
approval from SSC.
Ihe SSC however, advises that work on the proposed study can only start after
CRC approval.
Samm y Njenga, PhD 
SECRETARY. SSC
In Search of Bettor Health
11"’ July, 2011
KENYA MEDICAL RESEARCH INSTITUTE
P.O. Box 54840-00200 NAIROBI Konya 
Tel (254) (020) 2722541 2713349. 0722-205901. 0733400003; Fax; (254) (020) 2720030 
E-mail difector@kemri.ofg inte@kemri.org Website.www.kemri.org
KEMRI/RES/7/3/1 October 18, 2011
TO: GODFREY BIGOGO (PRINCIPAL INVESTIGATOR)
THROUGH : DR. JOHN VULULE,
DIRECTOR, CGHR
Kismu
D ear Sir,
RE: SSC PROTOCOL No. 2074 -  REVISED ( R E -SU B M ISSIO N ): COHORT STUDY
OF HUMAN GENETIC FACTORS AND CHILDHOOD MALARIA IN THE 
ASEMBO AREA OF WESTERN KENYA
W e a ck n o w led g e  rece ip t of:
a . T he R evised  S tu d y  Protocol -  version  d a ted  15 A ugust 2011;
b. T h e  R evised  Inform ed C on sen t D o cu m en ts  -  English, Kiswahili and D holu o version s
c. T he sep a ra te  c o n s e n t d o cu m en t for sa m p le /d a ta  co llection , s to r a g e  and fu ture u se
This is to  inform you th at th e  Ethics R eview  C om m ittee  (ERC) rev iew ed  th e  d o c u m en ts  listed  
a b o v e  and is sa tisfied  th at th e  is su es  raised a t th e  initial rev iew  h ave  b e e n  ad eq u a te ly
ad d ressed .
The study is gran ted  approval for im p lem entation  e ffe c tiv e  th is 18th day  of O ctober 2011. 
P lea se  n o te  that authorization to  co n d u ct th is  study will autom atically  exp ire  on  O ctober 
17, 2012. If you  plan to  co n tin u e  w ith d ata  collection  or an a lysis  b eyon d  th is d a te , p le a se  
subm it an  app lication for contin u ing approval to  th e  ERC S ecretaria t bv A ugust 3, 2012.
Any un antic ipated  p rob lem s resulting  from  th e  im p lem entation  o f  th is  protocol sh ou ld  b e  
brought to  th e  a tten tion  o f  th e  ERC. You are a lso  required to  subm it any  p rop osed  c h a n g e s  
to  th is protocol to  th e  ERC to  initiation and a d v ise  th e  ERC w h en  th e  stu d y  is co m p le ted  or
discon tin u ed .
You m ay em bark on  th e  stu d y .
Sincerely,
Caroline Kithinji,
FOR: SECRETARY,
EEMRI/.NAHPNAL ETHICS REVIEW COMMITTEE
f o r w a r d e B
K£S£aRCh !
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KENYA MEDICAL RESEARCH INSTITUTE
P.O. Box 54840-00200, NAIROBI. Kenya 
Te) (254) (020) 2722541 2713349, 0722-205901, 0733-400003, Fax (254) (020) 2720030 
f- nail d1rer.lof@k0mri.org inlo@kemn.Ofg Websrteavwwkertiri.org
K E M R I /R E S /7 /3 /1 A pril 2 0 , 2 0 1 2
TO: GODFREY BIGOGO (PRINCIPAL INVESTIGATOR)
THROUGH ; DR. JOHN VULULE, 
DIRECTOR, CGHR 
KISUMU
Dear Sir,
i o’:fV
SSC PROTOCOL No. 2 0 7 4 -  REVISED ( RE-SU BM ISSIO N ): COHORT STUDY 
OF HUMAN GENETIC FACTORS AND CHILDHOOD MALARIA IN THE 
ASEMBO AREA OF WESTERN KENYA
This IS to inform you th at a t th e  20 0 th m eetin g  o f  the KEMRI Ethics R eview  C om m ittee held  
on April 17, 2012 , th e  req u est for am end m ent 'or th e a b o v e  referen ced  research proposal
w as d iscussed .
T he following am en d m en ts are  proposed:
1 A description o f  th e  type o f care to  b e  provided to  children w ho are d iagn osed  with 
sickle ceil anem ia until th ey attain 2 years o f a ge .
2 Additional counseling  and education  on  th e  condition and indications for seek in g  care  
and referral will b e  offered  to th e  parents o f  th e  a ffected  children.
riu t om nitu?e concluded th at th e  am en d m en ts  are justified and do not alter th e  
11'.k/benefit sta tu s o f th e  study and th erefore granted approval for im plem entation. You are  
also required to subm it any further req uests  for ch a n g es  to  th e  approved protocol to  th e  SSC
and ERC prior to  initiation.
Sincerely,
DR. CHRISTINE WASUNNA,
ACTING SECRETARY,
KEMR3LEIHICS REVIEW COMMITTEE
In Search o» Better Health
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P O  B ox 157c, K istfw y
~KENYflnWEt)ICAL RESEARCH INSTITUTE
P.O. Box 54840-00200. NAIROBI, Kenya 
Tel (254) (020) 2722541,2713349,0722-205901,0733-400003; Fax: (254) (020) 2720030 
E-fpaB: director@kemri.org lnfo@kemr1.ofg Websitenvww.kemf1.org
KEMRI/RES/7/3/1 
TO: / D R .  GODfDR. FREY BIGOG INVESnGATOR)
July 3, 2012
THROUGH: DR. JOHN VULULE,
DIRECTOR, CGHR
m u m
Dear Sir,
RE: SSC PROTOCOL No. 2074 {RE-SUBMISSION: REQUEST FOR AMENDMENT 
2)i COHORT STUDY OF HUMAN GENETIC FACTORS AND CHILDHOOD 
MALARIA IN THE ASEMBO AREA OF WESTERN KENYA 
{VERSION 3  DATED JUNE 2013)
Reference is made to your letter dated 26 June 2012. The ERC Secretariat acknowledges 
receipt of your application on 28th June 2012.
This Is to Inform you that the Committee notes that more mothers enrolled in the study 
favour cord blood collection over heel prick collection and determines that the issue raised at 
the 202nd ERC meeting 28th May 2012 is adequately addressed. You are therefore authorized 
to implement Amendment 2 accordingly.
You are required to submit any further changes to this study to the SSC and ERC for review 
and the changes should not be initiated until written approval from the ERC is received. 
Please note that any unanticipated problems resulting from the conduct of this study should 
be brought to the attention of the ERC and you should advise the ERC when the study is 
completed or discontinued.
You may continue with the study.
Sincerely,
& 2 » i r
DR. CHRISTINE WASUNNA,
ACTING SECRETARY,
KEMRI ETHICS REVIEW COMMITTEE
In Search of Better Health
KENYA MEDICAL RESEARCH INSTITUTE
P.O. Box 54840-00200, NAIROBI. Kenya 
Tel (254) (020) 2722541,2713349, 0722*205901,0733-400003; Fax: (254) (020) 2720030 
E-mail; director®kemri.org info@kemri.org Website;wvAv.kemri.org
KEMRI/RES/7/3/1 May 30, 2013
TO: DR. GODFREY BIGOGO
PRINCIPAL INVESTIGATOR
THROUGH: DR. JOHN VULULE,
DIRECTOR, CGHR 
KISUMU
Dear Sir,
RE: SSC PROTOCOL No. 2074  {REQUESTFOR AMENDMENT3 ): COHORT STUDY 
OF HUMAN GENETIC FACTORS AND CHILDHOOD MALARIA IN THE 
ASEMBO AREA OF WESTERN KENYA
This is to  inform you that a t th e  215'" m eeting o f the KEMRI Ethics Review Com m ittee held 
on 21a May 2013 , the request for am endm ent to th e  above referenced research proposal 
w as discussed.
The Committee noted that:
(a ) The investigators are requesting to  am endm ent th e  recruitment criteria o f  study  
participants a s  enrolm ent has been  slower than expected . The investigators request 
to  enroll any siblings (up to  th e a g e  o f 12 years) o f both current and future recruits 
to  the study.
(b) To u se  logistic regression approach that will require data from asym ptom atic patients 
in th e community a s well a s  sick children during illness ep isodes.
The Committee concluded that th e suggested  am endm ents are justified and consequently  
granted approval for implementation. You are required to  subm it any further requests for 
changes to this version o f  the protocol to  th e SSC and ERC for review  and approval prior to  
implementing any additional changes.
Yours sincerely,
DR. ELIZABETH BUKUSI,
ACTING SECRETARY,
KEMRI ETHICS REVIEW COMMITTEE
In Search of Better Health
KENYA MEDICAL RESEARCH INSTITUTE
P.O. Box 54840-00200, NAIROBI, Kenya 
Tel (254) (020) 2722541, 2713349, 0722-205901, 0733-400003; Fax: (254) (020) 2720030 
E-mail: director@kemri.org lnfo@kemri.org Website:www.kemri.org
KEMRI/RES/7/3/1 September 21, 2012
TO: y /H K .  GODFREY BIGOGO (PRINCIPAL INVESTIGfpB^)0 R W A R D E D
THROUGH: DR. JOHN VULULE,
THE DIRECTOR, CGHR,
tflSVHM
Dear Sir,
DOCTOR 
'•? TOR C X ii lU  HEALTH RESEARCH
RE: SSC PROTOCOL No. 2074 {REQUEST FOR ANNUAL RENEWAL): HUMAN GENETIC
FACTORS AND CHILDHOOD MALARIA IN THE AS EM BO AREA IN WESTERN KENYA
The ERC Secretariat acknowledges receipt of the following documents;
1. Continuing Review Report for the period to 18* October 2011 to 30* July 2012.
2. Study Protocol Version No.03 dated June 2012.
3. Informed Consent Documents in English, Dholuo and Kiswahili - Version No.03 dated
This is to inform you that at the 207* meeting of the KEMRI Ethics Review Committee held on 05* 
September 2012, the Committee reviewed the above referenced application and made note of the 
following:
(a) Two hundred and twenty one (221) children have been enrolled into the study out of the total 
targeted ofl600 children.
(b) Preliminary analysis of genotypic data Is ongoing.
(c) The planned activity for the next project period Is to continue with recruitment, genotyping 
and surveillance for disease events, data analysis and report writing.
The study was granted approval for continuation effective the 5th day of September 2012. Please 
note that authoHzation to conduct this study will automatically expire on September 4 ,2013 . If you 
plan to continue with data collection or analysis beyond this date, please submit an application for 
continuing approval to the ERC Secretartat by July 24,2013.
You are required to submit any proposed changes to this study to the SSC and ERC for review and the 
changes should not be Initiated until whtten approval from the ERC is received. Ptease note that any 
unanticipated problems resulting from the conduct of this study should be brought to the attention of 
the ERC and you should advise the ERC when the study is completed or discontinued.
You the study.
June 2012.
DR. SUNNA,
ACTING SECRETARY,
KEMRI ETHICS REVIEW COMMITTEE
In Search of Better Health
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KENYA MEDICAL RESEARCH INSTITUTE
P.O. Box 54840-00200. NAIROBI. Kenya 
Tel (254) (020) 2722541. 2713349. 0722-205S01, 0733-400003; Fax: (254) (020) 2720030 
E-mail; diroctor@komri.org info@kemri.org Websiteiwww.kemri.org
KEMRI/RES/7/3/1 x /  October 11,2013
TO: MR. GODFREY BIGOGO, jV  ^ ^ W K R D E D
PRINCIPAL INVESTIGATOR >>
THROUGH: DR. STEPHEN MUNGA, ' v  }' DIRECTOR
ACTING DIRECTOR, CGHR I cam s For; oiosfl. ».E*gjjgggjSS!i
KISUMU
Dear Sir,
RE: SSC PROTOCOL No. 2074: RESUBMISSION {REQUEST FOR ANNUAL RENEW AL):
HUMAN GENETIC FACTORS AND CHILDHOOD MALARIA IN THE ASEMBO AREA OF 
WESTERN KENYA
Reference is made to your letter dated 8th October, 2013. The ERC Secretariat acknowledges receipt 
of the revised annual report on October 10, 2013.
This is to inform you that the Ethics Review Committee (ERC) reviewed the document listed above 
and approved the application for another year.
This approval is valid from today, 11th  O ctober 2013 through to 11th O ctober 2014. Please 
note that authorization to conduct this study will automatically expire on 10th O ctober 2014. If 
you plan to continue with data collection or analysis beyond this date please submit an application 
for continuing approval to the ERC secretariat by 29th A ugust 2014.
You are required to submit any amendments to this protocol and other information pertinent to 
human participation in this study to the SSC and ERC for review prior to initiation.
Yours faithfully,
DR. ELIZABETH BUKUSI,
ACTING SECRETARY,
KEMRI/ETHICS REVIEW COMMITTEE
In Search of Bolter Health
KENYA MEDICAL RESEARCH INSTITUTE
P.O. Box 54840-00200, NAIROBI, Kenya 
Tel (254) (020) 2722541, 2713349, 0722-205901, 0733-400003; Fax: (254) (020) 2720030 
E-mail: director@kemri.org info@kemri.org Website:www.kemri.org
KEMRI/RES/7/3/1 September 16, 2014
TO: MR. GODFREY BIGOGO,
PRINCIPAL INVESTIGATOR
THROUGH: DR. STEPHEN MUNGA, \  Qj\"
THE DIRECTOR, CGHR ^  ^  rofl c S E - ,  r s ^ ch|
k isu m u  v K   — --------  — ---------------------------  \j
Dear Sir,
RE: SSC PROTOCOL No. 2074: {REQUEST FOR ANNUAL RENEW AL): HUMAN GENETIC
__ FACTORS AND CHILDHOOD MALARIA IN THE ASEMBO AREA OF WESTERN KENYA
Thank you for th e  Continuing Review Report for the period 11th O ctober 2013 to  5th August 
2014.
This is to inform that during th e  231st m eeting o f th e KEMRI/ERC m eeting  held on th e  19th o f  August 
2014, the Com m ittee conducted the  annual review and approved th e  ab ove referenced  
application for another year.
This approval is valid from today, 16th August 2014 through to 15th A ugust 2015. Please note  
that authorization to  conduct this study will autom atically expire on  15th A ugust 2015 If you plan 
to continue with data collection or analysis beyond this d a te  p lease  subm it an application for 
continuing approval to  th e ERC secretariat by 4th August 2015.
You are required to  subm it any am endm ents to this protocol and oth er inform ation pertinent to  
human participation in th is study to  th e  SSC and ERC for review prior to  initiation.
Yours faithfully,
A % ■A -./
PROF. ELIZABETH BUKUSI,
ACTING SECRETARY,
KEMRI ETHICS REVIEW COMMITTEE
In Search o f Botter Health
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APPENDIX VI: Cross sectional survey form
7059277805
IBD Cross Sectional Survey Form (>12 year old) “I
Date of lnterview(dd/mm/yyyy)
□ □ / Q H / t
P art 1 . DEMOGRAPHICS
1.0 Names of the Child:
Facility Demographics filled by:
O Lwak j | |
O Mahaya 
O Ongielo
1.1a Child’s DSS Permanent ID
date16
Site
demoregcode
First name m-rrrm m
Juok name
Last name
0 0 0 © ©  ©  ©  © © o © © o ©1 o o o o  o  o  o o o o o o o2 0 0 0 ©  ©  ©  © o o o o o o3 o o o o o o © o o o o o o
4 o o o o  o  o  o o o o o o o5 o o o ©  ©  ©  © ©  ©  © © o ©6 o o o © o o o o o o ©  ©  ©
7 ooo o  o  o  o o o o o o o8 ooo ooo© ooo ©  ©  ©
9 ooo ooo© ooo ©  o ©
"Fill questions 1.1b and 1.1c only if the child is a new bom and does not 
have DSS permanent ID."
1.1b Child's Temporary
I— I— I
O O 0 G O 0  
© O 0 0 O 0  
©00©©© 
© 0 0 0 0 0  
© © 0 © © 0 
© © © © © © ©0 0© 
© 0  0 © 
O© O© 
00 0©
ID (newborns) 1.1c Mother's DSS Permanent ID
0 O O 0 O 0 O 0
oooooooo
00000000
oooooooooooooooooooooooo
oooooooooooooooooooooooooooooooo
1 1 1 1 1 1 - 1 1 1  l-l 1 1 I
0 ©oo © © © © ©  ©  © ©  © ©1 ooo o o o o ooo o o o
2 ooo ooo© ooo o ©©
3 ooo o o o o ooo o o o
4 ooo o o o o ooo o o o
5 ooo o o o o ooo o o o
6 ooo o o © o ooo o o ©
7 ooo o o o o ooo o o o
8 ooo o o o o ooo © o o
9 ooo ©  ©  ©  ©ooo © o o
1.2 Date of birth (dd/mm/yyyy
/ E C /
1.0 Names of the household head: 
First name
1,3a How many years and months old is the child? 
(If child < 1 month old, record # of days) Juok name
Years Months days
m C O G D Last name
1.4 For the head of household, what is the highest level of education completed?
O None 
O Higher
O Primary 
O Secondary
I Years Completed
jn a m e
dssid
Motherid
dob
chlidyee
childmonth
childdays
1.5 What type of wall was used for the construction of this house? Observe
O Mud O Brick O Cement/Plastered O Cement/Painted
1.6 What type of roof was used for the construction of this house?
O Grass thatch O Iron Sheet O Tiles O Other
O Other
1.7 Are the eaves open or closed?
L
O Open O Closed O Partially Open
J
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1.8 What is the main material of the floor? Observe
Natural Floor Rudimentary Finished Floor
O Earth/sand 
O Dung
O Wood planks 
O Bambo/palm
O Parquet or polished 
O Wood vinyl or Asphalt strips 
O Ceramic tiles 
O Cement 
O Carpet
Other Specify |
1.9 At any time in the past 12 months, has anyone sprayed the interior walls of your dwelling with 
chemical or liquid to kill or repel mosquitoes?(lf No/Don’t Know, skip next two questions)
OVES ONO ODON.TKNOW
1.9a How many months ago was the house sprayed? | | | j Months
1.9b Who sprayed the house?
Spray Agent
O PRIVATE COMPANY O HOUSEHOLD MEMBER O DON'T KNOW
O GOVERNMENT WORKER/PROGRAM O OTHER
Other Specify | | | j “  | | |
2.0 ) Have any of the following been used in your house over the last week?
Mosquito Coil O yes o  no Insecticide spray O yes O no Repellents O yes O no
2.1 Does your household have any mosquito nets that can be used while sleeping?
O YES O NO 
Part ll-Bednet Questionnaire:
2.2 : Ask respondent to show you the net in the house.
O Observed O Not Observed
2.2a Net description:
2.3 How long ago did your household obtain the mosquito net?(Please input the specific number of 
months (0-36) if less than 3 years)
O Less than /equal to 3 years O More than 3 years | j j | Months
2.4 Observe or ask the brand of net:
O PermaNet O Supanet
O Olyset O Other I M  I I I I I I I I I 1 [
O SupaNet extra power O Don.t know brand
2.5 Since you got the mosquito net, was It ever soaked or dipped in a liquid to repel mosquitoes or bugs? N
OYES ONO O Not sure
2.6 How many months ago was this bed net treated with insecticide? | |
2.7. What did you treat the net with?
OKO Tab 123
Months
O PowerTab 
O Don.t know O Other: I I I I "I I J
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2.8 Did anyone sleep under this net last night?
O YES O NO(skip to last question)
Part lll:-Person Questionnaire.- 
3.0 Client.s participation
O consent given 
O Dead
3..1 person answering
O Refusal 
O Not at home -
OSELF O PROXY
3.1b if proxy give reason
O person is under 15 years 
O too ill/sick to talk 
O other
3.2 )Does the child usually live here?
O YES O NO
3.3 Did the child sleep here last night?
O YES O NO
3.4 What is the highest education level of the primary caretaker for the child?
O Primary 
O Secondary
O Higher 
O None Years Completed
3.5 Has the child been ill with a fever at any time in the last 2 weeks?
O YES O NO O NOT SURE
3.6 Did you seek advice or treatment for the fever from any source?
O YES O NO O DONT KNOW
3.7 )Where did you seek advice or treatment? (Check all that apply)
O GOVT. HOSPITAL 
O GOVT. HEALTH CENTER 
O GOVT. DISPENSARY 
O PVT./MISSION HOSPITAL/CLINIC 
O PHARMACY/CHEMIST 
O shop
O Freiend/realative 
O private mobile clinic
O MOBILE CLINIC 
O COMMUNITY HW 
O OTHER PUBLIC
O PRIVATE DOCTOR/CLINIC
O Trad. Practitioner 
O religious leader
O Other
3.8 Has the child taken any drugs In the last 2 weeks/did you take any medicine for the fever? (Check all that apply)
Acetaminophen/paracetamoi/panadol/rofin O yes SP/FansidarOrodar/Metakelfin O yes
Coartem o  yes Quinine O yes Ibuprofen O yes
Aspirin o y e s Artemisinin O yes Septrin O yes
Choloroquln 0  yes Malaratabs O yes Dont Know O yes
Amodiaqulne//Melaraquln O yes
L Other Drug J
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Part lll:>Person Questionnaire.-
3.9 Has the child had a fever in the last 24 hours?
O YES O NO O DONT KNOW 
Part IV-RDT/Anemia Questionnaire:-
4.0 Blood sample taken
O YES ,if YES skip to question 4.2 
ONo
4.1)Reason not taken 
O REFUSED O NOT PRESENT O OTHER
4.2 RDT Result
O Positive 
O Negative 
O Invalid 
O Not done 
O Not applicable
4.3 Blood smear prepared
OYES
ONo
4.4 EDTA sample collected?
O YES O NO O NOT APPLICABLE 
4.4b Filter paper taken?
O YES O NO 
4.5) Sample ID number(Record on blood slide and filter paper)
Barcode ] #1 Fin9er pnc/heel prick Label
Here I
4.6 )Are there any other under 12's who live in this house that we have not tested?
APPENDIX VII: IEIP child clinic visit form
I 6527094478 IEIP Morbidity Surveillance Study
Clinic Visit Form- Children (<5 year old,Non-IPTi) n
Date of lnterview(dd/mm/yyyy)
m / m / m
P a r t i .  DEMOGRAPHICS
1.0 Name* o f th e  Child:
Facility Demographics filled by.
OLwak □ □
O  Mahaya
O  Ongielo
1.1a Child's DSS Permanent ID
datoieSit*
<Jomor<vjcodo
First name c r a - m T i - m D - c i D
Juok name
r m n
Last name
r r
© o ©
o o o
o o o
o o o
o o o
o o o
o o o
o o o
o o o
o o o
o o oo o oo o oo o oo o oo o oo o oo o oo o oo o o
o o oo o oo o o
o o oo o o
o o o
o o o
o o o
o o o
o o o
o o o o o o o o o o o o o o o o o o o o
mameoo
o o o o o o o
(nam e
"Fill q u e s tio n s  1.1b a n d  1.1c o n ly  If th e  ch ild  Is a n e w  born  a n d  d o e s  n o t  
h a v e  D S S  p e rm a n e n t ID."
1,1b Child's Temporary ID (newborns)rr
o o o o o o  o o o o o o o o  
o o o o o o  o o o o o o o o  
o o o o o o  o o o o o o o o  
o o o o o o  o o o o o o o o  
o o o o o o  o o o o o o o o  
o o o o o o  o o o o o o o o  
O O  0 0  o o o o o o o o  
O O  O O  o o o o o o o o  
O O  O O  o o o o o o o o  
O O  O O  o o o o o o o o
1.1c Mother's DSS Permanent IDrm-n-m-rm-r
o o o
o o o
o o o
o o o
o o o
o o o
o o o
o o o
o o o
o o o
O 0 0 O  
O  G  O  O
o  o  ©  oOO0O 
O  G  G  O  0 O 0 O  
O  O  G  G  
G  G  G  O  
G  G  G  O  O G  O G
000
O O Oo o oo o o
o o oo o oo o oo o oo o oo o o
o o oo o oo o oo o oo o oo o oo o oo o o
o o oo o o
Tsmpid
1.2 Dote of birth (dd/mm/yyvy)m /m /T
M onth* dnys
1.3a How many years and months old is the child? 
(If child < 1 month old, record # of days )
1.3b Weight
1,3c Height 
1.3d Gender
ChlidyfeAf!
chitoniwth*____ chtiddays
J | | KG (Kilograms)
m iD C Dum
| | | 1 | |  CM (Centimeters) Hrngw
1.4 What is the relationship of the caregiver to the child ?  O  Mother O  Father O  Babyslster O  Maid/Japidi carogivw
Part 2.
2.0 Vital signs
2.0.1 Pulse 
( beats per minute)
O  Other relative O  Other not related O  Unknown
Vital signs taken by:
2.0.2 Respiratory rate I I
( breaths per minute y  1
m
2.0.3 Temperature m . n 2.0.4 Oxygen saturation
Admit according to M W  
□  %
2.0.5 Blood pressure
(« s o n  adm it)
ptiH*
iwspration
fi.’i.it
L Fllenum I ILlf': Cimic visit torm < children VI r Page 1 of 8 J
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Part 3 Treatment History
History and symptoms taken by: □
3.1 What is the reason for today's visit ? (Ango momiyo ikelo nyathi e ospital kawuono)
O 1. need to consult since child is sick O 4. immunization (child is also ill)
O 2. return for further treatment (new/worse illness) O 5. immunization (child is not ill)
O 3. return after weekend consultation O 6. CCC Folow-up and Sick Visit
O 10. Other:_________________________________
3.1b How long have you had this symptoms?
3.1.0 Presenting Symptoms^ Mark an
that apply. Do not probe) O Fever 
O Sore throat O Diarrhea 
O Headache O Burn 
O Other______________
| | | days
O Cough O Difficult breathing 
O Snezzing
n
histregcode
opdwhy
O Chest pain 
O Ear problem 
O Yellow eyes/skin
Symptoms
3.1.1 Did the sick child visit anyone for health care before coming here? O Yes O No O unknown
3.1.1 .a If yes, which? (Do not probe. Mark all that apply) o :  o  i o :  o  : o  o  © :  ©
Other Specify  I I I I I I I
(KEY)
1=Famlly Friend, 2= Traditional healer, 3=Nyamrerwa, 4=Bush Doctor,5 «=Shop/Duka, 6=Health Facility, 
7=Chemlst, 8=Other.
3.2 Has the child taken any medications for this illness ? O Yes O No O Unknown 
3.2a What was your child given?
SP ,P»ratipiL
Duration purati,
O yes O no OUKNj [ j | Amodlaquine O yes O no OUKN [ [ j
Chloroqulne O yes O no OUKNj j | j Analgesics O yes O no OUKN J—
Quinine O yes O no OUKN| j | | Co-artem O yes O no OUKN [... |— f
Septrin (CTX) O yes O no OUKn [
Other antibiotic O yes O no OUKN
Penicillin/ _  _
amoxacillin O y e s  O no OUKN□ TraditionalMedicine
Oral RehydratlonO yes O no O UKN 
Solution (If yes. how many sachets ?)
visit
ipdhcb
Otherlpdhcb
medication
O yes O no O UKN j | | |
sp oq
cq onol
qu co_artem
ctx pen
antlb ipdmttm
ORS
Zinc O yes O no O UKN j | | |
(If yes, how many days ?) m
Other: O yes O no OUKNj | ]“ "[
Medication name
ors_sachet
Zinc
Zinc_days
other
Q trentname
L Filenum IE IP : C lin ic  v is it  fo rm  -  ch ild re n  V17 Page 2 of 8 J
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Part 4. RISK FACTORS
“ I
4.1 Have you travelled outside Nyanza in the last 1 month? 
If YES, to where
O  Yes O No O unknown
4.2 Has the patient traveled outside of Kenya in the last 1 month? 
if yes mark all that apply:
O Sudan O Ethiopia O Tanzania O Rwanda
O Uganda O Burundi
I
O Yes O No O unknown 
O Somali
Other 1: 
Other 2:
Part 5.
r m
EXAMINATION (To be done by clinical officer o r nurse)
Exams done by:
5.1.1 Is the child taking daily cotrimazole prophylaxis? OYes ONo O Unknown
5.1.2 Is the child taking antiretroviral meds (ART)? OYes ONo O Unknown
5.1.2b Did the child receive any vaccine In the last 7 days OYes ONo O Unknown
5.1 a Is this child able to drink or breastfeed at all? OYes ONo
5.1 b Does the child vomit everything with each feeding? OYes ONo
5.2 Does the child have difficult breathing ? OYes ONo
5.3 Does the child have chest pain when breathing ? OYes ONo O Unknown
5.4 Has the child had hot body or fever with this illness? O Yes 
( del maore /  maliet)
5.4 a If yes, how many days ?
ONo 
| | | | days
O Yes
□: ^Jdays
ONo
OYes
5.5 Does the child have cough ?(' ahonda)
5.5 a. If yes, how long has the child had cough ?
5.5 b. If yes, coughing blood ? ( fuolo remo) O Yes
5.6 Does the child have diarrhea ? ( diep)
5.6 a. If yes, how long has the child had diarrhea ?
5.6 a 1 How many loose stool did the child have In the last 24 Hrs? 
5.6b Is the stool watery?
5.6 b. Is there blood in the stool ?
5.6 b. Is there blood In the stool ? ( diep mar remo)
5.6 c. Is there mucus In the stool ? ( diep ma klrendarer
5.7 Does the child have a runny nose ? ( urn mamoi)
5.8 Does the child have sneezing ? (jlr)
5.9 Does the child have an ear problem ? ( It machendo)
Filenum
O Unknown
O No O Unknown
O Unknown 
O  No O Unknown 
| days
Hrs
OYes ONo O Unknown
OYes ONo O Unknown
OYes ONo O Unknown
O Yes ONo O unknown
OYes ONo O Unknown
OYes ONo 0  Unknown
OYes ONo 0  Unknown
travel
ai_country
otherl
other2
examregcode
dailyctx
art
vaccine
breastfeed_Co
Vomitany_Co
diffbreothsign
Chestpain
fever
feverdays
cough
coughdays
coughblood
diarrhea
diarrheadays
LooseStool
Waterystool
stool
stool
dlarrmuc
runnynose
sneezing
earproblem
L IE IP : C lin ic  v is it  fo rm  -  c h ild re n  V I7 Page 3 of 8 J
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5.9 a. If yes, how many days ?
5.10 Does the child have sore throat ? ( duol maremo)
5.11 Has the child had dark urine ? (lach rabuor)
511 b. Has the child had yellow eyes with this illness ?
5.11c. If yes, how many days ?
5.12 Has the child had pale stool ? ( oko ma marmar)
5.13 Is the child lethargic ?
days
ONo
ONo
ONo
OYes 
OYes 
O Yes 
| | | days
O Yes O No
O Yes O No
O Unknown 
O unknown 
O unknown
O unknown
5.25 Does the child have red eyes ?
5.26 Does the child have mouth ulcers ? 
Filenum IL
O Yes O No
O Yes O No
IE IP : C lin ic  v is it  fo rm  -  ch ild re n  V I7
eardays
sorethroat
darkurine
jaundicehx
jaundicedays
palestoo
lethargic
5.13 a) Is this child unconscious? O Yes O No ipdment
5.13 bAVPU Scale OA OV O P  OU avpu
5.14 a Is the child convulsing now ? O Yes O No convulsion
5.14 b Has the child had convulsions with this Illness? O Yes O No convulsion_Co
5.15 Is the child not able to drink or drink poorly ? OYes ONo poordrink
5.16 Is the child excessively breastfed ? O Yes O No BreastFeed
.050.16.1 Has the child vomited with this illness ? O Yes O No Vomit
5.17a Does the child have fast breathing?
_ .. .. If <2months and >59 bpm . . .  severe disease  O  Yes O  No r
breaths
If 2-12months and >49 bpm  \  
If >12 m onths and >39 bpm  *
"*■ pneumonia
5.17 b Chest Indrawing? O Yes O No indrawing
5.17 c Nasal flaring? O Yes O No flaring
5.17 d Stridor when calm? O Yes O No stridor
5.17 e Wheezing? O Yes O No wheezing
5.17 f Crackles/rales? O Yes O No crackles
5.17 g Grunting? O Yes O No grunting
5.18 Is the child restless or irritable ? O Yes O No restless
5.19 Does the child have sunken eyes ? O Yes O No sunkeneyes
5.20 Is the child drinking eagerly, thirsty ? O Yes O No thisty
5.20 b Does your child have tears when he/she cries 7 0  Yes O No ON/A tears
5.21 After pinching the skin, how does It go back ? O Very slowly O Slowly O Normally pinch
5.2 Does the child have stiff neck ? O Yes O No stiffneck
5.23 Does the child have bulging fontanelle ? O Yes O No fontonetle
5.23b. Does the child a sunken fontanelle ? OYes ONo fontonelsunk
5.24 Does the child have rash ? O Yes O No rash
5.24a. describe the rash ? o  Heat O Diaper O Maculopapular 0  Vesicular O Petechial dlaperrosh
O Abscess O Infected (purulent skin lesion)
redeyes
mouthulcers
Page 4 of 8 J
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5.27 Does the child have pus draining from the eyes ? 
5.27b. Does the child have pus draining from the ears ? 
5.27c. Was ear exam done ?
5.27d. If not normal
5.28 Is there visible severe wasting ?
5.29 Is there oedema of both feet ?
5.30 Does the child have jaundice ?
1
O Yes O No puseyes
O Yes O No pusears
O Normal O Not normal O Not done earexam
O Discharge O Inflamation O Any other earxam_notnomal 
O Yes O No wasting
O Yes O No
O Yes O No
5.31 Are there enlarged lymph nodes at 2 or 3 of the following sites, Neck, 
Axillae.Groin. ?
O Yes O No
oedema
jaundice
lymphnodes
5.32 Oral thrush ? O Yes O No
5.33 Any other sign of anemia (paleness of palms, nailbed, conjunctiva) ? O Yes O No
5.34 Other symptoms 1.
pale
othersympl
othersymp25.35 Other symptoms 2.
Part 6. SAMPLES
6.0 Case defination met: O None O SARI O ILI O Fever O Diarrhea O Admission O Jaundice caseDefintion
6.0 a Patient eligible for: ONP/OP O Blood Culture O Serum O Stool O Urine O X-rays SampEligibility
6.0 b Was chest X-ray ordered? O Yes O No If No, why? O Patient is pregnant O Done in last 3months XRay0rdered
_  — ........   — ------— n i i ■ ■ ■ ■ . XrayNo
O Others (specify)
6.0 b Nurse Code m
XrayNoOther
O Yes O Refused O Not done6.1 Haemoglobin I I I I 1 g/dl 6-4 Nasopharyngeal swab -   „
I— I— I-I— I a Not done why? | | p ] |  | | | \
6.4a Oropharyngeal swab XTre's U  Refused O Notdone6.2 Blood slide done ?
OYes O Refused O Not done 
6.3b Giemsa stain BS results?
O Positive O Negative
NurseCode
hb_16
npswab
orswab
Not done why?
6.5 a. Stool sample taken '
Not done why? |
6.6 Serum sample taken ?
Not done why? I
r  i i i  i i r ~ n  »«►
O Refused u  Notdone stools
6.7 Blood culture done ? 
6.3c parasite species? O Falciparum O Malariae O Ovale O Vivax
L  1 J  J , 1 1 1 1<5 res  £) Refused O Mot done
1 1  1 '1 1 1 □ H I D
bloodsiide 
amp
6.3d parasite count
X- RAY RESULT
X-ray done by:
6.3 e) Is the filim quality
per 200 wbc
OYes O Refused O Not done
f T l ' T T  I I I m
sera
giemsa
malspec
paracount
O Adequate O  Suboptimal O Unreadable
6.3 f) Does the filim contain significant pathology ? O Yes O No O Not Done
6.3 g) Primary end Point consolidation ? Right O Yes ONo
Left OYes ONo
6.3 h) Other consolidation / infiltrate ? Right O Yes ONo
Left O Yes ONo
6.3 i) Pleural fluid? Right O Yes ONo
Left O Yes ONo
6.3 J) Other abnornmalitles ? 
Filenuml
I I T I I I I I
L IE IP : C lin ic  v is it  fo rm  -  c h ild re n  V I 7
Filim_quolity
Pathology
Rlght_Consolldotlon
Left_Consolidntlon
Rlghtjnfiltrot
Leftjnfiltrnt
Pleural_Rlght
Pleural_Left
Other_Abnormolitles
Page 5 of 8 J
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Part 7: D iagnosis
“ 1
7.01 What do you diagnose the child with?
Malaria Oyes Dysentery Oyes
Pneumonia/Lower respiratory tract infection Oyes Intestinal worms Oyes
Upper Respiratory Tract Infection(URTI) O yes Anemia O yes
Wheezing/bronchospasm Oyes Malnutrition O yes
Otitis media Oyes Oral candidiasis O yes
Conjunctivitis Oyes Rash/skin problem O yes
Meningitis O yes Scabies O yes
Diarrhoea/ Gastroenteritis O yes Bum O yes
Dehydration O yes Wound/injury O yes
Pharyngitis/tonsillitis O yes Amoebiasis O yes
Viral syndrome Oyes Pulmonary TB O yes
Convulsions Oyes Influenza O yes
Measeles O yes Urinary Track Infection O yes
svmalaria
svdysentery
svpneumonia
swvorms
svurti
svanemia
svbronchospasm
svmalnutrition
svotitis
svcandidiasis
svdiarrhoea3
svconjuctiva
svrashd
svmeningitis
svscabies
svbum
svdehydration
svwound
svPharyngitis
svamoebiasis
svViralsyn
svptb
ipdocon
svflu
ipdamsl
Otherl
7.02 Was there any error in question 7.01? O yes # n o
11.5 Did the patient have an HIV test as part of DCT/PITC during the visit? O Yes O No O Don't Know
11.5a) If No, was it because: o  Illness not suspected to be HIV related O Already known to be HIV
O Patient refused 
O Other
anyerror6_1
hivtestother
11.5b) If yes,(Only answer if consent obtained) what was the result of DCT/PITC 
O Positive O Negative O Interminate
11.5c) Did the child have blood for PCR taken ? O Yes O No O N/A
11.5d)Was PCR O Positive O Negative O Unknown
pcrtoken
PCRresult
O no (If 'no', go to 8.2.)
Amodiaquine
Quinine
Part 8: MEDICATION
Antimalarials
8.1 Did you or will you give antimalarial treatment today? O yes
8.1a What was given?
SP O yes H T  CD days 
Coartem O yes u r m  days
8.2 Did you or will you give antibiotics treatment today?
8.2a What was given?
Septrin O yes | | | q* | j j days £  O yes| | | Q|y| | j Penicillin o  yes| j | \ | |
GentamicinO yesj j |  oty j | | doys Tetracycline O yes| j | o t / |~ J ~ ~ j  MetronidazoleO yesj j j Qv
Filenum
O yes
O yes
O yes
f f l
Oty CD days 
Of/ CD days
O no ( I f 'n o g o  to 8.3.)
L
antlmalarla_16
msp
moq
mco_nrtem
mqu
nntibiotics_16
ninm8xx ni pen
mgent
mtetro
mmet
IE IP ; C lin ic  v is it  fo rm  ■ ch ild re n  V17 Page 6 of 8 J
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Ciprofloxacin O yes| | ~ | 11 | 1 N l^fdixic Acid O yes | | | Qlyl \ | AntihelminthicQyes| | | j |
Erythomycin O y es [ _ j j °'yL _ L 1 cioxacillin Q y e s j | M  I I C eftr iaxoneQ yesr~ [~ l
Chloramphe O y e s f T I Q<yfTIf e c v c l i n  O y e s Q ^ f J ]
Other Antibiotic LI
mantih 
merythro 
mclo 
mceft 
mchloro 
mdoxy 
antibiother 16
8.3 Did you or will you give other treatment today?
8.3a What was given?
Analgesic q  yes Salbutamol/ventolin O yes Piriton
Oral Rehydration solution
O yes O no (If 'no', go to 9.)
O yes Valium
O yes MVl o yes
O yes Expectorant O yes Zinc O yes
Other Medicinl 
Other Medicin2
Part 9: DISPOSITION (Admit for any symptoms or signs in bold.)
9.1 What is the disposition of the child ?
O Home o  Admit Lwak O Refer Bondo District Hospital O Refused admission
O Refer PGH
_  ( s p e c i f y )
O Other
mother_16
m anal
m ors
m salbutamol
mval.mmvi
mpiriton
m expect
mzinc
otherm edl
othem ied2
disposition
dispother
9.2 Follow up appointment ONone O Hours O Days O Weeks O Months O Years
o . t  r u i i u v . u H O h / H u i m i M c m  I  I " I  hrs I T o d a y s  I  I I wks I I I ninths I I l y
Part 10: HOSPITAL COURSE
10.1 Did you give antimalarial medicines during the hospital course ? O yes O no
10.1a What was given?
Sp O yes
Coartem o  yes
(If 770* go to 10.2.)
Amodiaquine
Quinine
Oyes
Oyes
hantimalaria_16
hm sp
hm aq
hmco_arte
hmq
10.2 Did you give antibiotics medicines during the hospital course ? O yes O no (If 'no', go to 10.3.) h a n tib io tic s je  
10.2a What was given? hmamox h™,
hmgen hmPen 
hmmet hmtetra 
hmcipro hmnal 
hmantih 
hmerythro 
hmclox hn,ceft 
hmchloro 
hmdoxy 
ivflulds 
Ivbottles
Septrin O yes Amoxacillin/ampiclllin Oyes Penicillin O yes
Gentamicin O yes Tetracycline Oyes Metronidazole O yes
Ciprofloxacin O yes Nalidixic Acid Oyes Antihelminthic O yes
Ethomycin O yes Cioxacillin O yes Ceftriaxone O yes
Chloramphenicol O yes Doxycyclin Oyes
10.2b Did you give intravenous fluids? O yes O no 10.2b1 How many bottles given
10.3 Did you give other medicines during the hospital course ? O yes O no m
10.3a What was given? 
Salbutamol/ventolin O yes
Oral Rehydration solution O yes 
Other Medicinl
Zinc
Valium
O yes
O yes
If 'no', go to 11.
Analgestic
Multivitamin
Oyes
Oyes
hmanal hniother_16
hmsalbutamol 
hmmultlvit 
hmors hmval 
hmzlnc 
hothermedl
Other Medicin2 
Part 11: DISCHARGE
11.1 Date of discharge/death? (dd/mm/yyyy)
11.2 Outcome of hospital course ?
O Discharge home without sequelae 
O Discharge home with sequelae
m / m / m n
O Absconded 
O Transferred
ODied
hothermed2
hospddote
hospoutcome
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11.3 What is the discharge diagnosis ?
Malaria O yes Dysentery
Pneumonia/Lower respiratory tract infection O yes Intestinal worms
Upper Respiratory Tract Infection(URTI) O yes Anemia
Wheezing/bronchospasm O yes Malnutrition
Otitis media O yes Oral candidiasis
Conjunctivitis O yes Rash/skin problem
Meningitis O yes Scabies
Diarrhoea/ Gastroenteritis O yes Burn
Dehydration O yes Wound/injury
Convulsions O yes Pulmonary TB
Measles O yes Influenza
UTI O yes
Otherl
11.4 Was there any error in question 10.3? O yes •  no
Specim en Label Intake
12.1 Has specimen been taken? O yes O no
Time of blood draw | | | | |
I portion^H^^ Nasopharyngeal Swab /Oropharyngeal Swab Label 
| | NP/OPTime| M M
O yes
O yes
O yes
O yes
O yes
O yes
O yes
O yes
O yes
O yes
O yes
n
hdalaria
hddysentery
hdpneumonia
hdworms
hdurti
hdanemia
hdbronchospasn
hdmalnutrition
hdotitis
hdcandidiasis
hdconjuctiva
harasnd
hdmeningitis
hddehydration
MXnd
ipddcon
hdflu
ipddmsl
svotherdxl
specimenlabel 
Tim© BloodDraw
Place White” | 
Portion Here , #2 Blood, Serum Label 
Serum Time 1 | | | |
#5 Blood, Culture Label 
Culture Time | | | | j
Place White | 
Portion H ere.
Place White | 
Portion Here i #3 Stool Sample Label 
Stool Time M l
# 6 Blood culture 
Label Myco / F-Lytic
Myco/FLytlc Time | | | |
j Place White 
Portion Here
Place White |
Portion Here j# 4Urine Sample Label 
---------------- ' Urine Time | | | |
# 7 Blood Clot j Place White 
________  Portion Here
Clot Time
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